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A B S T R A C T
Background
Routine outcome monitoring of common mental health disorders (CMHDs), using patient reported outcome measures (PROMs), has
been promoted across primary care, psychological therapy and multidisciplinary mental health care settings, but is likely to be costly,
given the high prevalence of CMHDs. There has been no systematic review of the use of PROMs in routine outcome monitoring of
CMHDs across these three settings.
Objectives
To assess the effects of routine measurement and feedback of the results of PROMs during themanagement of CMHDs in 1) improving
the outcome of CMHDs; and 2) in changing the management of CMHDs.
Search methods
We searched the Cochrane Depression Anxiety and Neurosis group specialised controlled trials register (CCDANCTR-Studies and
CCDANCTR-References), the Oxford University PROMS Bibliography (2002-5), Ovid PsycINFO, Web of Science, The Cochrane
Library, and International trial registries, initially to 30 May 2014, and updated to 18 May 2015.
Selection criteria
We selected cluster and individually randomised controlled trials (RCTs) including participants with CMHDs aged 18 years and over,
in which the results of PROMs were fed back to treating clinicians, or both clinicians and patients. We excluded RCTs in child and
adolescent treatment settings, and those in which more than 10% of participants had diagnoses of eating disorders, psychoses, substance
use disorders, learning disorders or dementia.
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Data collection and analysis
At least two authors independently identiﬁed eligible trials, assessed trial quality, and extracted data. We conducted meta-analysis across
studies, pooling outcome measures which were sufﬁciently similar to each other to justify pooling.
Main results
We included 17 studies involving 8787 participants: nine in multidisciplinary mental health care, six in psychological therapy settings,
and two in primary care. Pooling of outcome data to provide a summary estimate of effect across studies was possible only for those
studies using the compound Outcome Questionnaire (OQ-45) or Outcome Rating System (ORS) PROMs, which were all conducted
in multidisciplinary mental health care or psychological therapy settings, because both primary care studies identiﬁed used single
symptom outcome measures, which were not directly comparable to the OQ-45 or ORS.
Meta-analysis of 12 studies including 3696 participants using these PROMs found no evidence of a difference in outcome in terms of
symptoms, between feedback and no-feedback groups (standardised mean difference (SMD) -0.07, 95% conﬁdence interval (CI) -0.16
to 0.01; P value = 0.10). The evidence for this comparison was graded as low quality however, as all included studies were considered
at high risk of bias, in most cases due to inadequate blinding of assessors and signiﬁcant attrition at follow-up.
Quality of life was reported in only two studies, social functioning in one, and costs in none. Information on adverse events (thoughts
of self-harm or suicide) was collected in one study, but differences between arms were not reported.
It was not possible to pool data on changes in drug treatment or referrals as only two studies reported these. Meta-analysis of seven
studies including 2608 participants found no evidence of a difference in management of CMHDs between feedback and no-feedback
groups, in terms of the number of treatment sessions received (mean difference (MD) -0.02 sessions, 95% CI -0.42 to 0.39; P value =
0.93). However, the evidence for this comparison was also graded as low quality.
Authors’ conclusions
We found insufﬁcient evidence to support the use of routine outcome monitoring using PROMs in the treatment of CMHDs, in
terms of improving patient outcomes or in improving management. The ﬁndings are subject to considerable uncertainty however, due
to the high risk of bias in the large majority of trials meeting the inclusion criteria, which means further research is very likely to have
an important impact on the estimate of effect and is likely to change the estimate. More research of better quality is therefore required,
particularly in primary care where most CMHDs are treated.
Future research should address issues of blinding of assessors and attrition, and measure a range of relevant symptom outcomes, as well
as possible harmful effects of monitoring, health-related quality of life, social functioning, and costs. Studies should include people
treated with drugs as well as psychological therapies, and should follow them up for longer than six months.
P L A I N L A N G U A G E S U M M A R Y
Using patient-reported outcome measures to monitor progress among adults with common mental health disorders
Why is this review important?
One in six people suffer from a common mental health disorder (CMHD), including depression and anxiety disorders. Patient reported
outcome measures (PROMs) are questionnaires on patients’ symptoms, functioning, and relationships. Using PROMs to monitor the
progress of people with CMHDs might improve treatment outcomes, and change the management of CMHDs.
Who will be interested in this review?
People with CMHDs; health professionals in primary care, psychological therapy and mental health services; health service commis-
sioners.
What questions does this review aim to answer?
Does the use of PROMs to monitor progress in people with CMHDs improve health outcomes, including symptoms, quality of life,
and social functioning?
Does the use of PROMs in people with CMHDs change the way their problems are managed, including drug therapy and referrals for
specialist help?
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Which studies were included in the review?
Trial databases were searched to ﬁnd all high-quality studies of the use of PROMs to monitor the treatment of CMHDs published
up to May 2015. Included studies had to be randomised controlled trials in adult participants, where the majority diagnosed had a
CMHD.
Seventeen studies involving 8787 participants were included in the review, nine from mental health, six from psychological therapy,
and two from primary care settings.
The quality of the studies was rated ‘low’ to ’moderate’.
What does the evidence from the review tell us?
Routine outcome monitoring of CMHDs using PROMs was not shown conclusively to be helpful in analyses combining study results,
either in terms of improving patient symptom outcomes (across 12 studies), or in changing the duration of treatment for their conditions
(across seven studies). It was not possible to analyse changes in drug treatment or referrals for further treatment as only two studies
reported these. Similarly, health-related quality of life, social functioning, adverse events, and costs were reported in very few studies.
What should happen next?
More research of better quality is required, especially in primary care where most CMHDs are treated. Studies should include people
treated with drugs as well as psychological therapies, and should follow them for longer than six months. As well as symptoms and
length of treatment, studies should measure possible harms, quality of life, social functioning, and the costs of monitoring.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Feedback of PROM scores for routine monitoring of common mental health disorders
Patient or population: People with common mental health disorders1
Settings: Primary care, mult idisciplinary mental health care, or psychological therapies
Intervention: Feedback of PROM scores to clinician, or both clinician and pat ient
Comparator: No feedback of PROM scores
Outcomes and length of fol-
low-up
Illustrative risk Number of participants
(number of studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk (range of
means in no-feedback
groups)
Relative effect (95% CI) in
feedback groups
M ean improvement in
symptom scores
Outcome Quest ionnaire-45
(OQ-45) or Outcome Rating
Scale (ORS)
Follow-up: 1-6 months2
Mean scores in no-feedback
groups ranged f rom 51.8 to
101.5 points for OQ-45 and
f rom 23.8 to 29.5 points for
ORS. Standard deviat ions
ranged f rom 17.8 to 28.6
points for OQ-45 and f rom
7.1 to 9.6 points for ORS
Standard mean dif ference
in symptom scores at end
of study in feedback groups
was 0.07 standard devia-
tions lower
(0.16 lower to 0.01 higher)
3,4
3696
(12 studies)
⊕⊕©©
low5,6
Neither study in the primary
care sett ing used the OQ-
45 or ORS PROMs, and so
could not be included in this
meta-analysis
Health- related quality of
life
Medical Outcomes Study
Short Form (SF-36)
Follow-up: 1-5 months2
Medical Outcomes Study
(SF-12) physical and mental
subscales)
Scale f rom 0-100
Follow-up: 0-1 year
Study results could not be combined in a meta-analysis
as data were not available in an appropriate format
Mathias 1994 reported no signif icant dif f erences between
feedback and control groups on all nine domains of the
SF-36
Scheidt 2012 reported no signif icant dif f erences between
feedback and no-feedback groups in physical or mental
sub-scale scores
583
(1 study)
587
(1 study)
⊕⊕⊕©
moderate7
Adverse events
PHQ-9 quest ionnaire8
Follow-up: 6 months
Chang 2012 reported no immediate suicide risk across
both feedback and no-feedback groups combined. Num-
ber per group not given
642
(1 study)
⊕⊕⊕©
moderate7
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Social functioning
Follow-up: 0-1 year2
Data for the social funct ioning subscale of the OQ-45
were considered separately in Hansson 2013 and no
dif ference was found
262
(1 study)
⊕⊕©©
low9
Costs Not est imable 0
(0 studies)
No study assessed the im-
pact of the intervent ion on
direct or indirect costs
Changes in the manage-
ment of CM HDs
Changes in drug therapy
and referrals for specialist
care
Follow-up: 1-6 months2
Study results could not be combined in a meta-analysis
as data were not available in an appropriate format
Chang 2012 and Mathias 1994 both reported no signif -
icant dif f erences in changes in drug therapy between
study arms
Mathias 1994 reported mental health referrals were sig-
nif icant ly more likely in the feedback group (OR 1.73, 95%
CI 1.11 to 2.70)
1215
(2 studies)
⊕⊕⊕©
moderate7
Changes in the manage-
ment of CM HDs
Number of treatment ses-
sions received
Follow-up: 1-6 months2
Mean in no-feedback
groups ranged f rom 3.7 to
33.5 treatment sessions
Mean dif ference in number
of treatment sessions in
feedback groups was 0.02
lower
(0.42 lower to 0.39 higher)
2608
(7 studies)
⊕⊕©©
low10
Post-hoc analysis. Changes
in medicat ion and referrals
for addit ional therapy were
not assessed by any of
these studies
CI: Conf idence interval
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1Studies were included if the majority of people diagnosed had CMHDs and no more than 10% had diagnoses of psychot ic
disorders, learning dif f icult ies, dementia, substance misuse, or eat ing disorders
2Durat ion of therapy was variable in all studies and determined by the clinician or the pat ient, or both
3OQ-45 range of scores 0-180 (0 best, 180 worst). Three studies (Murphy 2012, Reese 2009a and Reese 2009b) used the ORS
- range of scores 0-40 (0 worst, 40 best)
4 This is a dif ference in standard deviat ions. A standard deviat ion of 0-0.2 represents no to small dif f erence between groups
(rule of thumb according to Cohen’s interpretat ion of ef fect size)5
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5An expected ef fect size of 0.3 SD would require a minimum total sample size of 352 part icipants. An expected ef fect size of
0.1 SD would require 3142 part icipants
6Downgraded two levels due to risk of bias (all included studies were judged at high risk of bias in at least two domains, in
part icular blinding of part icipants and outcome assessment, and attrit ion), and indirectness (although symptom scores were
compared between feedback and non-feedback groups, wider social funct ioning and quality-of -lif e measurements were not
assessed in nearly all studies)
7Downgraded one level due to risk of bias (judged at high risk of bias in at least two domains, in part icular blinding of
part icipants and outcome assessment, and attrit ion)
8Number of PHQ-9 quest ionnaires which contained reports of self -harming thoughts
9Downgraded two levels due to risk of bias and imprecision, as total part icipant numbers were less than 400
10Downgraded two levels due to risk of bias and for imprecision: est imate of ef fect includes no ef fect and incurs very wide
conf idence intervals
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B A C K G R O U N D
Description of the condition
Common mental health disorders (CMHDs) are prevalent, of-
ten very disabling and very costly. They include depression (in-
cluding major depression, dysthymia and minor or mild depres-
sion);mixed anxiety and depression; and speciﬁc anxiety disorders,
namely generalised anxiety disorder (GAD), phobias, obsessive-
compulsive disorder (OCD), panic disorder and post-traumatic
stress disorder (PTSD) (McManus 2009). Katon and Schulberg
estimated in 1992 that depression fulﬁlling the criteria for ma-
jor depression in the American Psychiatric Association Diagnostic
and Statistical Manual, 4th edition (DSM-IV) (APA 2000) oc-
curred in 2% to 4% of people in the community, 5% to 10% of
primary care patients, and 10% to 14% of medical inpatients; but
in each setting there were two to three times as many people with
depressive symptoms that were short of the major depression cri-
teria (Katon 1992). Prevalence rates of major depression of 13.9%
in women and 8.5% in men, and of anxiety disorders of 10%
and 5% respectively, have been found in family practice attendees
across Europe (King 2008). The estimated one-week prevalence
of CMHDs among adults in England in 2007, according to the
criteria of the World Health Organization’s International Clas-
siﬁcation of Diseases (ICD-10) (WHO 1992) was found to be
17.6%, including mixed anxiety and depression in 9.7%; GAD
in 4.7%; depressive episode in 2.6%; phobia in 2.6%; OCD in
1.3%; and panic disorder in 1.2% (McManus 2009). In the US
National Comorbidity Survey, lifetime prevalence estimates were
16.6% for DSM-IV major depression; 6.8% for PTSD; 5.7% for
GAD; 4.7% for panic disorder; 2.5% for dysthymia; 1.6% for
OCD; and 1.4% for agoraphobia (Kessler 2005).
Depression is often chronic and relapsing, resulting in high levels
of disability and poor quality of life (Wells 1989), generally high
levels of health service use and associated economic costs (Simon
1997), and death from suicide in between 2% and 8% of cases
(Bostwick 2000). Major depressive disorder appears to be increas-
ing in prevalence (Compton 2006) and in the Global Burden of
Disease Study 2010 (Murray 2010) has moved up to 11th from
15th in the ranking of disorders according to burden in terms of
disability adjusted life years (a 37% increase), becoming the sec-
ond leading cause of years lived with disability, due to population
growth and ageing (Ferrari 2013).
The King’s Fund estimated that in the UK 1.45 million people
would have depression by 2026, and the total cost to the nation
would exceed GBP 12 billion per year, including prescriptions,
inpatient and outpatient care, supported accommodation, social
services and lost employment (McCrone 2008). The total medical
and productivity costs per person with any anxiety disorder were
estimated to be aroundUSD6500 in the USA in 1999 (Marciniak
2004), and across Europe the annual costs of anxiety disorders, in-
cluding health service costs, welfare beneﬁts and lost productivity,
were estimated to exceedUSD40 billion in 2004 (Andlin-Sobocki
2005).
Depression is usually treated in primary care with selective sero-
tonin reuptake inhibitor (SSRI) antidepressant drugs (in around
80% of cases), psychological treatments (in around 20%), or both
(Kendrick 2009); and in one-third to one-half of people with
major depression, the symptoms persist over a six to 12-month
period (Gilchrist 2007; Katon 1992). Evidence-based guidelines
recommend psychological treatments such as cognitive-behaviour
therapy (CBT) as ﬁrst-line treatment for anxiety disorders (NICE
2011a) but SSRIs are also frequently prescribed for their treat-
ment, often because psychological treatments are not available. It is
recommended that people prescribed antidepressants are seen for
regular follow-up during treatment. For example, theUKNational
Institute for Health and Care Excellence (NICE) 2009 guideline
on the management of depression in adults recommended that
people started on antidepressants who were not considered to be at
increased risk of suicide should normally be seen after two weeks,
then at intervals of two to four weeks in the ﬁrst three months,
and then at longer intervals if their response to treatment was
good (NICE 2009). At each visit clinicians were recommended
to evaluate response (symptoms and functioning), adherence to
treatment, drug side-effects and suicide risk (NICE 2009). This
evaluation is usually based on clinical judgement alone, but in re-
cent years clinicians have been advised to consider using patient
reported outcome measures (PROMs) to augment their clinical
judgement. NICE guidance states all staff carrying out the assess-
ment of common mental health disorders should be competent
in the use of formal assessment measures and routine outcome
measures (NICE 2011a).
Description of the intervention
PROMs assess patients’ experiences of their symptoms, their func-
tional status and their health-related quality of life. So they can
help to determine the outcome of care in terms of these aspects
from the patient’s perspective as an expert in the lived experience
of their own health. PROMs are different to measures of patients’
experience of, or satisfaction with, the care they receive (Black
2013). PROMs are often self-report measures that should there-
fore be free of observer rating bias, but they can also be interview-
based measures that involve the interviewer in interpreting the pa-
tients’ responses to questions.
The treatment of CMHDs has been augmented in a number of
studies by administering PROMs measuring symptoms of depres-
sion or anxiety, social functioning or health-related quality of life,
and feeding the results back to the treating clinician or both the
treating clinician and the patient. Feedback of the results is the
essential element. The intervention will usually include education
of the clinician, or both the clinician and patient, about the mea-
sures used and their interpretation. It may or may not also include
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speciﬁc instructions on action to take in light of the results, which
may be in the form of an algorithm.
How the intervention might work
Carlier 2012 identiﬁes two main theories concerning the links be-
tween the use of PROMs, the process of care and outcomes for pa-
tients, Feedback Intervention Theory (FIT) and Therapeutic As-
sessment (TA). FIT suggests that feedback of the results of PROMs
to healthcare professionals inﬂuences them to adjust treatment or
refer for alternative interventions, improving care when measured
against best practice guidelines; while TA focuses on the potential
therapeutic effects of feeding back the test results to patients.
Greenhalgh 2005 pointed out that feedback to the clinician may
initiate speciﬁc changes in management, including ordering fur-
ther tests, referring to other professionals, changing treatments,
and giving advice and education to the patient on better control
or management of the problem. Feeding the results back to the pa-
tient as well as to the clinician can potentially further improve the
process of care, as patients often like to be more involved in their
own care, which may be beneﬁcial in itself. This may promote
better communication and a greater understanding of the patient’s
personal circumstances, enabling joint decision-making between
clinician and patient, increasing concordance and patient adher-
ence to treatment through agreeing shared goals, and increasing
patient satisfaction, all of which in turn can potentially improve
the outcome for the patient.
Observational studies suggest that general practitioner (GP) treat-
ment decisions (to prescribe antidepressants, to subsequently
change prescriptions, or refer patients for specialist treatment)
might be inﬂuenced by the results of patient-completed depression
symptom questionnaires at diagnosis (Kendrick 2009) and follow-
up (Moore 2012), in line with the predictions of FIT. A trial of
feeding back depression symptom questionnaire scores to primary
care physicians and patients in the USA led to increased rates of
response to treatment and remission among patients in the inter-
vention arm (Yeung 2012) although this was despite an apparent
lack of signiﬁcant changes in the physicians’ management of the
patients’ depression (Chang 2012). The authors suggested that
frequent symptom measurement might have increased patients’
symptom awareness and their ability to report relevant symptoms
to their physicians, or made them feel more supported, contribut-
ing to a lower medication discontinuation rate in the intervention
group. Qualitative research suggests that patients with depression
do value the use of symptom questionnaires to assess their con-
dition (Dowrick 2009) and the effectiveness of their treatment
(Malpass 2010). It might be that if patients feel that they have
been assessed more thoroughly and become more involved in the
care of their disorder through the completion of PROMs, together
with feedback of the signiﬁcance of the results, this can help them
to improvemore quickly even in the absence of signiﬁcant changes
in management, in line with the predictions of TA.
Why it is important to do this review
The use of PROMs has been promoted in recent years as a way for
patients to become more involved in their own care and to help
health professionals make better decisions about their treatments
(Black 2013; Black 2015; Fitzpatrick 2009).
In particular, the use of PROMs in depression has been promoted
in important policy pronouncements. The US Federal Health Re-
sources and Services Administration (HRSA) Collaborative on
Depression included quality standards for the proportion of pa-
tients assessed using the self-complete Patient Health Question-
naire (PHQ-9) depression symptom measure (Spitzer 1999) at di-
agnosis and follow-up (HRSA 2005). The NICE 2009 depres-
sion guideline recommended that clinicians should consider us-
ing a validated measure (for example for symptoms, functions and
disability) to inform and evaluate treatment (NICE 2009). The
subsequent NICE quality standard on assessment of depression
recommended that practitioners delivering interventions for peo-
ple with depression should record the results of validated health
outcome measures at each treatment contact and use the ﬁndings
to adjust their delivery of interventions (NICE 2011b). In 2009
a performance indicator was added to the UK National Health
Service (NHS) GP pay for performance scheme (the Quality and
Outcomes Framework or QOF), ﬁnancially incentivising the fol-
low-up assessment of depressionwith symptomquestionnaires ﬁve
to 12 weeks after diagnosis (BMA &NHS Employers 2009). The
UK NHS Increasing Access to Psychological Therapies (IAPT)
programme, extending the provision of psychological treatments
for CMHDs nationwide, adopted an information standard with
an instruction to recordPROMs at every visit, including the PHQ-
9 for depression, the self-complete Generalised Anxiety Disorder
questionnaire (GAD-7) for anxiety (Spitzer 2006), and the Work
andSocial Adjustment Scale (WSAS,Mundt 2002) for social func-
tioning (IAPT 2011).
The potential for PROMs to improve the care and self-care of
CMHDs cannot be assumed however. The administration of
symptom, social functioning, or quality-of-life questionnaires to
each and every patient with a CMHD adds up to a signiﬁcant
investment of resources in terms of professionals’ time given the
high numbers of patients with CMHDs, especially in primary
care. Following the introduction of the QOF performance indica-
tor ﬁnancially incentivising the follow-up assessment of depression
with symptom questionnaires, GPs in the UK reported complet-
ing more than 1.1 million follow-up assessments between April
2009 andMarch 2013 (74% of 1.5million eligible cases identiﬁed
in those ﬁve years) (QOF Database 2013). The cost to the NHS
of those assessments added up to more than GBP 25 million per
year in terms of GP time and the incentive payments. Therefore,
even such relatively simple quality improvement strategies should
be supported by evidence of clinical beneﬁt and cost-effectiveness.
There have been a number of previous systematic reviews related
to this question including studies in different sectors of health care:
one of studies in non-psychiatric settings (Gilbody 2002); one of
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studies in clinical psychology practice (Lambert 2003), updated
in 2010 (Shimokawa 2010); two combining studies in multidis-
ciplinary mental health care (which we previously referred to as
’specialist psychiatric practice’, see section on Differences between
protocol and review) and clinical psychology practice (Davidson
2014; Knaup 2009); and one limited to studies in primary care
(Shaw 2013). The review byGilbody and colleagues failed to show
an impact of patient-centred outcome instruments assessing pa-
tient needs or measuring quality of life in non-psychiatric settings
(Gilbody 2002). However, Knaup and colleagues’ systematic re-
view of studies in specialist psychological and multidisciplinary
mental health care settings, which included the studies previously
reviewed by Lambert and colleagues (Lambert 2003), was more
positive, demonstrating beneﬁts of routine outcomemeasurement
for a range of mental health problems (Knaup 2009). Outcomes
were found to be improved with an effect size of between 0.1 and
0.3 standard deviations, being improved more when patients were
involved in rating their own problems and received feedback on
their progress in addition to feedback to the practitioner (Knaup
2009). However, this review included studies of people with more
severe mental illnesses as well as CMHDs. Conversely, the 2013
review (Shaw 2013) had a narrow focus as it was limited to stud-
ies of the assessment and monitoring of depression in primary
care using questionnaires recommended in the NHS GP contract
QOF, namely the PHQ-9, Hospital Anxiety and Depression Scale
(HADS) (Zigmond 1983) and Beck Depression Inventory (BDI)
(Beck 1961) or BDI-II (Beck 1996). Other systematic reviews
and meta-analyses have included studies of the use of PROMs as
screening or diagnostic tools together with studies of their use as
follow-up monitoring measures (Carlier 2012; Poston 2010) or
have included studies of the use of PROMs in the management
of physical disorders together with studies in mental health care
(Boyce 2013; Marshall 2006; Valdera 2008). One recent system-
atic review included only studies which evaluated feeding back the
results of PROMs in terms of changes in the particular PROM
score rather than other relevant outcome measures (Boyce 2013).
There has been no systematic review of the use of PROMs in the
routine outcome monitoring of CMHDs in adults across primary
care, psychological therapy, and multidisciplinary mental health
care settings. Given the high prevalence of CMHDs, the current
policy drive promoting routine outcome monitoring across these
settings, and the likely signiﬁcant cost of such widespread moni-
toring of highly prevalent conditions, there is an urgent need for
evidence to guide further developments in policy and clinical prac-
tice. We therefore aimed to conduct a comprehensive, up-to-date
systematic review of the use of PROMs in CMHDs, including
studies across primary care, multidisciplinary mental health care,
and psychological therapy settings. We aimed to include measures
of social functioning and health-related quality of life (QoL) as
well as measures of symptoms of depression and anxiety, because
functioning and QoL measures may also inﬂuence clinician treat-
ment decisions or patient involvement in their own care, or both,
and therefore outcomes for patients.
PROMs can be used as a tool to identify patients with CMHDs
whose problems would otherwise be missed, but in this review
we were not concerned with the use of PROMs as a screening
tool. This was the subject of a previous review, Gilbody 2008.
In this review we were concerned with the use of PROMS in
monitoring patients’ progress and response to treatment, which
requires feedback and assessment of the results at follow-up, after
a period of treatment, rather than screening or assessment only
before diagnosis or at the point of diagnosis.
We conducted this review according to the methods set out in the
protocol (Kendrick 2014).
O B J E C T I V E S
To assess the effects of routine measurement and feedback of the
results of PROMs during the management of CMHDs in 1) im-
proving the outcome of CMHDs; and 2) in changing the man-
agement of CMHDs.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included randomised controlled trials (RCTs), including clus-
ter RCTs and RCTs randomised at the level of individual partici-
pants. We excluded non-randomised trials.
We planned to include cluster trials where clusters were allocated
to intervention or control arms using a quasi-randomised method,
such asminimisation, to avoid signiﬁcant imbalance between arms
arising by chance when the number of clusters is relatively small,
but planned to exclude quasi-randomised trials where allocation
was at the level of individual participants. We planned to exclude
cross-over trials because of the very high risk of carry-over of the
intervention into the control arm after participating clinicians or
patients cross over.We also planned to exclude uncontrolled before
and after trials, and observational studies. However, none of these
types of studies was identiﬁed.
Types of participants
Participant characteristics
We selected studies which included participants with common
mental health disorders (CMHDs) aged 18 years and over, of both
genders and all ethnic groups. We excluded studies in child and
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adolescent treatment settings, as the diagnostic categories included
within the group recognised as CMHDs are limited to adults, and
in addition the presence of a parent or other carer accompanying
a child or adolescent patient complicates the issues of who is pro-
viding responses to PROMs administered tomonitor the outcome
of treatment, and to whom feedback of the results is given.
Diagnosis
We included adult patientswith anyCMHD, includingboth those
with formal diagnoses according to the criteria of the DSM (APA
2000) or ICD (WHO1992), and those diagnosed through clinical
assessment only, unaided by formal reference to speciﬁc diagnostic
criteria. The speciﬁc disorders included were:
1. depression (including major depression, dysthymia, and
minor or mild depression);
2. mixed anxiety and depression;
3. generalised anxiety disorder (GAD);
4. phobias;
5. obsessive-compulsive disorder (OCD);
6. panic disorder;
7. post-traumatic stress disorder (PTSD);
8. adjustment reaction.
We included studies in which the diagnoses of the majority of
participants were reported as CMHDs, even if a proportion of
participants were not given a speciﬁc diagnosis, or were reported
as having relationship or interpersonal difﬁculties, ’somatoform
disorders’, ’other’ diagnoses not further speciﬁed, or ’administra-
tive codes’. This was a change from the protocol as we planned
originally to include only studies with participants speciﬁcally di-
agnosed with one of the disorders listed above, but after discussion
within the review study group we decided to include these stud-
ies in order to be able to include studies which had a majority of
participants diagnosed with CMHDs (see section on Differences
between protocol and review).
We excluded studies with more than 10% of patients diagnosed
speciﬁcally with psychoses, substance use disorders, learning dis-
orders or dementia. We also excluded studies with more than 10%
of participants diagnosed with eating disorders, as they are a sep-
arate group of disorders not usually included within the group
recognised as CMHDs, and the PROMs used for eating disorders
are less generic and speciﬁcally concentrate on eating habits and
weight control measures. This was also a change from the proto-
col as we planned to exclude studies with any participants at all
in these categories, but again, after discussion within the review
study group we decided to include studies with fewer than 10% of
participants with these diagnoses, in order once again to be able to
include studies which had amajority of participants with CMHDs
(see section on Differences between protocol and review).
Where studies did not report the diagnoses of participants, we at-
tempted to contact the authors to request information on the par-
ticipant diagnoses, and whether they would have met the review
inclusion and exclusion criteria. This was an addition to the pro-
tocol (see section on Differences between protocol and review).
We carried out sensitivity analyses omitting studies which did not
report speciﬁc diagnoses of CMHDs for 20% or more of their
participants, to determine whether these decisions affected the
ﬁndings.This was an addition to the protocol agreed once again
after discussion within the review study group (see section on
Differences between protocol and review).
Co-morbidities
Participants diagnosed with or without co-morbid physical ill-
nesses were included to ensure as representative a sample as possi-
ble.
Setting
Three settings were included: primary care (where the clinicians
were all primary care physicians and available treatments post-as-
sessment included either drug therapy or referral for psychologi-
cal therapy); multidisciplinary mental health care (where the clin-
icians included psychiatrists, psychologists, mental health social
workers ormental health nurses, and available treatments included
drugs, psychological therapies, and physical treatments); and psy-
chological therapies (where the clinicians were psychologists, so-
cial workers or nurses and available treatments were all psycholog-
ical).
Subset data
Weplanned to include trials that provided data on a relevant subset
of their participants, for example studies which compared usual
care in one armwith routine outcomemonitoring in another, even
if there was a third arm with a more complex intervention, but we
did not identify any such trials. We also planned to include trials
that included a subset of participants who met our criteria for the
review, for example in terms of the types of disorder or age range, if
the data for those participants could be extracted separately from
the rest of the trial sample, but again we did not identify any such
trials.
Types of interventions
Experimental intervention
The intervention consisted of augmenting the assessment and
management of CMHDs by both of the following.
1. Measuring patient reported outcomes (PROMs), including
self-complete or administered measures of:
i) depressive symptoms, for example the PHQ-9 (Spitzer
1999). We planned to include the HADS depression subscale
(HAD-D) (Zigmond 1983); BDI (Beck 1961) and BDI-II (Beck
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1996), but found no relevant studies which used them as
PROMs;
ii) anxiety symptoms, for example the Beck Anxiety
Inventory (BAI) (Wetherall 2005). We planned to include the
GAD-7 (Spitzer 2006) but no trials used it;
iii) health-related QoL, for example with the Medical
Outcomes Study Short Form SF-36 (Wells 1989) or SF-12
(Ware 1996). We planned to include the EuroQol ﬁve item EQ-
5D questionnaire (Dolan 1997) but no trials used it;
iv) symptoms, individual functioning, and social
functioning as composite measures, for example the 45-item
Outcomes Questionnaire (OQ-45) (Lambert 2004), and the
Outcome Rating Scale (ORS) (Miller 2003). We planned to
include the Clinical Outcomes in Routine Evaluation Outcome
Measure (CORE-OM) (Barkham 2006) but no trials used it
2. Feeding the results back to the treating clinician, to both
the clinician and the patient, or to the patient only.
We also planned to include studies using the following as PROMs
but found no relevant studies:
1. measures of depression and anxiety combined, for example
the self-complete General Health Questionnaire (GHQ-28)
(Goldberg 1972) or the administered Mini-International
Neuropsychiatric Interview (MINI) (Sheehan 1998); and
2. measures of social functioning, for example the WSAS
(Mundt 2002) or the Social Adjustment Scale (SAS) (Cooper
1982)).
Comparator intervention
The comparator was usual care for CMHDs without feeding back
the results of PROMs. Routine care includes usual patient-clini-
cian interaction with non-standardised history-taking, investiga-
tion, referral, intervention and follow-up. Trials were excluded if
the comparator interventions involved the use of feedback of the
results of PROMs as a clinical tool to inform management of the
participants. Measures of depression, anxiety, social functioning
and quality of life may have been assessed independently by re-
searchers in both the intervention and control conditions to de-
termine the effects of the intervention, but the active component,
which was the feeding back of this information to the clinician, or
to the patient, or to both clinician and patient, had to occur only
in the intervention arm.
Excluded interventions
We excluded studies where the intervention arm was subject to
additional components over and above the feedback of PROM re-
sults, including pharmacological or psychological treatments that
were not available to both the intervention and control groups.
A number of more complex interventions have been advocated to
improve the quality of care of people with CMHDs including case
management (Simon 2004) and collaborative care (Archer 2012),
and these usually include feeding back the results of PROMs at
initial assessment and follow-up to inform treatment. However,
this review was limited to the effects of feedback of the results of
PROMs alone, rather than their use as a component of complex
interventions which also enhanced the process of care through case
management, collaborative care, active outreach or other systems
or processes over and above usual care. It would not have been
possible to distinguish the effects of outcome monitoring from
other active components in such studies.
Types of outcome measures
Studies that met the above inclusion criteria were included regard-
less of whether they reported on the following outcomes.
Primary outcomes
1. Mean improvement in symptom scores
Mean improvement in symptom scores (and standardised effect
size) frombaseline to follow-up on a symptom-speciﬁc scale, which
was either:
1. an interviewer-rated measure; or
2. a self-complete questionnaire measure.
Measures used included:
1. interviewer-rated measures of depression and anxiety
including the Diagnostic Interview Schedule (DIS) for DSM-III
disorders (Robins 1981); and
2. self-complete measures including the PHQ-9 (Spitzer
1999); BDI (Beck 1961) and BDI-II (Beck 1996) for depression;
the BAI (Wetherall 2005) for anxiety; and the Hopkins
symptom checklist SCL-90 (Derogatis 1974; Derogatis 1983)
for both anxiety and depression.
We also planned to include, but found no relevant studies which
used the following as primary outcome measures:
1. the interviewer-rated Hamilton Depression Rating Scale
(HDRS or HAMD) (Hamilton 1960); Montgomery-Asberg
Depression Rating Scale (MADRS) (Montgomery 1979);
Structured Clinical Interview for DSM-IV disorders (SCID)
(First 1997); and the interviewer-rated version of the Quick
Inventory of Depressive Symptomatology (QIDS) (Trivedi
2004);
2. the self-complete Community Epidemiologic Survey
Depression (CES-D) scale for DSM-III depression (Radloff
1997); Zung depression scale (SDI) (Zung 1965); GAD-7
anxiety scale (Spitzer 2006); GHQ (Goldberg 1972); HADS
(Zigmond 1983); Hopkins symptom checklist (Derogatis 1974;
Derogatis 1983); Clinical Interview Schedule, Revised (CIS-R)
for ICD-10 disorders (Lewis 1992); and the self-complete
version of the Quick Inventory of Depressive Symptomatology
(QIDS) (Trivedi 2004).
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2. Health-related quality of life
Health-related quality of life, assessed using speciﬁc measures at
baseline and follow-up, including the SF-36 (Wells 1989).We also
planned to include the EQ-5D (Dolan 1997) but identiﬁed no
relevant trials which used it.
3. Adverse events, including:
1. numbers and types of antidepressant drug side-effects;
2. numbers of incidences of self-harm, and
3. numbers of suicides.
Secondary outcomes
4. Changes in the management of CMHDs
Changes in themanagement of CMHDs following administration
and feedback of the results of PROMs, including:
1. number of changes in drug prescribing (a new prescription,
a change in dose or type of drug, or the ending of a prescription);
2. number of referrals for psychological assessment or
treatment;
3. number of referrals for psychiatric assessment or treatment.
These are relevant secondary outcomes, as they indicate more
proactive care, which might lead to more positive outcomes, al-
though a change in management cannot by itself be regarded as
necessarily a positive outcome.
5. Social functioning
Social functioning assessed using speciﬁc measures at baseline and
follow-up, for example theWSAS (Mundt 2002).We also planned
to include the SAS (Cooper 1982) but identiﬁed no relevant trials
which used it.
6. Costs, including:
1. the direct costs of administering PROMs and delivering
feedback of the results;
2. costs to the health service, including consultations,
prescriptions, outpatient attendances and hospital admissions;
and
3. societal costs, including costs to the patient and to society
in terms of loss of employment and costs of sickness beneﬁts.
Timing of outcome assessment
We planned to divide the reporting of research outcomes into:
1. short-term, up to six months after baseline assessment; and
2. long-term, beyond six months.
Hierarchy of outcome measures
We planned to select self-complete research outcome measures in
preference to interviewer-ratedmeasures of symptoms, social func-
tioning or health-related quality of life as they are less prone to de-
tection bias due to unblinding of the researcher assessing the out-
come. In completing an interviewer-rated measure the researcher
ﬁlters all patient reported responses, while for self-complete mea-
sures only those responses which the patient chooses to discuss
with the researcher can be inﬂuenced by an unblinded researcher.
Search methods for identification of studies
The Cochrane Depression, Anxiety and Neurosis
Review Group’s Specialised Register (CCDANCTR)
The Cochrane Depression, Anxiety and Neurosis Group (CC-
DAN)maintain two clinical trials registers at their editorial base in
Bristol, UK: a references register and a studies-based register. The
CCDANCTR-References Register contains over 39,000 reports
of RCTs in depression, anxiety and neurosis. Approximately 50%
of these references have been tagged to individual, coded trials.
The coded trials are held in the CCDANCTR-Studies Register
and records are linked between the two registers through the use
of unique Study ID tags. Coding of trials is based on the EU-Psi
coding manual using a controlled vocabulary (please contact the
CCDAN Trials Search Co-ordinator for further details). Reports
of trials for inclusion in the Group’s registers are collated from
routine (weekly), generic searches of Ovid MEDLINE (1950 -),
EMBASE (1974 -) and PsycINFO (1967 -); quarterly searches of
the Cochrane Central Register of Controlled Trials (CENTRAL);
and review speciﬁc searches of additional databases. Reports of
trials are also sourced from international trials registers through
the World Health Organization’s trials portal (the Clinical Trials
Registry Platform (ICTRP)) and the handsearching of key jour-
nals, conference proceedings and other (non-Cochrane) system-
atic reviews and meta-analyses.
Details of CCDAN’s generic search strategies (used to identify
RCTs) can be found on the Group’s website.
Electronic searches
1. The CCDANCTR (References and Studies Register) was ini-
tially searched to 30 May 2014 using the following terms:
#1 (“affective disorder*” or “common mental disorder*” or “men-
tal health” or “acute stress” or adjustment or anxi* or compulsi*
or obsess* or OCD or depressi* or dysthymi* or neurosis or neu-
roses or neurotic or panic or *phobi* or PTSD or posttrauma* or
“post trauma*” or “stress disorder*” or trauma* or psychotrauma*):
ti,ab,kw,ky,emt,mh,mc
#2 PROMS
12Routine use of patient reported outcome measures (PROMs) for improving treatment of common mental health disorders in adults
(Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
#3 (“patient reported outcome*” or “patient reported assessment*”
or “patient reported symptom*”)
#4 “patient outcome*”
#5 ((patient* or client* or tailored) NEAR2 feedback)
#6 (patient* NEXT (“self assess*” or “self report” or “self moni-
tor*”))
#7 (patient* NEAR2 progress*)
#8 “client report*”
#9 ((active or routine* or regular*) NEAR2 (feedback or measure-
ment* or monitor*))
#10 (monitor* and feedback*)
#11 (“feedback to” or “feed back to” or “fed back to”):ab
#12 ((symptom* or treatment) NEXT monitor*)
#13 (monitor* NEAR2 (“common mental disorder*” or anxi* or
compulsi* or obsess* or OCD or depressi* or neurosis or neuroses
or neurotic or panic or *phobi* or PTSD or posttrauma* or “post
trauma*” or “acute stress” or “stress disorder*” or trauma*))
#14 ((follow-up* or “follow up*”) and assess*):ti
#15 (needs NEAR3 assess*)
#16 (outcome* NEAR (clinical or feedback or manag* or moni-
tor*)):ti
#17 “severity questionnaire*”
#18 severity:ti,kw,ky and (assess* ormeasure* or outcome* or ques-
tionnaire* or score*):ti
#19 (“case management” or “enhanced care”)
#20 (#2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11
or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19)
#21 (#1 and #20)
[Key. ab:abstract; emt:EMTREE headings; kw:CRG keywords; ky:
other keywords; mc:MesH check words; mh:MeSH headings]
Due to the nature of the intervention (patient reported outcome
measures) the search strategy was designed to favour speciﬁcity
(precision) over sensitivity (recall of all potentially relevant re-
ports). A sensitive search would retrieve too much noise as most
of the measures and questionnaires under review are much more
frequently used to assess symptom severity or quality of life as re-
search outcomes in treatment trials in patients with CMHDs than
as PROMs used for clinical assessment.
2. Complementary searches were conducted on the following bib-
liographic databases using relevant subject headings (controlled
vocabularies) and search syntax that were appropriate to each re-
source. Searches initially performed to 5 June 2014:
(i) Ovid PsycINFO (all years)
Although PsycINFO is routinely searched to inform the CC-
DANCTR, we conducted an additional search of this database
to increase the sensitivity of our search methods, adding wait-list
control and treatment-/care-as-usual to CCDAN’s standard RCT
ﬁlter. The search strategy is described in Appendix 1.
(ii) PROM Bibliography database (all years to 2005)
The PROM Bibliography was searched for RCTs inmental health.
This database, which is available through The Patient-Reported
Outcomes Measurement Group at the University of Oxford, was
ﬁrst published in 2002 with funding from the Department of
Health (DH). It was further developed with DH funding to 2005
and contains over 16,000 records relating to patient reported out-
come measures.
(iii) Web of Science (WoS): Science Citation Index (cited
reference search, all years as appropriate)
3. International trial registries were also searched on 19 February
2015 and 9 April 2015 via the World Health Organization’s trials
portal (ICTRP) and ClinicalTrials.gov to identify unpublished or
ongoing studies. We searched for depression OR depressive OR
mental OR psychiatric OR anxiety OR PTSD OR phobia OR
OCD AND feedback.
There were no restrictions on date, language or publication status
applied to the searches.
4. Update searches 2015
An update search was performed on 18 May 2015 to identify
additional RCTs eligible for inclusion. At this time we thought
it appropriate to validate the 2014 searches by checking the (a)
the provenance of included studies (to date) and (b) information
contained in the title,abstract and subject heading ﬁelds of study
reports in MEDLINE, EMBASE and PsycINFO. This exercise
revealed that eight of the eleven included studies (>70%)were only
identiﬁed from screening reference lists or from theWeb of Science
citation search and four of these studies made no mention of the
patients’ mental health condition. The searches were overhauled
and the PsycINFO and CCDANCTR databases re-searched all
years to 18 May 2015, together with a search of the Cochrane
Library (Appendix 2). A further citation search of WoS was also
conducted, to 27 May 2015.
5. Update searches 2016
In compliancewithMECIRconduct standard 37we ran anupdate
search within 12 months of publication (on 25 May 2016), in-
cluding the followingdatabases: PsycINFO,CCDANCTR,CEN-
TRAL, Web of Science, and the ICTRP/ClinicalTrials.gov inter-
national trial registries. These results have not yet been incorpo-
rated into the review.
Searching other resources
Grey literature
Google Scholar (top 100 hits) and Google.com were searched
(verbatim) for: “Patient Reported Outcome Measures” and “men-
tal health” and (randomised or randomized). Search results were
screened for relevant reports and reviews.
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Reference lists and correspondence
We screened reference lists (of trial reports and systematic reviews)
to identify additional studies missed from the original electronic
searches (including unpublished or in-press citations); used the
related articles feature in PubMed; and contacted other experts
and trialists in the ﬁeld for information on unpublished or ongo-
ing studies, or to request additional trial data. ’Patient reported
outcome measures’ and ’PROMs’ are relatively recently adopted
terms in the literature. For earlier studies, where the terminology
used may be ambiguous, we had to rely more on these informal
methods of discovery.
Data collection and analysis
Selection of studies
Two review authors (TK andME-G) independently screened titles
and abstracts for inclusion of all the potential studies identiﬁed
as a result of the search, coded as ’retrieve’ (eligible or potentially
eligible or unclear) or ’do not retrieve’. We resolved disagreements
through discussion and consultation with a third author (MM).
We retrieved the full-text study reports or publications and the
same two review authors independently screened the full texts,
identiﬁed studies for inclusion, and identiﬁed and recorded reasons
for exclusion of the ineligible studies. Again, disagreements were
resolved through discussion and consultationwith the third author
MM.We excluded duplicate records and collated multiple reports
that related to the same study so that each study rather than each
report became the unit of interest in the review. We recorded the
selection process in sufﬁcient detail to complete a PRISMA ﬂow
diagram (Moher 2009) and ’Characteristics of excluded studies’
table.
Data extraction and management
We designed and used a data collection form which was piloted
on one study in the review to extract study characteristics and
outcome data. Five review authors (TK, ME-G, AB, LA, ALB)
independently extracted study characteristics and outcome data
from the included studies. We extracted the following study char-
acteristics.
1. Methods: study design (cluster or individual
randomisation), total duration of study, number of study centres
and location, study setting, withdrawals, and dates of study.
2. Participants: n, mean age, age range, gender, severity of
condition, diagnostic criteria (clinical only, DSM or ICD, etc.),
inclusion criteria, exclusion criteria, and co-morbidities.
3. Interventions: intervention including the speciﬁc
instrument(s) used and whether the results were fed back to the
treating clinician only or also to the participant; whether
education about interpretation and an algorithm were also
provided; and details of treatment as usual provided to the
comparison group.
4. Outcomes: primary and secondary outcomes speciﬁed and
collected, and time points reported.
5. Notes: funding for trial, and notable conﬂicts of interest of
trial authors.
We noted in the ’Characteristics of included studies’ table if out-
come data were not reported in a usable way.We resolved disagree-
ments by consensus and also by involving a third person (MM).
Two review authors (TK, ME-G) transferred data into Review
Manager (RevMan) (RevMan 2014), and double-checked that
data were entered correctly by comparing the data presented in
the systematic review with the study reports. Another two review
authors (BS, AG) spot checked the accuracy of data extracted,
against the original study reports.
Main comparison
1. Treatment informed by feedback of patient reported
outcome measures compared with treatment as usual.
Assessment of risk of bias in included studies
Two review authors (TK and ME-G) independently assessed the
risk of bias for each study using the criteria outlined in theCochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011).
We resolved any disagreements by discussion and by involving
other authors (MM, BS, RC, SG). We assessed the risk of bias
according to the following domains:
1. Random sequence generation.
2. Allocation concealment.
3. Blinding of participants and clinicians (performance bias,
which will be high due to the nature of the intervention).
4. Blinding of researchers conducting outcome assessments
(detection bias).
5. Incomplete outcome data.
6. Selective outcome reporting.
7. Other bias.
We judged each potential source of bias as high, low or unclear
and provided supporting quotations from the study report where
available, togetherwith a justiﬁcation for our judgment in the ’Risk
of bias’ table. We summarised the risk of bias judgements across
different studies for each of the domains listed. We considered
blinding separately for different key outcomes where necessary.
Where information on risk of bias related to correspondence with
a trialist, we noted this in the ’Risk of bias’ table.
When considering treatment effects, we took into account the risk
of bias for the studies that contributed to that outcome.
Measures of treatment effect
Continuous data
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We calculated mean differences (MD) and the associated 95%
conﬁdence interval (CI) for continuous outcomes where there was
a common measure across studies, and standardised mean differ-
ences (SMD) and the associated 95% CI where different scales
were used to measure the same underlying construct. We entered
the data presented as a scale with a consistent direction of effect.
Dichotomous data
We carried out a narrative analysis to describe categorical out-
comes. See Differences between protocol and review.
Unit of analysis issues
Cluster randomised trials
Clustering by clinician, clinic, practice or service would be the
preferred design over randomising individual participants since a
clustered design reduces the risk of contamination between arms,
as the PROMs are not routinely available in the control settings
and are therefore much less likely to be used inadvertently in con-
trol patients. However, failure to account for intra-class correlation
in clustered studies is commonly encountered in primary research
and leads to a ’unit of analysis’ error (Divine 1992) whereby P
values are spuriously low, CIs unduly narrow, and statistical signif-
icance overestimated, causing type I errors (Bland 1997; Gulliford
1999). For studies that employed a cluster randomisation, we
sought evidence that clustering was accounted for by the authors
in their analyses.
Studies with multiple treatment groups
Where multiple trial arms were reported in a single trial, we in-
cluded all relevant arms that compared treatment as usual with
routine outcome monitoring.
Where we found three-armed trials that compared PROMs fed
back to the clinician only, versus PROMs fed back to both the
clinician and patient, versus treatment as usual, we divided the
control group between the two comparisons so as not to use the
same data twice, which would constitute a unit of analysis error.
However, we also performed a sensitivity analysis excluding any
trials with this three-arm design from the subgroup analysis (see
below) to see whether this signiﬁcantly affected the results of the
subgroup analysis.
Dealing with missing data
We contacted investigators in order to verify key study character-
istics and obtain missing numerical outcome data, where possible.
We documented all correspondence with trialists and report which
trialists responded below. (If standard deviations were missing, we
planned to calculate them, if possible, from the available informa-
tion reported (including 95% CIs and P values) or impute stan-
dard deviations from similar studies using the same instruments,
but in the event we did not need to do this).
Assessment of heterogeneity
Between-study heterogeneity was assessed using the I2 statistic
(Higgins 2003), which describes the percentage of total variation
across studies that is due to heterogeneity rather than chance. A
rough guide to interpretation is as follows: 0% to 40% might not
be important; 30% to 60%may representmoderate heterogeneity;
50% to 90% may represent substantial heterogeneity; and 75%
to 100% considerable heterogeneity. We investigated the sources
of heterogeneity as described below where the I2 value was greater
than 50%. Where I2 was below 50% but the direction and mag-
nitude of treatment effects suggested important heterogeneity, we
also investigated the potential sources.
Assessment of reporting biases
We created funnel plots where feasible and where there were suf-
ﬁcient studies (that is 10) (Egger 1997) to investigate possible
publication bias. Funnel plot tests for asymmetry were separately
conducted in STATA (StataCorp. 2015), using the metabias com-
mand.
Data synthesis
We undertook meta-analyses only where it was meaningful, that
is where the PROM feedback interventions, participants and the
underlying clinical question were similar enough for pooling to
make sense. We pooled change scores as a ﬁrst preference where
these were available, checking assumptions about the approximate
normality of data by ensuring that the difference between themean
and lowest or highest possible value divided by the standard devia-
tion was greater than two. Less than two would indicate some skew
and less than one would indicate substantial skew. We planned
not to attempt pooling for data that were substantially skewed and
where the skew could not be reduced by transforming the data.
We planned to describe skewed data as medians and interquartile
ranges.
We anticipated signiﬁcant heterogeneity between studies (I2 value
of over 50%) as we were including a range of CMHDs, a range of
settings, and both self-complete and administered outcome mea-
sures. Therefore we used a random-effects model when combin-
ing data to minimise the effect of heterogeneity between studies.
Where studies were combined which used outcome measures that
scored treatment effects in opposite directions, the mean values of
one set of studies were multiplied by -1 to ensure the scales iden-
tiﬁed beneﬁted in the same direction, in accordance with section
9.2.3.2 of the Cochrane Handbook (Deeks 2011).
Where cost data were presented and a formal cost-effectiveness
analysis had been undertaken, we planned simply to describe the
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methods and results. We did not plan to attempt formal statistical
pooling of cost data because studies often adopt different perspec-
tives; account for different types of cost data; use differentmethods
of discounting future healthcare costs and beneﬁts; are conducted
at different points in time; and are conducted in different coun-
tries with varying funding and reimbursement systems, making
international comparisons difﬁcult.
Subgroup analysis and investigation of heterogeneity
Weplanned to conduct the following six subgroup analyses, which
should be regarded as exploratory since they are observational and
not based on randomised comparisons. We planned to restrict
these six subgroup analyses to the three primary outcomes (namely
improvement in symptom scores, health-related quality of life, and
adverse effects).
1. Whether the setting of the study (primary care,
multidisciplinary mental health services, or psychological
therapies) inﬂuenced the success of the strategy.
2. Studies in which a formal diagnosis (according to DSM or
ICD criteria) was made prior to treatment using a validated
assessment, versus studies of participants diagnosed on clinical
assessment only, as the formally diagnosed group were likely to be
more homogeneous and more alike in their responses to PROMs.
3. Studies of participants aged 18 to 65 years versus those with
participants aged over 65 years, as the older age group may have
more complex disorders with co-morbid cognitive changes and it
is plausible that recovery follows a different pathway.
4. Studies where feedback of the results of PROMs was given
only to the clinician versus studies where feedback was given to
both clinician and participant, as the previous review by Knaup
2009 showed a greater effect when patients were also given
feedback.
5. Studies where feedback of the results of PROMs was given
only to the participating patient versus studies where feedback
was given to the clinician only, or to both clinician and patient, if
any such studies were identiﬁed (we thought this was unlikely
given the results of previous systematic reviews of outcome
monitoring in mental health, which have not identiﬁed any
studies of feedback to patients alone).
6. Studies where feedback to the clinician included treatment
instructions or an algorithm for actions to be taken for particular
results, compared to studies where feedback was limited to the
results of the PROM alone, to determine whether treatment
recommendations in addition to PROM results inﬂuenced the
results.
Post-hoc subgroup analyses
We decided post-hoc to conduct an additional subgroup analysis,
comparing studies involving Michael Lambert, the originator and
owner of the OQ-45 system, with studies not involving him, to
explore whether potential beneﬁts of the system were identiﬁed
in independent evaluations. This was because the OQ-45 was the
PROM used in the large majority of studies in the meta-analyses,
and Michael Lambert was author or co-author of a signiﬁcant
proportion of those studies (see section on Differences between
protocol and review).
We also decided during the course of the review to meta-anal-
yse results for subgroups of participants within studies who were
identiﬁed as being at higher or lower risk for treatment failure,
which was determined by the trajectory of their initial response to
therapy. The low risk group was described as ’on-track’ (OT) for
a good clinical response, and the high risk group as ’not on track’
(NOT). This was a post-hoc change to the methods which we
agreed due to the fact that several identiﬁed studies reported po-
tentially important ﬁndings in analyses of outcomes for subgroups
of OT and NOT participants. One comparison included only the
NOT subgroup, comparing outcomes in terms of symptom scores
between feedback and non-feedback arms. The second compari-
son included both the OT and NOT subgroups, comparing the
number of treatment sessions received between feedback and non-
feedback arms, and including a formal test for subgroup differ-
ences to look for evidence of differences between OT and NOT
subgroups. This was a further change from the protocol, as the
number of treatment sessions was a secondary outcome, and orig-
inally we planned to conduct subgroup analyses restricted to the
three primary outcomes, namely symptoms, health-related qual-
ity of life, and adverse effects (see section on Differences between
protocol and review).
Sensitivity analysis
Weplanned to conduct the following sensitivity analyses to explore
their effects on the results obtained in the review, and to test the
robustness of decisions made in the review process:
1. Whether the mode of administration (self-complete versus
clinician-rated) inﬂuenced the success of the strategy, by re-
analysing after removing studies using clinician-rated PROMs
and seeing whether the result was signiﬁcantly different.
2. Whether cluster randomised studies produced a different
result from non-clustered studies, to see whether possible
contamination between arms in non-clustered designs reduced
the difference between arms, by re-analysing after removing non-
clustered studies.
3. Within cluster RCTs, whether adjustment for unit of
analysis error inﬂuenced the results, to test the robustness of the
results arising from non-adjusted analyses.
4. Whether the inclusion of quasi-randomised cluster trials
signiﬁcantly affected the results, by re-analysing after removing
quasi-randomised cluster trials.
5. Whether losing the data from three-arm trials that
compared PROMS fed back to the clinician only, versus
PROMS fed back to both the clinician and patient, versus
treatment as usual, made a signiﬁcant difference to the results of
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the subgroup analysis (4 above), by excluding such trials from
the subgroup analysis.
’Summary of findings’ tables
We developed ’Summary of ﬁndings’ tables to summarise the key
ﬁndings of the review, for the populations in primary care, mul-
tidisciplinary mental health care, and psychological therapy set-
tings. We tabulated the comparisons between PROMs and usual
care in terms of effects on participant outcomes including symp-
toms, social functioning, quality of life and adverse effects; and on
the process of care including drug prescriptions and referrals. De-
cisions on which measurements to incorporate into the ’Summary
of ﬁndings’ table were based on those most relevant to clinical
practice, taking into consideration the speciﬁc nature of the scale
and also the time points at which measurements were made. We
used the GRADE criteria to assess the body of evidence for each
comparison.
R E S U L T S
Description of studies
Seventeen studies met our inclusion criteria: Amble 2014; Berking
2006; Chang 2012; De Jong 2012; De Jong 2014; Hansson 2013;
Hawkins 2004; Lambert 2001; Mathias 1994; Murphy 2012;
Probst 2013; Reese 2009a; Reese 2009b; Scheidt 2012; Simon
2012; Trudeau 2001; and Whipple 2003
Results of the search
The initial searches of CCDANCTR, OVID PsycINFO and
PROM bibliographies (to 30 May 2014) yielded 1052, 2535, and
186 references respectively (see PRISMA diagram, Figure 1). The
WoS citation search to 5 June 2014 yielded 262 references, and
we identiﬁed a further 59 references through searching the in-
ternational trial registers, screening reference lists, and personal
communication with trial authors. An updated search (to 18 May
2015) was conducted to validate identiﬁed references by re-search-
ing PsycINFO and CCDANCTR along with The Cochrane Li-
brary, which yielded a further 752 references. Following de-dupli-
cation, we screened a total of 4258 references obtained through
these searches, of which we excluded 4136 on assessment of the
title alone. Of the remaining 122, 99 were excluded on the ba-
sis of reading and discussing the abstract (80) or full-text arti-
cle (19), including 25 reviews or descriptive articles, 22 where
PROMs were not used for outcome monitoring, 19 with ineligi-
ble populations (adolescents, severe mental illness, eating disor-
ders, or substance misuse), 14 non-randomised studies, 13 which
included complex quality improvement programmes, three be-
cause we were unable to retrieve full references, and three ongoing
studies (NCT01796223; NCT02023736; NCT02095457); see
PRISMA diagram (Figure 1). Further information is given below
on the 19 studies excluded on the basis of reading and discussing
the full-text articles (see Excluded studies).
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Figure 1. PRISMA flow diagram
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In compliance with MECIR conduct standard 37 we ran an up-
date search within 12 months of publication (on 25 May 2016),
including the following databases: PsycINFO (which identiﬁed 72
references), CCDANCTR (29 references), CENTRAL (37), Web
of Science (139), and the ICTRP/ClinicalTrials.gov international
trial registries (28): in total 305, and de-duplicated 281 references.
This update search identiﬁed two additional completed studies
(Gibbons 2015 and Rise 2016) which are awaiting classiﬁcation,
and four additional ongoing studies (Metz 2015; NCT02656641;
NTR5466; and NTR5707). These results will be fully incorpo-
rated into the review at the next update (as appropriate).
The remaining 23 references described 17 included studies, of
which 13 (Amble 2014; De Jong 2012; De Jong 2014; Hansson
2013;Hawkins 2004; Lambert 2001;Murphy 2012; Probst 2013;
Reese 2009a; Reese 2009b; Simon 2012; Trudeau 2001; and
Whipple 2003)were included in quantitativemeta-analyses as they
used comparable outcome measures (either the Outcome Ques-
tionnaire (OQ-45, Lambert 2004) or Outcome Rating System
(ORS, Miller 2003), see interventions below), and the remaining
four (Berking 2006; Chang 2012; Mathias 1994; Scheidt 2012)
were included in the qualitative assessment (see PRISMA ﬂow di-
agram, Figure 1).
The results of attempts to clarify study details through contact-
ing authors are given in the table below. Contact details were un-
obtainable for the authors of Mathias 1994. Of those contacted
seven authors responded (with regard to De Jong 2012; De Jong
2014; Haderlie 2012; Hansson 2013; Hawkins 2004; Puschner
2009; Reese 2009a; Reese 2009b; and Trudeau 2001;), and the
remainder failed to respond (with regard to Chang 2012; Lambert
2001; Probst 2013; Simon 2012; and Whipple 2003).
Included studies
The individual studies are described in detail in the Characteristics
of included studies table below.
Design
Thirteen studies were randomised at the individual level and
four were cluster randomised (Chang 2012; Mathias 1994; Reese
2009b; Scheidt 2012). Fourteen studies had one intervention arm
in which feedback of patient reported outcomes was given, and
one control arm in which patients completed the measures but
the results were not fed back. De Jong 2014; Hawkins 2004; and
Trudeau 2001 included three arms: De Jong 2014 and Hawkins
2004 included two intervention arms, one in which feedback was
given to the clinician only and one where feedback was given to
both clinician and patient; and Trudeau 2001 included an addi-
tional control arm in which patients were not asked to complete
the measures at all.
Sample sizes
The number of participants per study ranged from 96 to 1629
with a total of 8787 participants. A substantial proportion of par-
ticipants were not used in data analysis due to withdrawal or loss
to follow-up, with all but two studies (De Jong 2012; Hansson
2013) utilising only a per protocol analysis. This number totaled
2650 (30.1%).
Setting
Themajority of the studies (nine)were carried out in theUSA.The
remainder were carried out in Germany (three), The Netherlands
(two), Sweden (one), Norway (one) and Ireland (one). Fifteen
studies were conducted exclusively in outpatient settings, and two,
Berking 2006 and Probst 2013, were inpatient studies. One study
(Amble 2014) included both inpatients and outpatient clinics.
Seven studies were multi-centre with the remainder conﬁned to
one site.
Two studies were based in primary care settings (Chang 2012;
Mathias 1994); nine in multidisciplinary mental health care set-
tings (Amble 2014; Berking 2006; De Jong 2012; De Jong
2014; Hansson 2013; Hawkins 2004; Probst 2013; Simon 2012;
Trudeau 2001); and six in psychological therapy settings (Lambert
2001; Murphy 2012; Reese 2009a; Reese 2009b; Scheidt 2012;
Whipple 2003).
Participants
The 17 included studies comprised 8787 randomised participants
(pre-attrition total), of whom 6137 (69.9%) provided follow-up
data and were included in the study analyses. The age of partic-
ipants ranged between 18 to 75 years, but in several studies the
range was not reported. The median age across the studies was
35.1 years. The proportion of women among participants ranged
from 58% to 73%, although there was inconsistency in report-
ing, with some studies providing the proportion of women among
participants randomised, and some the proportion among partic-
ipants included in the analysis. Reporting of demographic details
was quite variable between studies, with marital status and em-
ployment being the most commonly recorded demographics. In
studies which reported on ethnicity, the majority of participants
were white.
Fourteen studies reported speciﬁc diagnoses for their participants,
of which three used ICD diagnostic criteria (Amble 2014; Berking
2006; Scheidt 2012), and three usedDSM criteria (De Jong 2012;
De Jong 2014; Mathias 1994). The remaining studies charac-
terised participants on the basis of clinical diagnoses rather than di-
agnostic criteria. Three studies did not report the speciﬁc diagnoses
of their participants (Reese 2009a; Reese 2009b; Trudeau 2001),
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and ﬁve did not assign a speciﬁc diagnosis of a CMHD to 20%
or of their participants, reporting that they had interpersonal or
relationship difﬁculties, other diagnoses including personality or
behavioural disorders, or were given administrative codes (Amble
2014; De Jong 2014; Lambert 2001; Murphy 2012; Whipple
2003).
Interventions
Feedback was usually given in the form of scores on the PROMs,
together with information on whether this meant the participant
had improved or not. Feedback was given only to the clinician
in six studies: Chang 2012; Hawkins 2004 (one arm); Mathias
1994; Probst 2013; Scheidt 2012; and Trudeau 2001. Feedback
was given explicitly to both the clinician and participant in seven:
De Jong 2014 (one arm); Hansson 2013; Hawkins 2004 (one
arm);Murphy 2012; Reese 2009a; Reese 2009b; and Simon 2012.
In the other seven studies clinicians were permitted or encouraged
to share feedbackwith the participant: Amble 2014; Berking 2006;
De Jong 2012; De Jong 2014 (one arm); Lambert 2001; Probst
2013; and Whipple 2003.
Eight different PROMs were used across the studies, the most
commonbeing theOutcomeQuestionnaire-45 (OQ-45, Lambert
2004), a compound measure of psychiatric symptoms, individ-
ual functioning, interpersonal relations, and performance in so-
cial roles, which was used in 10 studies (Amble 2014; De Jong
2012; De Jong 2014; Hansson 2013; Hawkins 2004; Lambert
2001; Probst 2013; Simon 2012; Trudeau 2001; Whipple 2003).
As well as the OQ-45 scores, feedback was colour coded to allow
quick appreciation of the extent of change during a busy clinic. In
three of these studies (Probst 2013; Simon 2012; Whipple 2003)
additional interventions were applied in the ’not on-track’ (NOT)
groups, giving clinicians speciﬁc instructions on whether or not to
change treatment according to the results of the outcome measure,
and what further treatments to apply, known as the ’Assessment
of Signal Cases’ (ASC), and ’Clinical Support Tool’ (CST) respec-
tively.
Three studies (Murphy 2012; Reese 2009a; and Reese 2009b)
used a shorter measure derived from the OQ-45, known as the
Outcome Rating System (ORS, Miller 2003) which includes the
same domains as the OQ-45.
The duration of the treatment period was variable, being deter-
mined by the clinician or patient terminating treatment in most
studies, and so the duration of follow-up was also variable, as the
ﬁnal measure of outcome was usually collected at the last treat-
ment session.
Outcomes
Our primary outcome (mean change in symptom score) was re-
ported by all studies, but of the remaining two primary outcomes
health-related quality of life was assessed by only two of the tri-
als (Mathias 1994; Scheidt 2012), and adverse effects (includ-
ing suicide and self-harm) were also assessed by only one (Chang
2012). Changes in the management of the CMHD (pharmaco-
logical treatment and referral to secondary care) were reported by
two studies (Chang 2012; Mathias 1994), and eight studies re-
ported effects on the number of treatment sessions received by par-
ticipants (Amble 2014; De Jong 2014; Hawkins 2004; Lambert
2001; Reese 2009a; Reese 2009b; Simon 2012; Whipple 2003).
Timing of outcome assessment
All but two of the studies reported research outcomes only in the
short-term, up to six months after baseline assessment. De Jong
2014 and Scheidt 2012 also reported longer-term outcomes, after
35 weeks and 12 months respectively.
’On track’ and ’not on track’ participants
In 10 studies (De Jong 2012; De Jong 2014; Hansson 2013;
Hawkins 2004; Lambert 2001;Murphy 2012; Reese 2009a; Reese
2009b; Simon 2012;Whipple 2003) results were reported for sub-
groups of participants according to whether they were identiﬁed
early in their treatment as ’on-track’ (OT) or ’not on track’ (NOT)
for a good clinical response. The NOT group were also sometimes
labelled as ’at risk’, ’signal cases’, or ’signal alert cases’.
Excluded studies
After obtaining and assessing the full text of the report we excluded
19 studies. Six studies were non-randomised, six did not use the
PROM for outcome monitoring or did not report patient out-
comes, ﬁve included an ineligible population, and two involved
the use of a PROM as part of a more complex quality improve-
ment programme. See Characteristics of excluded studies for fur-
ther details.
Ongoing studies
We identiﬁed seven ongoing studies that ﬁtted our inclusion
criteria. Three of these studies are comparing feedback to the
therapist only with treatment as usual (TAU) (NCT01796223;
NCT02023736 and NCT02095457); two are comparing feed-
back to both therapist and participant with TAU (Metz 2015 and
NTR5466); one is comparing feedback to the participant only
with TAU (NTR5707), and one has a three-arm design com-
paring feedback to the participant only, versus feedback to the
participant and therapist, versus TAU (NCT02656641). Out-
come is being measured with the OQ-45 and Beck Depression
Inventory (BDI) in NCT02023736; with the CORE-OM rating
scale (Barkham 2006) in NCT02095457 (together with health
service utilisation and level of functioning); with the Outcome
Rating Scale (ORS) in NCT01796223 and NTR5466; with the
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PHQ-9 and GAD-7 in NCT02656641; and with the Inven-
tory of Depressive Symptomatology (IDS) plus the OQ-45 in
NTR5707. The primary outcome inMetz 2015 is the enablement
of shared decision making measured using the Decisional Con-
ﬂict Scale (DCS), but the OQ-45 outcome measure is one of the
secondary outcomes. Four studies are taking place in multidisci-
plinary mental health care settings (Metz 2015; NCT01796223;
NCT02095457; NTR5707), two in psychological therapy set-
tings (NCT02023736; NCT02656641), and one in both primary
care andmultidisciplinarymental health care settings (NTR5466).
See Characteristics of ongoing studies for further details.
Studies awaiting classification
We identiﬁed two completed andpublished studies,Gibbons 2015
and Rise 2016, which are awaiting classiﬁcation.
Gibbons 2015 cluster randomised people with depression attend-
ing a community mental health centre in Philadelphia, USA, to
eight weeks of individual therapy with either a clinician receiving
weekly feedback reports, or a clinician not receiving weekly feed-
back reports, using the BASIS-24 (24-Item Behavior and Symp-
tom Identiﬁcation Scale) as both a PROM and outcome measure.
The study reported a medium effect size in favour of the feedback
condition for symptom improvement (Effect size (Cohen’s d) =
0.50, P value = 0.017), and 36% of feedback participants com-
pared to 13% of participants in the no feedback condition demon-
strated clinically signiﬁcant change across treatment (P value =
0.013).
Rise 2016 cluster randomised outpatients attending a mental
health hospital in Norway to feed back to both client and therapist
using the PCOMS system PROMs (Outcome Rating Scale (ORS)
and Session Rating Scale (SRS)), or to care without feedback, mea-
suring outcomes with the Behaviour and Symptom Identiﬁcation
Scale 32 (BASIS-32), and Patient ActivationMeasure (PAM). The
study reported that, at 6 and 12 months after starting treatment
therewere no signiﬁcant effects on the primary outcomes ofmental
health symptoms or patient activation, but compared to baseline
assessment the PCOMS group had signiﬁcantly improved their
patient activation scores after 12 months.
See Characteristics of studies awaiting classiﬁcation for further
details.
Risk of bias in included studies
We categorised the overall risk of bias for each study, with all
studies considered at high risk of bias (a plausible presence of bias
that seriously weakens conﬁdence in the results), as one or more
domains received a judgement of high risk. In most studies, we
judged inadequate blinding and attrition at high risk of bias, see
sections below for further details. For details of the risk of bias
judgement for each study, see Characteristics of included studies.
A graphical representation of the overall risk of bias of included
studies is presented in Figure 2 and Figure 3.
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Figure 2. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Figure 3. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
Allocation
This review included studies using either an individual randomi-
sation or cluster randomisation method. The studies that were
cluster randomised may be, by method, at risk of selection bias,
where concealment of group allocation prior to obtaining consent
is not ensured, thereby increasing the likelihood that participants
allocated to the intervention group have a propensity to using
PROMs. This bias risk is not commented upon by any of those
studies using a cluster randomisation, and therefore, it is not pos-
sible to exclude a high risk of selection bias.
Sequence generation
Seven of the studies described the means to generate the allocation
sequence in sufﬁcient detail to make a favourable assessment of
whether comparable groups should be produced (Amble 2014; De
Jong 2014; Hansson 2013; Hawkins 2004; Murphy 2012; Simon
2012;Trudeau 2001). After contactwith the authors, Reese 2009a;
Reese 2009b; and De Jong 2012 were also deemed to have used
an adequate means of sequence generation, therefore in total 10
studies were judged at low risk of bias for this domain. A lack of
adequate reporting in four studies (Lambert 2001; Probst 2013;
Scheidt 2012; Whipple 2003) resulted in a judgement of unclear
risk of bias. The remaining three studies were judged at high risk
of bias for this domain, as Berking 2006 used coin tossing, and
Chang 2012 and Mathias 1994 assigned clinics and call centres,
respectively, to feedback and no-feedback groups without details
of how they were randomised.
Allocation concealment
Insufﬁcient detailswere reported regarding allocation concealment
in nine studies, rendering a judgement of unclear risk (Amble
2014; Hawkins 2004; Lambert 2001; Probst 2013; Reese 2009a ;
Scheidt 2012; Simon 2012; Trudeau 2001; Whipple 2003). Four
studies were considered at low risk of bias (De Jong 2012; De
Jong 2014; Hansson 2013; Murphy 2012), while Chang 2012;
Mathias 1994; Reese 2009b; Scheidt 2012 were considered to be
at high risk, due to their cluster randomised design.
Blinding
Due to the nature of the intervention, it is very difﬁcult to blind
the clinicians in studies ﬁtting the inclusion criteria for this review.
However, we judged the majority of the studies at high risk of
bias as the group allocation was clearly known to the participating
clinicians in all but two studies. Chang 2012 was considered to
be at low risk as participants in both arms received feedback but
the frequency of feedback varied between the two arms, and the
participants were unaware of which arm they were in. In the inter-
vention arm feedback was monthly through the six-month study
period and could therefore inﬂuence outcome, while in the con-
trol arm feedback was not provided until the end of the six-month
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period, and so could not affect outcome. Insufﬁcient details were
reported in Scheidt 2012, so the risk of bias for this study was
judged as unclear.
Similarly, the risk of bias related to blinding of outcome assessors
was judged as high for all but three of the 17 studies. In 13 studies
the PROM used for feedback was also used for outcome assess-
ment, so the participants themselves were the outcome assessors
and they were not blind to whether or not they received the inter-
vention. In the remaining three, the risk of bias was judged to be
high in one (Mathias 1994) as the researchers assessing outcome
were apparently aware of group allocation; unclear in two, as it was
not reported whether allocation was concealed from the outcome
assessors (Berking 2006; Scheidt 2012); and low in one (Chang
2012), as, although the PROM used for feedback was also used
for outcome assessment, the participants receiving the feedback
were unaware of which arm they were in.
Incomplete outcome data
The attrition rate, through loss to follow-up, was considered to
put study results at high risk of bias in all but two of the studies,
Berking 2006 and Lambert 2001. This was usually because partic-
ipants were excluded from the analysis if they did not have at least
two outcome measures completed (and sometimes three), as the
change in outcome from baseline was measured by the clinician
at the last therapy session, and there was no measure of outcome
outside the clinical setting by an independent researcher at a pre-
determined follow-up point. This may be justiﬁed in the sense
that only participants who have at least a second outcome measure
completed might be considered to have had the ’minimum dose’
of feedback necessary to examine its effects, but it means that all
of the studies except two were analysed on a per protocol basis
rather than according to intention to treat (ITT). Hansson 2013
did report an ITT analysis, and De Jong 2012 used multiple im-
putation to deal with the problem of missing data at follow-up.
Lambert 2001 reported no drop-outs, with all 609 study partici-
pants recruited apparently completing the study, but we were un-
able to conﬁrm that with the author. The risk of incomplete out-
come data was low for Berking 2006 as that study of inpatients
collected follow-up data on more than 98% of the participants.
Selective reporting
We looked for published protocols for the included studies, in or-
der to determine whether selective reporting had taken place, but
were unable to identify any. Judged from the aims and methods
described in the included study reports, the risk of selective re-
porting bias was judged to be low for nine studies (Amble 2014;
Berking 2006; De Jong 2012; De Jong 2014; Hansson 2013;
Mathias 1994; Probst 2013; Trudeau 2001;Whipple 2003), while
four were judged to have a high risk of reporting bias due to in-
complete reporting of primary outcomes (Chang 2012; Lambert
2001; Reese 2009a; Reese 2009b), and for four (Hawkins 2004,
Murphy 2012, Scheidt 2012; Simon 2012) it was unclear whether
selective reporting had taken place.
Ten studies using the OQ-45 or ORS PROMs reported results
separately for ’on track’ (OT) and ’not on track’ (NOT) subgroups
of participants, but the criteria for deﬁning these subgroups were
speciﬁedusing a priori deﬁnitions in theOQ-45 andORS systems,
and the results were usually reported for both OT and NOT sub-
groups, except for Simon 2012 which did not report data for OT
participants.
Other potential sources of bias
We did not identify any other sources of bias.
Effects of interventions
See: Summary of findings for the main comparison Treatment
informed by feedback of patient reported outcome measures
compared with treatment as usual
Comparison 1: Treatment informed by feedback of
patient reported outcome measures compared with
treatment as usual
Primary Outcomes
1.1 Mean improvement in symptom scores
Our primary analysis compared feedback to clinician (with or
without feedback to the participant in addition), to no feedback
(usual care). Pooling of patient outcome data across studies to
provide a summary estimate of effect was possible only for those
studies measuring outcome using the OQ-45 or ORS compound
outcome measures as PROMs. There was no evidence of skew,
with all values being greater than 2.
a) OQ-45 PROM
Nine studies (Amble 2014;De Jong 2012;De Jong 2014;Hansson
2013;Hawkins 2004; Lambert 2001; Probst 2013; Trudeau 2001;
Whipple 2003) including 3438 participants contributed data to
a comparison of studies using the OQ-45 as both PROM and
outcome measure. (Simon 2012 also used the OQ-45 but could
not be included as the study reported results only for ’not on track’
patients, see post-hoc analysis below). This analysis revealed no
evidence of a difference between feedback and no-feedback groups
in terms of symptom scores (mean difference (MD) -1.14, 95%CI
-3.15 to 0.86; P = 0.26, I2 = 25%), see Analysis 1.1. The evidence
for this comparisonwas considered lowquality. All but one of these
studies reported outcomes only in the short-term, up to 26 weeks
post-baseline. De Jong 2014 reported no signiﬁcant differences
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overall between outcomes for short-term (up to 35 weeks) and
long-term (35 to 78 weeks) treatment.
b) OQ-45 and ORS PROMs
We combined an additional three studies (Murphy 2012; Reese
2009a; Reese 2009b), with a further 258 participants using the
ORS as both a PROM and outcome measure with the studies
above in Analysis 1.2 (see Summary of ﬁndings for the main
comparison). Again, this analysis revealed no evidence of a differ-
ence between feedback and no-feedback groups in terms of symp-
tom scores (standardised mean difference (SMD) -0.07 95% CI-
0.16 to 0.01; P = 0.10, I2 = 30%). The evidence for this compar-
ison was also considered low quality.
c) Other outcome measures
Four studies identiﬁed used a variety of measures of global symp-
toms, depressive symptoms alone, anxiety symptoms alone, or
quality of life alone, which we judged too dissimilar to combine,
in terms of the domains measured, with the results for the OQ-
45 or ORS, which are compound outcome measures combining
symptoms, functioning and relationships, and so these four stud-
ies were not included in the meta-analyses.
Two studies in US primary care populations reported mixed ﬁnd-
ings.
Chang 2012 measured depressive symptoms using the PHQ-9
depression questionnaire as both PROM and outcome measure,
and reported a signiﬁcantly greater odds of response in terms of
changes in scores on the PHQ-9 signiﬁcant difference between
feedback (n = 364) and no feedback (n = 278) groups (odds ratio
(OR) 2.02, 95% CI 1.36 to 3.02).
Mathias 1994 developed a composite PROM, the Mental Health
Patient Proﬁle, constructed from the symptom checklist SCL-90,
diagnostic interview schedule DIS, and quality of life short form
SF-36 scales. Outcome was measured in terms of overall symptom
severity using the Global Severity Index (GSI), and anxiety symp-
toms using the Highest Anxiety Subscale Score (HASS). They re-
ported no signiﬁcant differences between feedback (n = 367) and
no feedback (n = 216) groups in either GSI or HASS. At comple-
tion of the study, the mean GSI for the feedback group was 59.90
and for no feedback 60.89, P = 0.89. Similarly, no signiﬁcant
difference between feedback and no-feedback groups was seen in
mean HASS scores (feedback group 64.72, no feedback 68.23, P
= 0.74).
The quality of evidence for these outcomes was graded as moder-
ate.
Two German studies used compound questionnaires as both
PROMs and outcome measures.
Berking 2006 used a compound questionnaire for assessing suc-
cess and course of psychotherapeutic treatment (FEV) to monitor
progress in inpatients in multidisciplinary mental health care. The
FEV included an emotionality inventory (EMI-B); a brief symp-
tom inventory (BSI); an inventory of interpersonal problems (IIP-
D); and a measure of cognitive changes (INK), and gave a com-
pound score. FEV scores were compared between feedback (n =
40) and no-feedback groups (n = 39) at the end of their inpatient
stay, and a more favourable effect was reported in the feedback
group: a change from a mean pre-study score of 2.90 (SD 0.62)
to 2.25 (0.71), compared with 2.91 (0.69) to 2.54 (0.77) in the
no feedback group.
Scheidt 2012 also used a compound comprehensive inventory of
psychometric measurement instruments to monitor psychother-
apy outpatients. Based on the scores, decision rules (’reorienta-
tion of the expert system’) were developed and optimised to guide
decisions about indications for, and prolongation of, psychother-
apy based on the feedback received (‘TK system’). The compound
measure also assessed several outcomes: a brief symptom inventory
(BSI), inventory of interpersonal problems (IIP-D), Beck Depres-
sion Inventory (BDI); and a questionnaire on body-related anx-
iety and cognitions (AKV). There was no difference seen in the
BSI between the feedback (302) and no-feedback groups (160) at
12 months post treatment (MD 1.00, 95% CI -2.22 to 4.22; P =
0.54). There was a slightly better outcome seen in the IIP-D score
in the feedback group (n = 305, control n = 158) but this was not
signiﬁcant (MD 2.30, 95% -0.37 to 4.97; P = 0.09). However, the
feedback group (n = 205) scored signiﬁcantly better on the BDI
questionnaire than the no feedback group (n = 124) (MD 4.60,
95% CI 0.79 to 8.41; P = 0.02). On assessment with the AKV,
there was no difference seen between groups (feedback n = 71,
control n = 24) (MD -1.50, 95% C.I. -7.31 to 4.31; P = 0.61).
The quality of evidence for these outcomeswas graded asmoderate
to low.
1.2 Health-related quality of life
We did not pool data for this outcome as it was reported by only
two studies.
Mathias 1994 assessed quality of life using the 36-item Short Form
(SF-36) scale. They reported no signiﬁcant difference between
feedback (n = 367) and no feedback (n = 216) groups in any of the
nine sub scales of the SF-36. Mean mental sub scale scores were
66.0 for feedback and 64.8 for no-feedback groups (P = 0.31).
Scheidt 2012 assessed quality of life using the 12-item Short Form
(SF-12) scale, reporting results for mental and physical sub scales.
There were no signiﬁcant differences seen between feedback (n =
376) and no feedback (n = 211) groups at the end of treatment,
for both physical (MD -0.90, 95%CI -3.11 to 1.31; P = 0.55) and
mental sub scales (MD 1.20, 95% CI -0.51 to 2.91; P = 0.55).
The quality of evidence for these comparisons was graded as mod-
erate to low.
1.3 Adverse events
Only one study reported any ﬁndings in relation to adverse events:
in Chang 2012, 273 PHQ-9 questionnaires elicited thoughts of
suicide or self-harm and no immediate suicide risk was discerned.
However, information on which arms these ﬁndings were in was
not provided.
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Adverse events from prescribed medication were not assessed in
any of the included studies.
Secondary outcomes
1.4 Changes in management of CMHDs
a) Changes in prescribed drug treatment
Only two studies reported differences in changes of prescribed
drug treatment. Chang 2012 showed that, at six months, 200/
352 in the feedback and 115/252 in the no feedback group had
no change in pharmacological treatment. Percentages without a
change in antidepressant therapy did not differ signiﬁcantly be-
tween study arms (OR 1.21 95% CI 0.78 to 1.88; P = 0.06).
Mathias 1994 also reported no signiﬁcant difference between feed-
back and no-feedback groups in changes in prescriptions for psy-
chotropic medications (OR 1.09, 95% CI 0.94 to 1.85).
b) Referrals
OnlyMathias 1994 assessed levels of referral to ’mental health spe-
cialists’, without distinguishing between psychiatry and psychol-
ogy referrals, and reported that referrals were signiﬁcantly more
likely in the feedback group (OR 1.73, 95% CI 1.11 to 2.70).
c) Number of treatment sessions received
An addition to the planned comparisons of changes in manage-
ment of CMHDs was made post-hoc (see Differences between
protocol and review section), namely an analysis of differences in
the mean number of treatment sessions received between feed-
back and no-feedback groups. Data from seven studies that re-
ported numbers of treatment session (Amble 2014; De Jong
2014; Hawkins 2004; Lambert 2001; Reese 2009a; Reese 2009b;
Whipple 2003) were pooled, including 2608 participants, in an
analysis which showed no evidence of a difference in the mean
number of treatment sessions between feedback and no-feedback
groups (MD -0.02 sessions, 95% CI -0.42 to 0.39; P = 0.93, I
2 = 0%), see Analysis 1.3 and Summary of ﬁndings for the main
comparison.The quality of evidence for this outcome was graded
as low.
Probst 2013 also reported no signiﬁcant differences between feed-
back and no-feedback groups in the number of weeks (rather than
sessions) of treatment received.
1.5 Social functioning
Only one study reported differences in social functioning.
Hansson 2013 found no differences between feedback and no-
feedback groups in mean scores on the sub scale of the OQ-45
relating to social functioning (feedback group (n = 136) 13.9, no
feedback group (n = 126) 14.9, P = 0.10).
1.6 Costs
No studies reported any cost data.
Subgroup analyses
2. Whether the setting of the study influenced the success of
the strategy
We could only carry out subgroup comparisons for the primary
outcome of mean improvement in symptom scores, due to the
lack of data on health-related quality of life and adverse effects.
2.1 Setting 1: Primary care
2.1.1 Mean improvement in symptom scores
Neither study from a primary care setting was included in the
meta-analyses above, as they did not use the OQ-45 or ORS, and
so could not be considered within this subgroup analysis.
2.2 Setting 2: Multi-disciplinary mental health care settings
2.2.1 Mean improvement in symptom scores
Seven studies in multidisciplinary mental health care (Amble
2014; De Jong 2012; De Jong 2014; Hansson 2013; Hawkins
2004; Probst 2013; Trudeau 2001) comprising 1848 participants
assessed the effect of the OQ-45 questionnaire as a PROM feed-
back tool. These data were pooled in a meta analysis, see Analysis
2.1.1 This showed no evidence of a difference between feedback
and no-feedback groups (SMD -0.05, 95% CI -0.18 to 0.07; P =
0.40, I2 = 37%). The quality of evidence for this comparison was
also graded as low.
2.3 Setting 3: Psychological therapies
2.3.1 Mean improvement in symptom scores
Five studies undertaken in psychological therapy service set-
tings (Lambert 2001; Murphy 2012; Reese 2009a; Reese 2009b;
Whipple 2003) comprising 1848 participants were pooled in a
meta-analysis assessing the effect of the OQ-45 or ORS as a feed-
back tool, see Analysis 2.1.2. This again showed no evidence of a
difference between feedback and no-feedback groups in terms of
symptom scores (SMD -0.10, 95% CI -0.23 to 0.03; P = 0.14, I
2 = 29%). The quality of evidence for this comparison was also
graded as low.
There was no signiﬁcant difference between the results obtained
for the subgroupof studies carried out inmulti-disciplinarymental
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health care settings and those carried out in psychological therapy
settings (test for subgroup differences: Chi² = 0.23, df = 1 (P =
0.63), I² = 0%).
3: Whether participants who had a formal diagnosis made
using ICD or DSM criteria were likely to do better than
those where no formal diagnosis was made
3.1 Mean improvement in symptom scores
In three studies within the meta-analysis (Amble 2014; De Jong
2012; De Jong 2014), including 1144 participants, the partici-
pants were given formal diagnoses. There was no evidence of a dif-
ference between feedback and no-feedback groups (SMD -0.01,
95% CI -0.23 to 0.21), see Analysis 3.1.1 and no evidence of ben-
eﬁt was observed in the subgroup analysis limited to the nine stud-
ies in which no formal diagnoses were given (SMD -0.08, 95% CI
-0.15 to 0.00; P = 0.06, I2 = 0%), see Analysis 3.1.2. There was
no signiﬁcant difference between the subgroup of studies where a
formal diagnosis was given and those without a formal diagnosis
(test for subgroup differences: Chi² = 0.28, df = 1 (P = 0.60), I²
= 0%). The quality of evidence for these outcomes was graded as
low.
4: Studies of participants aged 18 to 65 years versus those
with participants aged over 65 years
This planned subgroup comparison was not possible as no studies
distinguished subgroups of participants in the two age categories.
5: Studies where feedback was given only to clinicians versus
studies where feedback was given to both clinicians and
participants
5.1: Mean improvements in symptom scores
Feedback was given only to the clinician in six studies: Chang
2012; Hawkins 2004 (one arm); Mathias 1994; Probst 2013;
Scheidt 2012; and Trudeau 2001. Feedback was given explicitly to
both the clinician and patient in seven: De Jong 2014 (one arm);
Hansson 2013; Hawkins 2004 (one arm); Murphy 2012; Reese
2009a; Reese 2009b; and Simon 2012. In the other seven studies
clinicians were permitted or encouraged to share feedback with
the patient: Amble 2014; Berking 2006; De Jong 2012; De Jong
2014 (one arm); Lambert 2001; Probst 2013; and Whipple 2003.
Subgroup analyses showed no evidence of differences in outcomes
between these three groups as the conﬁdence intervals overlapped
for all analyses (a formal statistical test for difference between sub-
groups was not carried out as some studies contributed data to
more than one subgroup, potentially violating the assumption of
independence). See Analysis 4.1.
6: Studies where feedback of PROM results was given only to
the participants and not to the clinicians
This planned subgroup analysis was not possible as no studies were
identiﬁed in which feedback was given only to participants and
not to clinicians.
7: Studies where feedback to the clinician included
treatment instructions or an algorithm in addition to a score
on a PROM
7.1 Mean improvement in symptom scores
Two studies in the meta-analysis, including 1184 participants,
included treatment instructions in the form of a clinical support
tool (CST) for those found to be not on track (NOT): Probst
2013 and Whipple 2003. (Simon 2012 also included a CST but
provided data only for theNOTparticipants). A subgroup analysis
comparing these two with the remainder showed no signiﬁcant
differences in either subgroup (test for subgroup differences: Chi²
= 0.64, df = 1 (P = 0.42), I² = 0%). For those studies with a CST:
SMD -0.03 (95% CI -0.14 to 0.09; P = 0.66, I2 = 0%), compared
to: SMD -0.09 (95% CI -0.20 to 0.02; P = 0.11, I2 = 38%) for
those studies without a CST, see Analysis 5.1.1 and 5.1.2.
Post-hoc sub-group analysis of studies involving Michael
Lambert, the originator of the OQ-45 PROM and feedback
system, versus studies not involving him
8.1 Mean improvement in symptom scores
Six studies included in this review involved Michael Lambert as
either ﬁrst author or co-author. There was no signiﬁcant difference
in the overall ﬁndings in terms of outcomes observed between a
subgroup of ﬁve studies which included him as an author (see
Analysis 6.1.1) and four which did not (Analysis 6.1.2) (test for
subgroup differences Chi² = 0.18, df = 1 (P = 0.67), I² = 0%).
Post-hoc analyses of subgroups of ’on track’ and ’not on
track’ participants
1. Improvement in symptom scores among ’not-on-track’ participants
Ten studies including 923 participants identiﬁed participants who
were considered ’not on track’ (NOT), ’at risk’, or ’signal alert cases’
early on during their treatment, and provided separate data for
these participants, see Analysis 7.1. Symptom scores were slightly
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lower in the feedback group compared to the no feedback group in
this subgroup (SMD = -0.22, 95% CI -0.35 to -0.09; P = 0.001,
I2 = 0%). The quality of evidence for this comparison was graded
as low.
2. Number of treatment sessions received: ’on track’ and ’not on track’
participants
Five studies reported differences in the number of treatment ses-
sions received between feedback and no-feedback groups for NOT
participants. Data from De Jong 2014; Hawkins 2004; Lambert
2001; Reese 2009b and Whipple 2003 were pooled in a meta-
analysis which demonstrated no evidence of a difference in the
mean number of therapy sessions received (see Analysis 7.2). In
addition, Probst 2013 reported that for the NOT subgroup of
participants, there was no signiﬁcant difference between feedback
and no-feedback groups in the number of weeks (rather than ses-
sions) of treatment received: 6.22 (SD 3.29) compared to 5.49
(3.17), P = 0.46. Four studies (De Jong 2014; Lambert 2001;
Reese 2009b; Whipple 2003) reported differences in the amount
of therapy received between feedback and no-feedback groups for
the subgroup of ’on track’ (OT) participants only. Themean num-
ber of treatment sessions was slightly fewer in the feedback group:
(MD -0.69, 95% CI -1.10 to -0.29; P = 0.0007, I2 = 0%). How-
ever, a formal test for subgroup differences revealed no signiﬁcant
difference between ﬁndings for OT and NOT participants (chi2
= 0.99, df = 1 (P = 0.32), I2 = 0%, see Analysis 7.2). The quality
of evidence for this comparison was also graded as low.
Sensitivity analyses
The following planned sensitivity analyses were not possible:
1. Whether the mode of administration (self-complete versus
clinician-rated) inﬂuenced the success of the strategy, because the
main analysis did not include any studies using clinician-rated
PROMs.
2. Whether cluster randomised studies produced a different
result from non-clustered studies, because the main analysis
included only one cluster randomised study, Reese 2009b.
3. Within cluster RCTs, whether adjustment for unit of
analysis error inﬂuenced the results, again because the main
analysis included only one cluster randomised study, and Reese
2009b did report that the results were adjusted for clustering.
4. Whether the inclusion of quasi-randomised cluster trials
signiﬁcantly affected the results, because the main analysis did
not include any quasi-randomised cluster trials.
The only sensitivity analysis which could be carried out was:
5. Whether losing the data from three-arm trials (that compared
PROMs fed back to the clinician only, versus PROMs fed back
to both the clinician and participant, versus treatment as usual),
made a signiﬁcant difference to the results of the subgroup analysis,
by excluding such trials from the subgroup analysis.
Two studies (De Jong 2014; Hawkins 2004) included the three
arms.Nodifferencewas seen in the overall resultwhen these studies
were omitted altogether from themeta-analysis: (SMD-0.02, 95%
CI -0.011 to 0.07; P = 0.68, I2 = 39%), although the direction
of the treatment effect was slightly more in favour of the feedback
group. Excluding the two studies which included three arms did
not make a difference to the subgroup analysis which still showed
no signiﬁcant difference between the subgroups (test for subgroup
differences: Chi² = 1.92, df = 2; P = 0.38, I² = 0%).
Post-hoc sensitivity analysis: unreported or
incomplete diagnoses of study populations
Three studies included in themeta-analyses did not report the spe-
ciﬁc diagnoses of their participants (Trudeau 2001; Reese 2009a;
Reese 2009b), and ﬁve did not assign a speciﬁc diagnosis of a
CMHD to 20% or more of their participants (Lambert 2001;
Whipple 2003; Murphy 2012; De Jong 2014; Amble 2014). A
sensitivity analysis of themeta-analysis of studies using theOQ-45
(Analysis 1.1) omitting Lambert 2001; Trudeau 2001; Whipple
2003; De Jong 2014 and Amble 2014 showed no evidence of a
difference in the overall result (MD -0.94, 95% CI -3.67 to 1.78).
Similarly, a sensitivity analysis of the meta-analysis of studies us-
ing either the OQ-45 or ORS (Analysis 1.2), omitting all eight
studies, showed no evidence of a difference (SMD -0.03, 95% CI
-0.12 to 0.06).
Exploration of heterogeneity
We found I2 values between 30% and 69%, indicating moderate
to signiﬁcant heterogeneity, in our main meta-analysis of the dif-
ference in outcome feeding back OQ-45 or ORS scores versus no
feedback, and in seven of our subgroup analyses. Investigating the
sources of heterogeneity in these comparisons, we found that they
nearly all included Amble 2014 which reported distinctly positive
ﬁndings. The authors reported that only 25% of the therapists
employed at their clinics agreed to participate, which is a small
proportion compared to the other studies included, which usually
involved all or most of the therapists working in a service. Also,
three quarters of the participants included were seen in the clinic
where the project leader and main coordinator worked, underlin-
ing “the importance of having a dedicated local advocate monitor-
ing and following up the procedures for using a feedback system”
(Amble 2014, p.6). It seems likely therefore that the therapists
seeing clients in that study were self-selected for their enthusiasm
for routine monitoring.
Reporting Bias
Funnel plots conducted for publicationbias in relation to themeta-
analyses of outcomes measured using the OQ-45 only (Analysis
1.1) and OQ-45 plus ORS (Analysis 1.2), are shown in Figure 4
and Figure 5 respectively. The Egger test (Egger 1997) indicated
that there was no evidence of publication bias in Analysis 1.1 (P
= 0.499) or Analysis 1.2 (P = 0.512).
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Figure 4. Funnel plot of comparison: 1 Difference in outcome feeding back OQ-45 or ORS scores versus no
feedback, outcome: 1.1 Mean improvement in symptom scores: OQ-45 PROMS.
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Figure 5. Funnel plot of comparison: 1 Difference in outcome feeding back OQ-45 or ORS scores versus no
feedback, outcome: 1.2 Mean improvement in symptom scores: OQ-45 or ORS PROMs.
D I S C U S S I O N
Summary of main results
In terms of improvements in the outcome of CMHDs, we found
no evidence of a difference between feedback and no-feedback
groups in ourmeta-analysis of 12 studies using theOQ-45 orORS
PROMs. We also found no evidence of an effect on the manage-
ment of CMHDs in terms of the number of treatment sessions
participants received, in an analysis combining the results of seven
studies using theOQ-45 or ORS (see Summary of ﬁndings for the
main comparison). However, because the evidence we identiﬁed
is of low quality, we are uncertain about this result, and further
research is very likely to have an important impact on our conﬁ-
dence in the estimate of effect and is likely to change the estimate.
The majority of the eligible studies we identiﬁed were conducted
in multidisciplinary mental health care settings (nine) or psycho-
logical therapy settings (six). We identiﬁed only two eligible stud-
ies conducted in primary care settings, and we were unable to in-
clude them in our meta-analyses as they measured research out-
comes with single symptom, global improvement, or quality-of-
life domains, which were different to the OQ-45 and ORS which
are compound outcome measures combining symptoms, social
functioning and interpersonal relationships. A qualitative assess-
ment of the two primary care studies showed conﬂicting ﬁnd-
ings: Chang 2012 found a signiﬁcant difference in outcome but
Mathias 1994 found none, while Mathias 1994 found signiﬁcant
effects on the management of CMHDs but Chang 2012 found
none (see Summary of ﬁndings for the main comparison).
We did ﬁnd a difference in outcomes favouring feedback, but
with a small effect size (a standardised mean difference of -0.22),
in a post-hoc meta-analysis including only the subgroup of ’not
on track’ (NOT) participants monitored in 10 studies using the
OQ-45 or ORS PROMs. We also found a small reduction in
the number of treatment sessions received for the ’on-track’ (OT)
subgroup in another post-hoc analysis of four studies using the
OQ-45 or ORS (a mean difference of -0.69 sessions), but a formal
test of subgroup differences revealed no evidence of a difference in
the number of treatment sessions received between OT and NOT
subgroups of patients.
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Overall completeness and applicability of
evidence
Most of the outcomes that we anticipated might be affected were
not addressed by the majority of studies. Health-related quality of
life, social functioning, and adverse events were each considered
only in one or two studies, while the costs of intervention were
not considered in any (see Summary of ﬁndings for the main
comparison). Similarly, most studies did not report changes in the
management of CMHDs in terms of drug treatment or referrals
to other specialities, and only a minority reported effects on the
number of sessions of treatment received by participants. We were
therefore unable to answer all the questions we set out to address.
The meta-analyses we conducted included studies in multidisci-
plinary mental health care and psychological therapy settings only,
with no inclusion of studies in primary care, as both primary
care studies we identiﬁed used outcome measures with different
domains which were not directly comparable to the OQ-45 or
ORS.The evidence we have been able to analyse is therefore largely
limited to the effects of compound PROMsmeasuring psycholog-
ical symptoms, functioning, and relationships in one instrument
rather than single domain instruments, and in multidisciplinary
mental health care and psychological therapy settings, rather than
in primary care. This is unfortunate given that the large majority
of people with CMHDs are treated in primary care, if they receive
treatment at all (McManus 2009), at least in countries with well
developed systems of primary care. This contrasts with the rela-
tively large number of studies which have been conducted using
patient reported measures for screening and initial identiﬁcation
of CMHDs in primary care (Gilbody 2008). Our ﬁndings are
therefore consistent with those of Shaw 2013, who concluded that
there is a lack of evidence to support recommendations for routine
monitoring of people with CMHDs using PROMs in primary
care.
It is perhaps not surprising that most of the studies have been
conducted in psychological therapy or multidisciplinary mental
health care settings, given that people attending these services have
a relatively more homogeneous set of presenting problems, and
the service staff have a relatively homogeneous professional back-
ground, because the services are limited to mental health prob-
lems. Introducing routine outcome monitoring of CMHDs in
primary care is more challenging, given that primary care deals
with the whole range of initially undifferentiated physical, mental
and social problems, and so only a minority of people seen in that
setting will have CMHDs. In services dedicated to psychological
therapies and mental health it is likely to be easier to train staff
to routinely administer PROMs to all attending patients, and de-
velop efﬁcient administrative systems and information technology
to support monitoring, whereas in primary care staff ﬁrstly have to
decide which patients have CMHDs and then whether to admin-
ister PROMs when relevant, and developing systems to deal with
routine outcome monitoring may be regarded as less worthwhile
when the patients to be monitored are in a minority. It is ques-
tionable therefore whether any beneﬁts identiﬁed from routine
outcome monitoring in psychological therapy or mental health
care settings can be extrapolated to primary care, as patient en-
gagement, the development of routine systems for administering
PROMs, and the technical resources and healthcare professional
training required to interpret them, may all be more challenging
in the primary care setting where only a proportion of patients
present with CMHDs.
Quality of the evidence
We rated the quality of the evidence, summarised in Summary
of ﬁndings for the main comparison, as low or moderate. The
main reasons for the low quality rating were limitations in study
design, with regard to lack of blinding of clinicians, participants
and outcome assessors; attrition; and indirectness of the evidence.
All of the included studies were judged to be at high risk of bias and
so we exercise caution in our interpretation of the ﬁndings based
on the low to moderate quality observed. Speciﬁc considerations
are discussed below.
Limitations in study design and implementation
The quality of evidence in almost all studies was downgraded due
to issues of blinding. Chang 2012 was the only study that exe-
cuted a study design that blinded clinicians and participants to
the differences in frequency and timing of feedback between in-
tervention and control arms, and this study was not included in
any of the meta-analysis. Due to the absence of such blinding,
most studies were considered high risk with respect to this do-
main (see Figure 2). Additionally, all but three studies were judged
at high risk of bias when considering the blinding of outcome
assessors, as in most studies the PROMs used for feedback were
also used for outcome assessment. Shimokawa 2010 called this the
“monomethod”, and it increases the risk of observer rating bias,
as the therapist using the PROM as a clinical intervention can
potentially inﬂuence the research outcome when it is based on the
same PROM. Only one study, Chang 2012 was judged to be at
low risk of bias for outcome assessment as, although the PROM
used for feedback was also used for outcome assessment, the study
was cluster randomised and participants receiving the feedback
were not aware of the two conditions operating.
Problems contacting several of the study authors meant no clariﬁ-
cation could be obtained regarding randomisation and blinding,
so we could not upgrade the evidence for these studies.
A signiﬁcant proportion of the participants were lost to follow-
up, around 30% altogether, and in all but two studies a per pro-
tocol analysis was carried out. Only two studies, Berking 2006
and Lambert 2001, were graded at low risk of bias as there was no
attrition at all reported in these two studies. Per protocol analyses
were usually conducted because the PROM was used not only as
the clinical intervention but also tomeasure the research outcome,
and there was no independent follow-up by researchers after par-
ticipants had completed therapy.
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Consistency of effect
The effect of treatment across the studieswas fairly consistent, with
minimal heterogeneity observed in the main analyses. The effect
of feeding back PROMs was modest and present in most studies
and any inconsistency was minimal within a small and overall
insigniﬁcant treatment effect. Heterogeneity was more apparent
in those subgroup analyses which included Amble 2014, which
was unusual in demonstrating an apparently high level of clinician
commitment to using PROMs.
Imprecision of the results
The evidence was not downgraded for imprecision in Summary of
ﬁndings for the main comparison as the sample sizes exceeded the
optimal information size with resultant narrow conﬁdence inter-
vals. However, due to the limitations of study design and imple-
mentation, we have been cautious in interpreting the precision of
results overall. Precision was reduced in the analysis of subgroups
of OT and NOT participants although this is to be expected due
to the reduced sample size for each subgroup.
Indirectness of the results
The review included studies involving several groups of partici-
pants: primary care patients, clients attending for psychological
therapies, and clients under the care of multidisciplinary health-
care teams, both as inpatients and outpatients. A broad spectrum
of participants was therefore included, but only two studies were
based in primary care, and pooling of data was not possible for
these studies as they used PROMs which did not measure the
same domains as those used in psychological therapy and multi-
disciplinary mental health care settings. The OQ-45 compound
outcome measure was used in 10 of the included studies and the
ORS, which was derived from the OQ-45, was used in another
three. The preponderance of studies using these scoring systems
means we have minimal evidence on which to base judgements
of the use of other, quicker to administer, single domain PROMs
such as the PHQ-9 which is widely used in the USA (HRSA 2005)
and UK (IAPT 2011).
All included studies provided outcome data on the change in
symptom scores, but it was disappointing that most of the other
outcomes pre-speciﬁed for this review were not considered by the
trials identiﬁed. Numbers of treatment sessions were reported in
half of the studies, but other important indicators of changes in
management such as drug prescription changes or referral for fur-
ther treatment were reported in only two, and consideration of
adverse events, social functioning, and estimates of costs, were al-
most completely lacking. Consequently, the quality of evidence
has to be rated as low in relation to the indirectness of the results.
Publication bias
The funnel plots (Figure 4; Figure 5) and Egger tests for publi-
cation bias suggest publication bias was not an issue in this re-
view. However it must be noted that there were only just sufﬁcient
numbers of studies to be considered for a formal publication bias
assessment.
Potential biases in the review process
We carried out a comprehensive search for eligible studies, us-
ing multiple electronic databases, followed up with searching of
reference lists, citation searches, and contact with study authors
who identiﬁed further studies in some cases, in particular Kim de
Jong who was therefore invited to be a co-author. We were also
able to include two German studies, as we recruited Anna Brütt,
who is German, as a co-author to help with data extraction. How-
ever, all but two of the studies identiﬁed were published after the
year 2000, apart from Brody 1990 andMathias 1994, which gives
cause for concern that we might have missed studies published
in the period 1994-2000. Although thorough and comprehensive
searches were performed to identify all potential studies for inclu-
sion, the searches were initially very inefﬁcient due to the rather
non-speciﬁc terms ’feedback’ and ’monitor*’ capturing many pa-
pers which were not actually about using feedback as an interven-
tion to monitor patients’ progress. This became more apparent
on running the citation searches which yielded further study re-
ports which were not originally identiﬁed. We were also unable to
contact study authors in a number of cases, in particular Michael
Lambert who was a co-author on six studies, who might have been
able to identify further studies for us. It is possible therefore that
we failed to identify relevant studies.
A number of studies did not characterise a signiﬁcant proportion of
their participants in terms of underlying diagnoses, as indicated in
the Characteristics of included studies section, and in three studies
no diagnoses were reported at all (although the lead authors con-
ﬁrmed the largemajority participants hadCMHDs).We intended
to include samples without a formal diagnosis, as they are com-
mon especially in the psychological therapy setting, but we also
made post-hoc decisions to include studies where 20% or more
of participants were reported to have relationship or interpersonal
problems, or received administrative codes only, as long as the ma-
jority of those diagnosed were given a diagnosis of a CMHD, and
as long as fewer than 10% were diagnosed with a severe mental
illness, substance misuse, learning difﬁculty, dementia, or eating
disorder. The lack of speciﬁc diagnoses for many participants is
a signiﬁcant limitation of the available literature, and we recom-
mended that future studies characterise the diagnoses of all their
participants systematically.
Agreements and disagreements with other
studies or reviews
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Our results are less positive in terms of favouring the routine
use of PROMs than those reported in an earlier meta-analysis of
three studies in psychological therapy settings using the OQ-45
(Lambert 2003), which reported a small but signiﬁcant overall
positive effect on outcome (an effect size of 0.09), and a larger
signiﬁcant positive effect in the subgroup of NOT participants
(effect size of 0.39, compared to 0.22 in our analysis). However,
Lambert 2003 included a study (Lambert 2002) which we judged
non-randomised as it used ’historical controls’ (i.e. it used archived
data from clients previously treated in the clinic as control data,
rather than randomising subjects to a control arm) and was there-
fore excluded from our analysis, as non-randomised studies confer
a greater risk of bias.
Our ﬁndings also differ from those of Knaup 2009, who reported
an overall signiﬁcant positive effect of routine monitoring on out-
comes (effect size 0.10) from a meta-analysis of 12 studies in mul-
tidisciplinary mental health care and psychological therapy set-
tings. Knaup 2009 also reported a greater effect size (0.30) for
studies including feedback of PROM results to patients than for
those where feedback was given only to the clinician (0.09), which
we did not ﬁnd. However, Knaup 2009 included only ﬁve of the
studies included in our review (Berking 2006; Hawkins 2004;
Lambert 2001; Trudeau 2001;Whipple 2003), and a further seven
studies which were excluded from this study, including two non-
randomised studies (Lambert 2002; Slade 2008), and ﬁve which
were conducted with people with eating disorders or severe mental
illness. Again, non-randomised studies confer a greater risk of bias,
and studies including people with severe mental illness might be
more positive, as patients’ symptoms are more severe, so the poten-
tial for improvement is greater than among people with CMHDs,
where a possible ’ﬂoor effect’ might limit the potential to show a
beneﬁt from monitoring with PROMs.
More positive ﬁndings than ours were also found by Shimokawa
2010 in an update of the Lambert 2003 meta-analysis, which
added three more studies using the OQ-45, and reported an over-
all effect size of 0.12 in favour of outcome monitoring. They also
reported a larger effect size among the NOT subgroup of partici-
pants, of 0.28, in an intention to treat (ITT) analysis utilising last
observations carried forward (LOCF), and an even larger effect
size among NOT participants in a per protocol analysis, of 0.53.
However, three of the six studies included in Shimokawa 2010
were not randomised trials (Harmon 2007; Lambert 2002; Slade
2008), as they used ’historical controls’ and so again were excluded
from our analyses due to the increased risk of bias. We were unable
to carry out any corresponding ITT analyses using LOCF data, as
we could not obtain further data from study authors for several of
the studies we included.
Another possible reason for differences between our review and
the earlier reviews is that ours included later studies which did not
involve the originators of theOQ-45 system, whose authors might
therefore have had less allegiance to the system, and less adherence
to its founding principles, thereby diluting its effects.However, we
found no evidence of differences between intervention and control
groups in a post-hoc subgroup analysis of the results of ﬁve studies
authored or co-authored by Michael Lambert, the originator of
the OQ-45 system, which was similar to the ﬁndings among four
studies which did not involve him.
Our ﬁndings are consistent with those of a more recent system-
atic review of studies limited to the use of the OQ-45 or ORS
in psychological therapy settings (Davidson 2014), which also
concluded that the beneﬁt of feedback monitoring appeared to
be limited to NOT participants, although Davidson 2014 did
not conduct a meta-analysis. Their review also included the three
studies with historical controls (Harmon 2007; Lambert 2002;
Slade 2008), as well as a study of people with substance misuse
(Crits-Christoph 2012), and one of people with eating disorders
(Simon 2013), all of which were ineligible for inclusion in this
review. Davidson 2014 pointed out, as we have, that many studies
were of low quality due to methodological issues.
Our ﬁndings relating to the primary care setting are also consistent
with those of Shaw 2013, the main ﬁnding being a distinct lack of
research on the monitoring of CMHDs with PROMs in primary
care when comparedwithmultidisciplinarymental health care and
psychological therapy settings. We were able to identify only two
trials (one of which, Chang 2012, was considered by Shaw 2013),
which reported conﬂicting ﬁndings in terms of impacts on the
outcome and management of CMHDs. Our ﬁndings in primary
care settings are also consistent with Gilbody 2002 who failed to
identify a positive impact of patient-centred outcome instruments
assessing patient needs or quality of life in non-psychiatric settings.
Our ﬁndings are less positive than those ofCarlier 2012 andPoston
2010 which both included studies of the use of PROMs as screen-
ing or diagnostic tools together with studies of their use as follow-
up monitoring measures, and so were not directly comparable.
They are more consistent with Boyce 2013, Marshall 2006 and
Valdera 2008, who all found the evidence of beneﬁt from moni-
toring with PROMs to be weak, although again they are not di-
rectly comparable to our review, as they included studies of the
use of PROMs in the management of physical disorders as well
as studies in mental health care. Carlier 2012 recommended fur-
ther research was needed in mental health care, a recommendation
we make below. Boyce 2013 and Valdera 2008 pointed out that
most of the studies they identiﬁed suffered from methodological
limitations, as we have found in this review, and that there was
signiﬁcant heterogeneity.
Heterogeneity in this review was apparently related to clinician
commitment to using PROMs, as the outstandingly positive ﬁnd-
ing was found by Amble 2014 in which therapists self-selected
as participants for their interest in using the OQ-45 PROM. De
Jong 2012 looked at therapist variables that moderated feedback
effects, and found that improved outcomes in NOT patients were
associated with greater commitment to using feedback, perceived
validity of feedback, and self-efﬁcacy among participating thera-
pists.
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Other factors which have been suggested by Krageloh 2015 as
important in explaining differences in the ﬁndings between trials
include: having a formalised structure which maximises the like-
lihood that feedback is discussed with clients; the use of comput-
erised support tools; greater frequency of feedback; and whether
PROMs are discussed with clinicians, although Krageloh 2015 did
not conduct any meta-analyses to support those suggestions. We
found no difference in outcome between our subgroup analysis of
two studies where a clinical support tool (CST) was used to guide
responses to scores on the OQ-45, compared to the remaining
studies without CSTs. It has also been suggested that feedback
given to both clinicians and patients is more effective than feed-
back to clinicians alone (De Jong 2012; Hawkins 2004; Knaup
2009), but we did not ﬁnd that to be the case in our analyses of
three subgroups: feedback limited to the clinician; feedback which
could be shared with the patient; and feedback routinely provided
to the patient as well as the clinician.
Our ﬁndings may be contrasted with those of a Cochrane review
of collaborative care for depression and anxiety disorders, which
found that, compared to usual care, it was associated with signif-
icant improvement in symptoms, quality of life, and patient sat-
isfaction (Archer 2012). Collaborative care usually includes feed-
ing back the results of PROMs at initial assessment and follow-
up to inform treatment, but collaborative care includes a number
of other active components such as medication management and
increased liaison between healthcare professionals, and the process
of measuring and feeding back patient outcomes was actually the
control condition in some trials of collaborative care interventions
(Archer 2012).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
On the basis of this review, no ﬁrm conclusions can be drawn
about the effects of routine monitoring of patients with common
mental health disorders using patient reported outcome measures.
The meta-analyses including all participants monitored with the
OQ-45 or ORS PROMs across both psychological therapy and
multidisciplinary mental health care settings found very small dif-
ferences between the feedback and no-feedback groups in terms
of outcome, which may not be clinically meaningful (see below).
There was no difference in management in terms of the number
of treatment sessions received by participants overall.
The two studies conducted in primary care which were not in-
cluded in the meta-analyses showed conﬂicting ﬁndings in terms
of both outcome and changes in management, and the lack of
studies conducted in primary care means no conclusions can be
drawn about the likely value of routine outcome monitoring in
that setting.
This review therefore provides little support for policy recommen-
dations in the UK and USA that people with CMHDs should
be routinely monitored using PROMs (HRSA 2005; IAPT 2011;
NICE 2011b). In particular we agree with Davidson 2014 that
the available trial evidence, coming largely from the USA and Eu-
rope, and mostly using the compound OQ-45 or ORS outcome
measures, has limited generalisability to the IAPT psychological
therapy settings in the UK, where routine outcome monitoring
of hundreds of thousands of people with CMHDs takes place ev-
ery year using a range of single domain PROMs (HSCIC 2015).
Our ﬁndings are also consistent with those of Shaw 2013, who
concluded there is a lack of evidence to support recommendations
for routine monitoring of people with CMHDs with PROMs in
primary care.
The low quality of evidence found means we are uncertain about
these results however, and further research is very likely to have an
important impact on our conﬁdence in the estimate of effect, and
is likely to change the estimate.
Implications for research
More trials of routine outcome monitoring in CMHDs using
PROMs are needed, particularly in primary care settings in the
UK and elsewhere, where most people with CMHDs are treated,
and should include more people treated with antidepressants as
well as those treated with psychological therapies, since antide-
pressants are the commonest treatments for CMHDs provided in
primary care (Kendrick 2009). PROMs which have fewer items,
such as the ORS or PHQ-9, may be preferable due to the ease
with which they can be completed by patients and results fed back
to the treating clinician in very time-limited primary care or low
intensity psychological therapy consultations.
Future trials should not limit the measurement of outcome
to the data on psychological symptoms, individual functioning
and interpersonal relationships provided by the PROMs used as
the monitoring intervention (the ’monomethod’ as described by
Shimokawa 2010). Instead blinded outcome assessors should col-
lect additional data, independently of the treating clinicians, on
symptoms and functioning, and also on possible harms, health-
related quality of life, social functioning, and costs of the interven-
tion. Studies should characterise their participants systematically,
in terms of diagnoses, using standard classiﬁcations such as the
ICD or DSM criteria.
Post-hoc analyses of subgroups of participants identiﬁed early in
treatment as either ’on-track’ (OT) or ’not on track’ (NOT) for a
good clinical response suggest that monitoring with theOQ-45 or
ORS might improve outcomes for NOT participants, and reduce
the number of sessions received by OT participants, but the effect
sizes were small, and the quality of evidence for these effects was
graded as low. The identiﬁed improvement in outcome for NOT
participants of a standardised mean difference of -0.22 equates to
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a reduction in OQ-45 score of around 4 to 6 points, which is of
questionable clinical signiﬁcance, given the total score on theOQ-
45 ranges from 0 to 180, and a difference of 14 points is judged to
represent meaningful change (Lambert 2004). No signiﬁcant dif-
ferences between feedback and no-feedback groups in the propor-
tions of patients achieving clinically signiﬁcant change on theOQ-
45 or ORS PROMs were reported in most of the studies identiﬁed
(De Jong 2014; Hawkins 2004; Lambert 2001; Murphy 2012;
Reese 2009a; Reese 2009b; Simon 2012), although the numbers
of patients achieving signiﬁcant change in either group were small,
and the studies lacked power to determine differences. One iden-
tiﬁed study (Whipple 2003) did report that signiﬁcantly more
patients in the feedback plus clinical support tool (CST) group
achieved clinically signiﬁcant or reliable change than the no-feed-
back group. Future studies recruiting larger samples are needed to
address the clinical signiﬁcance of any beneﬁts found.
The identiﬁed mean reduction in length of treatment received
by OT participants of 0.69 sessions might improve the efﬁciency
of treatment overall, through enabling targeting of therapist time
more appropriately to NOT patients, but again the overall dif-
ference was small, and none of the studies collected information
about costs in relation to the intervention and its effects, so the
cost-effectiveness of the approach has not yet been assessed. It
should be stressed that these ﬁndings among NOT and OT sub-
groups of participants are the results of post-hoc analyses which
were not planned in our original protocol, and should be regarded
as hypothesis-forming rather than hypothesis-testing, requiring
examination in future, larger, and better-designed studies.
Study designs should be developed which reduce the bias due to
patient and clinician awareness that routine outcome monitoring
is being applied in the intervention arm, although we acknowl-
edge it is impossible to blind participants and treating clinicians
completely since they are being asked to consider the results of
PROMs fed back to them. Designs such as Chang 2012 used,
which vary the amount and timing of feedback of PROM results,
may be helpful in reducing such bias, in addition to utilising a
different outcome measure from the PROM being used as the in-
tervention to assess change in symptom scores.
Independent assessment of research outcomes by staff who are not
involved in treating the patients should improve outcome assess-
ment, at a speciﬁed interval, and reduce the relatively high attri-
tion rates found when follow-up is left entirely to the treating clin-
ician, and no data are collected on patients who do not return. To
reduce bias due to incomplete follow-up, researchers should also
consider using multiple imputation or other methods to deal with
missing data, and report intention to treat in addition to per pro-
tocol analyses. Studies are also needed which determine long-term
outcomes beyond six months, as only two studies in this review
included longer term follow-up.
These measures will make studies more complicated and more
costly to conduct, but are needed to address the signiﬁcant problem
of the low quality of evidence overall on the routine outcome
monitoring of CMHDs using PROMs.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Amble 2014
Methods Study design: Individual randomised controlled trial
Setting: 2 inpatient clinics and 4 outpatient clinics in mental health care institutions
Country: Norway
Participants Diagnosis:
• 47% Affective disorder
• 33% Anxiety disorder
• 7% ADHD
• 4% Substance abuse
• 4% Eating disorders
• 3% Personality disorders
• 1% Schizophrenia
• 1% No diagnosis
Method of diagnosis: Routine diagnosis by the treating therapist, using the ICD-10
Age: Mean age 35.8, SD 11.6, range 18-65
Sex: 231 (68%) female
Number: 377 invited, 340 accepted, 321 randomised, (feedback group 174, controls
147), of whom 259 (81%) were followed up (feedback group 144, controls 115)
Inclusion criteria:
• Attending IP or OP psychiatric clinic for a minimum of two sessions and willing
to complete outcome measures.
Exclusion criteria:
• Fewer than 2 outcome questionnaire administrations
• Inability to complete the OQ-45
Co-morbidities:
• Not stated
Losses to follow-up/withdrawal: 19 excluded as incorrectly randomised;
62 (19%) failed to complete follow-up outcome measures:
14 in the feedback group failed to complete the initial OQ-45, 15 in the non-feedback
group
16 in the feedback group only completed one OQ-45 questionnaire, 17 in the non-
feedback group
Demographics considered: Not stated, beyond age and gender
Ethnicity: Not stated
Interventions PROM used as intervention: Outcome Questionnaire 45 (OQ-45)
Participants were randomly assigned to either:
1) Feedback to therapist
Duration: variable, number of clinic visits determined by therapist
Therapist given feedback prior to seeing participant. (Therapist free to discuss feedback
with participant)
2) Control group
Duration: variable, number of clinic visits determined by therapist
The comparison group also completed OQ-45s but their scores were kept hidden from
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the therapists and participants
Outcomes Time points for assessment: at last clinic visit
Outcomes of the trial (as reported):
• Change in OQ-45 total score*
• Proportions recovered, improved, unchanged, and deteriorated
• Effect of clinic type on outcome
Subgroups: Effect of being a ’signal’ case (not on track) examined in general linear
modelling
*outcomes prespeciﬁed for this review
Notes Dates of study: Inclusion period June 2010-September 2013
Funding: Not stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “patients were randomized into the FB or
NFB conditions in blocks of 8 and by gen-
der” (p3)
Allocation concealment (selection bias) Unclear risk No details provided
Blinding of participants and personnel
(performance bias)
All outcomes
High risk “The OQ-Analyst software provides the
therapist and patient with a report showing
the session-by-session progress” (p3)
Blinding of outcome assessment (detection
bias)
All outcomes
High risk ThePROMused for feedbackwas also used
for outcome assessment, so the participants
themselves were the outcome assessors and
they were not blind to whether or not they
received the intervention
Incomplete outcome data (attrition bias)
All outcomes
High risk 19% failed to complete the outcome mea-
sure, with an imbalance between groups
(30/174 (17%) in feedback group versus
32/147 (22%) in the non-feedback group
Selective reporting (reporting bias) Low risk No evidence of selective reporting found
Other bias Unclear risk Only 25% of the therapists employed at
the clinics agreed to participate, and three
quarters of the patients included were seen
in the clinic where the project leader and
main coordinator worked, suggesting that
the therapists seeing clients in that study
were self-selected for their enthusiasm for
44Routine use of patient reported outcome measures (PROMs) for improving treatment of common mental health disorders in adults
(Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Amble 2014 (Continued)
routine outcome monitoring
Berking 2006
Methods Study design: Individual randomised controlled trial
Setting: Inpatient psychotherapy
Country: Germany
Participants Diagnosis:
• 33% Depressive disorders
• 23% Anxiety disorders
• 19% Adjustment
• 25% not recorded
Mean (SD) number of F-diagnoses according to ICD-10: Intervention group 1.59 (0.
90), Control group 1.66 (0.89)
Method of diagnosis: Clinician diagnosis according to ICD-10
Age: mean 49.41 years, SD 8.63. Range not reported
Sex: 73 (61.9%) female
Number: 118 randomised, (58 intervention group, 60 control group)
Inclusion criteria: Consecutive admissions to inpatient psychotherapy
Exclusion criteria: Not reported
Co-morbidities: Not reported
Losses to follow-up/withdrawals: None (all inpatients, ﬁnal assessment conducted at
discharge)
• Pre data sets: Intervention group: 88%, Control group: 78%. Pre data sets for
CGI, VEV: Intervention group: 98%, Control group: 100%
• Post data sets: Intervention group: 81%, Control group: 77% Post data sets for
CGI, VEV: Intervention group: 97%, Control group: 98%
Demographics considered: Age and gender only
Ethnicity: Not reported
Interventions PROM used as intervention: Questionnaire for assessing success and course of psy-
chotherapeutic treatment (FEV)
Participants were randomly assigned to either:
Intervention group (58): Mean values of FEV at admission were converted into T-
scores and were presented together with the percentage of goal attainment (agreed on at
admission) on a feedback form
Feedback was provided to therapists the following working day. Feedback to clinician
only, but they were allowed to discuss results with participants
Control group (60): No feedback to clinician or participant
Outcomes Outcomes:
• Set of short forms for assessing success and course of psychotherapy* FEV and
FEP: Fragebögen zur Erfassung von Erfolgen und Verläufen psychotherapeutischer
Behandlungen (Lutz et al., 2006) including: Short form of Emotionalitätsinventar
(EMI-B); Short form of Brief Symptom Inventory (BSI); Short form of Inventar zur
Erfassung Interpersonaler Probleme (IIP-D); and Short form of
Inkongruenzfragebogens (INK)
45Routine use of patient reported outcome measures (PROMs) for improving treatment of common mental health disorders in adults
(Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Berking 2006 (Continued)
• Clinical Global Impression (CGI)
• Changes in experience and behaviour (VEV: Veränderungen des Erlebens und
Verhaltens)
Time points for assessment: FEV and FEP values were assessed at admission, 2 days
later and on a weekly basis. CGI and VEV were assessed at discharge
*outcomes prespeciﬁed for this review
Notes Dates of study: Not stated
Funding: Not stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Quote: “Der Randomisierungsprozess er-
fasste alle Patienten und erfolgte per
Münzwurf” (tossing a coin) p.23
Allocation concealment (selection bias) High risk Quote: “Der Randomisierungsprozess er-
fasste alle Patienten und erfolgte per
Münzwurf” (tossing a coin) p.23
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not possible to blind participants and per-
sonnel due to the nature of the intervention
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
Low risk • Pre data sets: Intervention group:
88%, Control group: 78%. Pre data sets
for CGI, VEV: Intervention group: 98%,
Control group: 100%
• Post data sets: Intervention group:
81%, Control group: 77% Post data sets
for CGI, VEV: Intervention group: 97%,
Control group: 98%
Selective reporting (reporting bias) Low risk No evidence of selective reporting found
Other bias Low risk No other perceived bias
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Chang 2012
Methods Study design: Cluster randomised controlled trial
Setting: Primary care across 74 sites
Country: USA
Participants Diagnosis: Major depressive disorder
Method of diagnosis: Not speciﬁed
Age: Intervention group, M = 46.6 (SD = 15.0); control group, M = 45.3 (SD = 15.4);
range = 18-65+
Sex: 216 Male, 425 Female, 274 not reported
Number: 915 randomised, 642 in analysis (364 intervention group, 278 control group)
Inclusion criteria:
• Physician diagnosis of major depressive disorder
• Being capable of self-management
• Sufﬁcient comprehension of English to complete surveys and telephone interviews
Exclusion criteria:
• Antidepressant use within previous 120 days
• Baseline PHQ score < 5
• Bereavement < 8 weeks prior to enrolment
• Current postpartum depression or pregnancy
• Need for psychiatric hospitalisation at enrolment visit
• History of psychotic disorder
• History of bipolar disorder
• History of suicide attempts or current suicide plan
• Previous electroconvulsive therapy
• Previous vagus nerve stimulation
• Previous transcranial magnetic stimulation
• Previous magnetic seizure therapy
• Previous deep brain stimulation
Co-morbidities:
• Anxiety disorder
• Chronic pain
• ’Other co-morbidity’
Losses to follow-up/withdrawals:
• Intervention group 139/503 (27.6%). Did not complete follow up surveys = 42,
did not participate in 6 month interview = 81. Baseline PHQ < 5 = 16
• Control group 134/412 (32.5%). Did not complete baseline survey = 1, did not
complete follow up surveys = 85, did not participate in 6 month interview = 42.
Baseline PHQ < 5 = 6
Demographics considered:
• Region
• Urbanicity
• Type of insurance
• Employment status
• Education
• Marital status
Ethnicity:
• White 484 (75.4%)
• Black 110 (17.1%)
• Asian 7 (1.1%)
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• Native Hawaiian or Paciﬁc Islander 2 (0.3%)
• American Indian or Alaska native 8 (1.2%)
• Hispanic/Latino 74 (11.6%)
• Other 32 (5.0%)
(Patients could indicatemultiple options for ethnicity; groups are notmutually exclusive)
Interventions PROM used as intervention: PHQ-9
Participants were randomly assigned to either:
Intervention group (503)
Duration: 6 months, number of clinic visits determined by physician
PHQ-9 scores of each participant faxed to physicians on a monthly basis along with
previous scores obtained, percentage change in baseline score, criteria for interpreting
the results, general reminders and possible treatment adjustments
Control group (412)
Duration: 6 months, number of clinic visits determined by physician
PHQ-9 scores of each participant faxed to physicians after 6 months (end of study
period) along with previous scores obtained, percentage change in baseline score, criteria
for interpreting the results, general reminders and possible treatment adjustments
Outcomes Time points for assessment: (7), Baseline, months 1-6
Outcomes of the trial (as reported):
• Remission (PHQ score < 5)*
• Response (PHQ score reduced by at least 25%)*
• Pharmacological treatment patterns*
• Reports of self harm/suicide*
• Physician use of interview results
*outcomes prespeciﬁed for this review
Notes Dates of study: 2009-2010
Sources of funding: Bristol-Myers Squibb, Otsuka Pharmaceutical Co., Ltd
Characteristics and data obtained from both Chang 2012 (primary reference) and Yeung
2012
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk “Investigator sites were alternately (1:1)
cluster-assigned to usual care and interven-
tion arms prior to patient enrolment.” (p.
106)
We judged this at a high risk of bias due to
the alternate assignment of sites
Allocation concealment (selection bias) High risk See comments above in ’Random sequence
generation’
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Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Physicians were blinded as to which study
arm their practice was assigned to, and
all physicians were not informed of the
frequency at which patient status reports
would be delivered for either arm.” (p. 867
Yeung 2012). We judged this as adequate
blinding given the study design
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcome was measured using the PROM
used for feedback, but “Physicians were
blinded as to which study arm their prac-
tice was assigned to, and all physicians were
not informed of the frequency at which pa-
tient status reports would be delivered for
either arm” (p. 867 Yeung 2012)
Incomplete outcome data (attrition bias)
All outcomes
High risk Per protocol analysis performed - 273/915
(29.9%) participants not included. Imbal-
ance in numbers excluded between groups
Selective reporting (reporting bias) High risk The CGI-S and PGI-S were both recorded
at baseline and different time points
throughout the study but not reported.
They were not used as interventions but
should have been reported as outcomes. See
p. 867 Yeung 2012 for full details
No response was forthcoming from the au-
thors on enquiring about these data
Other bias Low risk No other perceived bias
De Jong 2012
Methods Study design: Individual randomised controlled trial
Setting: 3 outpatient clinics in 2 mental health care institutions
Country: Netherlands
Participants Diagnosis:
• 24% Mood disorder
• 22% Adjustment disorder
• 22% Anxiety disorder
• 7% Personality disorder
• 3% Eating disorder
• 3% Diagnosed in childhood
• 2% Substance related
• 2% Somatoform disorder
• 2% Impulse control disorder
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De Jong 2012 (Continued)
• 11% Other diagnoses
Method of diagnosis: Routine diagnosis by the treating therapist, using the DSM-IV
Age: Mean age 36.8, SD 12.0, range not given
Sex: 61% female
Number: 544 randomised, (feedback group 269, controls 275), of whom 413 (76%)
were followed up (feedback group 206, controls 207)
Inclusion criteria
• Attending OP psychotherapy clinic for a minimum of 3 sessions and willing to
complete outcome measures
Exclusion criteria
• Fewer than 3 outcome questionnaire administrations
• Psychotic disorder
• Mental retardation
• Current crisis at time of referral
• Non-verbal treatment
• Group therapy as main treatment
• Re-referral within same treatment centre within 6 months
• Insufﬁcient command of Dutch
Co-morbidities
• 8% Personality disorder
• 37% Multiple Axis 1 disorders
• 24% Comorbidity Axis 1 and 2
Losses to follow-up/withdrawal: 131 failed to complete baseline or 3 follow-up out-
come measures
Feedback group: < 3 sessions of treatment (24), < 33% OQ-45 administration (21)
, stopped completing OQ-45 questionnaires before session 3 (13), baseline OQ-45
missing (5)
Control group: < 3 sessions of treatment (30), < 33% OQ-45 administration (17),
stopped completing OQ-45 questionnaires before session 3 (17), baseline OQ-45 miss-
ing (4)
Demographics considered: Marital status, education
Ethnicity: Not stated
Interventions PROM used as intervention: Outcome Questionnaire 45 (OQ-45)
Participants were randomly assigned to either
1) Feedback to therapist
Duration: variable, number of clinic visits determined by therapist
Therapist given feedback prior to seeing client. (Therapist free to discuss feedback with
participant)
2) Control group
Duration: variable, number of clinic visits determined by therapist
The comparison group also completed OQ-45s but their scores were kept hidden from
the therapists and participants
Outcomes Time points for assessment: collected at every visit for ﬁrst 5 visits, then every 5 visits
for a year and at last clinic visit
Outcomes of the trial (as reported):
• Rate of change of OQ-45 total score*
• Reliable change (change >14 points)
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Subgroups: Intervention and control groups were sub-divided into ’on-track (OT)’, and
’not on track (NOT)’, and rate-of-change results reported separately for two subgroups
*outcomes prespeciﬁed for this review
Notes Dates of study: Not stated
Funding: Not stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Author reported that participants were as-
signed completely at random to feedback
or no feedback using the feedback software
Allocation concealment (selection bias) Low risk Author reported that participants were not
aware of their condition, unless therapists
in the feedback group decided to discuss
the feedback with the participant - this was
explicitly allowed
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not possible to blind clinicians and study
personnel due to the nature of the inter-
vention
Blinding of outcome assessment (detection
bias)
All outcomes
High risk ThePROMused for feedbackwas also used
for outcome assessment, so the participants
themselves were the outcome assessors and
they were not blind to whether or not they
received the intervention
Incomplete outcome data (attrition bias)
All outcomes
High risk High rates of attrition:
• Feedback group 63/269 (23%) did
not complete 3 PROMs
• Control group 68/275 (25%) did
not complete 3 PROMs
Selective reporting (reporting bias) Low risk No evidence of selective reporting found
Other bias Low risk No other perceived bias
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De Jong 2014
Methods Study design: Individual randomised controlled trial
Setting: Outpatient clinics in mental health care institutions or private practices
Country: Netherlands
Participants Diagnosis:
• 27% Mood disorder
• 18% Adjustment disorder
• 10% Anxiety disorder
• 14% Relational problems (V codes)
• 18% Other diagnoses
• 13% No diagnosis
Method of diagnosis: Routine diagnosis by the treating therapist, using the DSM-IV
Age: Mean age 38.2, SD 12.0, range not given
Sex: 68% female
Number: 604 randomised, (therapist feedback only 205, therapist and patient feedback
207, controls 192), of whom 475 (79%) were followed up (therapist feedback only 159,
therapist and patient feedback 172, controls 144)
Inclusion criteria:
• Attending OP psychotherapy clinic for a minimum of three sessions and willing
to complete outcome measures
Exclusion criteria:
• Fewer than three outcome questionnaire administrations
Co-morbidities:
• 39% Personality disorder
• 46% Comorbidity within axis 1
• 37% Comorbidity axes 1 and 2
Losses to follow-up/withdrawal: 129 failed to complete the three outcome measures
Demographics considered: Education beyond high school
Ethnicity: Not stated
Interventions PROM used as intervention: Outcome Questionnaire 45 (OQ-45) and message com-
paring current OQ-45 total score, baseline score, and cut-off score for normal function-
ing
Participants were randomly assigned to either:
1) Feedback to therapist only
Duration: variable, number of clinic visits determined by therapist
Therapist given feedback prior to seeing client. (Therapist free to discuss feedback with
participant)
2) Feedback to therapist and participant
Duration: variable, number of clinic visits determined by therapist. Participants received
the same feedback as the therapists
3) Control group
Duration: variable, number of clinic visits determined by therapist
The comparison group also completed OQ-45s but their scores were kept hidden from
the therapists and participants
Outcomes Time points for assessment: at last clinic visit. Analyses were conducted for subgroups
of short-term (up to 35 weeks) and long-term (35-78 weeks) therapy
Outcomes of the trial (as reported): Rate of change of OQ-45 total score*
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Subgroups: intervention and control groups were sub-divided into ’on-track (OT)’, and
’not on track (NOT)’, and rate-of-change results reported separately for NOT subgroups
only
*outcomes prespeciﬁed for this review
Notes Dates of study: 1 July 2006- 30 June 2011
Funding: Netherlands Organization for Health Research and Development (ZonMW)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “the online feedback system allocated the
patient to one of the three conditions” The
author reported that block randomisation
was used to ensure each clinician had par-
ticipants in all three conditions
Allocation concealment (selection bias) Low risk “the online feedback system allocated the
patient to one of the three conditions”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not possible to blind participants and per-
sonnel due to the nature of the intervention
Blinding of outcome assessment (detection
bias)
All outcomes
High risk ThePROMused for feedbackwas also used
for outcome assessment, so the participants
themselves were the outcome assessors and
they were not blind to whether or not they
received the intervention
Incomplete outcome data (attrition bias)
All outcomes
High risk High rates of attrition:
• Feedback to therapist group 46/205
(22%) did not complete 3 PROMs
• Feedback to therapist and
participant group 35/207 (17%) did not
complete 3 PROMs
• Control group 48/192 (25%) did
not complete 3 PROMs
Selective reporting (reporting bias) Low risk No evidence of selective reporting found
Other bias Low risk No other perceived bias
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Hansson 2013
Methods Study design: Individual randomised controlled trial
Setting: Psychiatric outpatients: 2 sites in Malmö
Country: Sweden
Participants Diagnosis:
• Depression 119 (32%)
• Bipolar disorder 29 (8%)
• Anxiety syndrome 94 (25%)
• Personality disorder 45 (12%)
• Other diagnoses 14%
• Missing/no diagnosis 32 (9%)
Method of diagnosis: Not speciﬁed
Age: Mean (SD): 38 (12.8) intervention group, 39 (14.1) control group
Sex: 274 (73%) female, 100 (27%) male
Number: 374 randomised (188 intervention group, 186 control group), all in ITT
analysis; 262 followed up and in per protocol analysis (136 intervention group, 126
control group)
Inclusion criteria:
• Clinic attenders with mental disorders
Exclusion criteria:
• Substance use disorders
• Schizophrenia
• Other psychotic disorders
Co-morbidities: Not stated
Losses to follow-up/withdrawals:
• Intervention group 52/188 (28%) did not complete follow up PROM
• Control group 60/186 (32%) did not complete follow-up PROM
Demographics considered:
• Employment status
• Marital status
Ethnicity:
• 32/238 (13%) with Social Insurance System data not born in Sweden
Interventions PROM used as intervention: Outcome Questionnaire 45 (OQ-45) with feedback to
both therapist and client
Participants were randomly assigned to either:
1) Intervention group (188)
Duration: variable, number of clinic visits determined by therapist
Therapist received a feedbackmessage showing total score onOQ-45, the subscales and a
diagram of treatment progress. Therapist could read feedback prior to seeing participant.
Participant received feedback via treatment progress diagram
2) Control group (186)
Duration: variable, number of clinic visits determined by therapist
Participants completed OQ-45 but no feedback to clinician or participant
Outcomes Time points for assessment: Each clinic visit, reported at last clinic visit
Outcomes of the trial (as reported):
• Total OQ-45 scores*
• Symptom distress sub scale scores*
• Interpersonal difﬁculties sub scale scores*
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• Social function sub scale scores*
• Frequency of OQ-45 scores representing alert status
*outcomes prespeciﬁed for this review
Notes Dates of study: 12 February 2007 to 10 February 2008
Source of funding: A grant from the Improved process for reporting of illness in Skåne,
Skåne County Council; the Skåne County Council’s Research and Development Foun-
dation and the Swedish Social Insurance Agency, Malmö
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Two different versions (feedback
and control) of patient information were
put into envelopes in a pre-randomized or-
der. The randomization list was prepared
using a computer program, which assigned
the patient to one of the two groups at ran-
dom”
Allocation concealment (selection bias) Low risk Quote: “The sealed envelopes were avail-
able at the reception and handed out in the
same order as the patients were registered.”
“Everyone involved - patient, receptionist,
therapist and researcher - were blinded to
the allocation”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not possible to blind participants and per-
sonnel due to the nature of the intervention
Blinding of outcome assessment (detection
bias)
All outcomes
High risk ThePROMused for feedbackwas also used
for outcome assessment, so the participants
themselves were the outcome assessors and
they were not blind to whether or not they
received the intervention
Incomplete outcome data (attrition bias)
All outcomes
High risk High rates of attrition:
• Intervention group 52/188 (28%)
did not complete follow up PROM
• Control group 60/186 (32%) did
not complete follow-up PROM
However, ITT analysis performed as well
as per protocol
Selective reporting (reporting bias) Low risk ITT analysis performed as well as per pro-
tocol
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Other bias Low risk No other perceived bias
Hawkins 2004
Methods Study design: Individual randomised controlled trial
Setting: Psychotherapy clinic
Country: USA
Participants Diagnosis:Axis Imood disorders (74%) and anxiety disorders (21%); 65 (32%) received
two diagnoses
Method of diagnosis: Routine diagnosis by the treating therapist
Age: Mean age 30.8, SD 10.5, range not given.
Sex: 137 female, 64 male, 112 not reported
Number: 313 randomised, of whom 201 were followed up (therapist feedback only 70,
therapist and client feedback 67, controls 64)
Inclusion criteria:
• Attending OP psychotherapy clinic for a minimum of 2 sessions and willing to
complete outcome measures
Exclusion criteria:
• Failure to attend for a second session
• Prescribed new medications or a change in medications during treatment
Co-morbidities: Not stated
Losses to follow-up/withdrawal: 108 failed to attend for a second session, 1 was re-
moved by the therapist because it was thought the feedback was potentially detrimental,
and 3 declined to complete the outcome measure and removed themselves from the
study
Demographics considered: Marital status, employment status
Ethnicity:
• 190 (94%) white
• 3 (1.5%) African American
• 3 (1.5%) Hispanic/Latino
• 2 (1%) Asian American
• 3 (1.5%) Paciﬁc Islander/other
Interventions PROM used as intervention: Outcome Questionnaire 45 (OQ-45) and algorithm on
recommended actions as a function of number of treatment sessions provided and level
of distress; 13 different instructions for therapists and 9 for clients
Participants were randomly assigned to either:
1) Feedback to therapist only
Duration: variable, number of clinic visits determined by therapist
Therapist received feedback that included 4 colour codes with actions recommended for
each (white: consider termination; green: no change; yellow: consider altering treatment;
red: review and decide on new course of action). Therapist given feedback prior to seeing
client
2) Feedback to therapist and client
Duration: variable, number of clinic visits determined by therapist
3) Control group
Duration: variable, number of clinic visits determined by therapist
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Hawkins 2004 (Continued)
The comparison group also completed OQ-45s but their scores were kept hidden from
the therapists and clients
Outcomes Time points for assessment: at last clinic visit
Outcomes of the trial (as reported):
• OQ-45 total score*
• Proportion with reliable change in score (14+) reported for ’NOT’ subgroup only
• Proportion with clinically signiﬁcant change in score (to below 64/180) reported
for ’NOT’ subgroup only
• Outcome of potential treatment non responders
• Effect of feedback on amount of psychotherapy
Subgroups: Both intervention and control groups were sub-divided into ’on-track (OT)
’, i.e. green or white coded, and ’not on track (NOT)’, i.e. yellow or red coded, and
extent of change results reported separately for NOT subgroup only
*outcomes prespeciﬁed for this review
Notes Dates of study: Not stated
Source of funding: Not stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Patients were assigned to treat-
ment conditions using a randomized block
design, with therapists serving as the block-
ing variable”
Allocation concealment (selection bias) Unclear risk Nodetails available, no response to enquiry
to author
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not possible to blind participants and per-
sonnel due to the nature of the intervention
Blinding of outcome assessment (detection
bias)
All outcomes
High risk ThePROMused for feedbackwas also used
for outcome assessment, so the participants
themselves were the outcome assessors and
they were not blind to whether or not they
received the intervention
Incomplete outcome data (attrition bias)
All outcomes
High risk 112/313 participants (35.8%) were ex-
cluded from the analysis (108 did not at-
tend at least one follow-up session after ini-
tial assessment, 3 did not complete the out-
comemeasures, and 1was removed by their
therapist)
57Routine use of patient reported outcome measures (PROMs) for improving treatment of common mental health disorders in adults
(Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Hawkins 2004 (Continued)
Selective reporting (reporting bias) Unclear risk Reliable change and clinically signiﬁcant
change results not reported for ’on-track
(OT)’ subgroup
Other bias Unclear risk Clients started on medication, or receiving
a change in medication, during treatment
were excluded
Lambert 2001
Methods Study design: Individual randomised controlled trial
Setting: University counselling centre
Country: USA
Participants Diagnosis: 80% diagnosed, of whom:
• 27% mood disorder
• 14% adjustment disorder
• 9% anxiety disorder
• 5% somatoform disorder
• 19% V-code diagnosis
• 26% a variety of other disorders
• 20% undiagnosed
Method of diagnosis: Routine diagnosis by the treating clinician
Age: Mean 22.23 years, range 17-57
Sex: 427 female, 183 male
Number: 609 randomised (307 intervention group, 302 control group), all followed up
and in per protocol analysis
Inclusion criteria:
• Consecutive centre clients who had at least one follow-up appointment
Exclusion criteria:
• None stated
Co-morbidities: Not stated
Losses to follow-up/withdrawal: None reported
Demographics considered: Not stated
Ethnicity:
• 88% white
• 4% Hispanic
• 3% Paciﬁc Islander/Asian
• 5% mixed
Interventions PROM used as intervention: Outcome Questionnaire 45 (OQ-45) and algorithm on
recommended actions. Feedback to clinician (but could be shared with client and was
in some cases at least by all but 6 therapists)
Participants were randomly assigned to either:
1) Intervention group (307)
Duration: variable, number of clinic visits determined by therapist
Therapist received feedback that included 4 colour codes with actions recommended for
each (white: consider termination; green: no change; yellow: consider altering treatment;
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Lambert 2001 (Continued)
red: review and decide on new course of action) Therapist given feedback prior to seeing
client
2) Control group (302)
Duration: variable, number of clinic visits determined by therapist
The comparison group also completed OQ-45s but their scores were kept hidden from
the therapists and clients
Outcomes Time points for assessment: collected at baseline, weekly and at last clinic visit
Outcomes of the trial (as reported):
• OQ-45 total score*
• Proportion with reliable change in score (14+)
• Proportion with clinically signiﬁcant change in score (to below 64/180)
• Effect of feedback on amount of psychotherapy
• Exploratory analyses of timing of feedback
• Assessment of therapist experience of recipient of feedback
Subgroups:Both intervention and control groups were sub-divided into ’on-track (OT)
’, i.e. green or white coded, and ’not on track (NOT)’, i.e. yellow or red coded, and
results reported separately for each subgroup within intervention and control arms
*outcomes prespeciﬁed for this review
Notes Dates of study: Enrolment from October 1998-April 1999
Source of funding: University funded
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: ”Approximately half (n = 307)
were randomly assigned to the experimen-
tal (feedback) group andhalf (n =302)were
randomly assigned to the control (no feed-
back) group’
Allocation concealment (selection bias) Unclear risk Quote: ’Approximately half (n = 307) were
randomly assigned to the experimental
(feedback) group and half (n = 302) were
randomly assigned to the control (no feed-
back) group’
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not possible to blind participants and per-
sonnel due to the nature of the intervention
Blinding of outcome assessment (detection
bias)
All outcomes
High risk ThePROMused for feedbackwas also used
for outcome assessment, so the participants
themselves were the outcome assessors and
they were not blind to whether or not they
received the intervention
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Lambert 2001 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk According to the paper, 609 were ran-
domised and all were included in the anal-
ysis without a single dropout (we were un-
able to conﬁrm this with the author)
Selective reporting (reporting bias) High risk Clinically signiﬁcant change details not
provided for on-track participants (major-
ity of participants)
Other bias Low risk No other perceived bias
Mathias 1994
Methods Study design: Cluster randomised controlled trial
Setting: Primary care (Health Maintenance Organisation (HMO))
Country: USA
Participants Diagnosis:
Method of diagnosis: Diagnostic Interview Schedule (DIS) for the DSM-III-R
Age: Mean 42 yrs (SD 10) in intervention group; 44 (11) in controls. Range 21-65
Sex: 336 female, 237 male, 45 not reported
Number: 618 randomised (389 intervention, 229 control)
Inclusion criteria:Symptomsof anxiety and depression onHopkins SymptomChecklist
(SCL-90) above ‘threshold’ on two occasions
Exclusion criteria: Previously diagnosed mental health condition or received treatment
in the past 6 months
Co-morbidities: 394 (69%) had co-morbidities; not speciﬁed further
Losses to follow-up/withdrawals:
• 45 (7.3%) dropped out: (32 (8.2%) intervention, 13 (5.7%) control)
Demographics considered:
• Gender
• Age
• Education
• Income
• Marital status.
Ethnicity: 112 non-white
Interventions PROMused as intervention: Mental Health Patient Proﬁle, constructed from SCL-90,
DIS, and SF-36
Participants were randomly assigned to either:
1) Intervention group (389): The PROMs were administered by researchers outside
the practice and the results summarised for the treating physicians. Feedback to clinician
only
2) Control group (229): No feedback of PROM scores to clinician or participant
Outcomes Outcomes:
Mathias 1994:
• Global anxiety score (GAS)*
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Mathias 1994 (Continued)
• Global severity index (GSI)
• Highest Anxiety Subscale Score (HASS) (GAS, GSI, and HASS all derived from
SCL-90)
• SF-36 (nine subscale scores)*
Mazonson 1996:
• Chart notation of anxiety, depression or other mental health diagnosis or
symptoms
• Referral to mental health specialist*
• Prescription of psychotropic medications*
• Hospitalisation
• Clinic visits
Subgroups: 4 severity subgroups (anxiety symptoms only, anxiety symptoms and disor-
der, anxiety and depression symptoms, anxiety and depression disorders)
Time points for assessment: 12 weeks and 5 months
*outcomes prespeciﬁed for this review
Notes Duration: Not stated
Funding: Supported by a grant from the Upjohn Company, and Take Care Colorado
Characteristics and data obtained from both Mathias 1994 (primary reference) and
Mazonson 1996
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Quote: “The physicians were randomized
by call group to either the demonstration
or control arm.”
Baseline imbalances in participant num-
bers and demographics
Allocation concealment (selection bias) High risk Cluster randomisation means physicians
were aware of allocation
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not possible to blind participants and per-
sonnel due to the nature of the intervention
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Outcome assessment was carried out by the
researchers administering the PROMs and
feeding back the results to the physicians,
who were therefore aware of allocation
Incomplete outcome data (attrition bias)
All outcomes
High risk The 45 participants lost to follow-up had
higher mean scores for SF-36 than the par-
ticipants followed up
Selective reporting (reporting bias) Low risk No evidence of selective reporting found
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Other bias Low risk No other perceived bias
Murphy 2012
Methods Study design: Individual randomised controlled trial
Setting: University counselling service
Country: Ireland
Participants Diagnosis: 4 ’dominant representations’:
• Anxiety (29.1%)
• Depression (29.1%)
• Relationships (19.1%)
• Other (22.7%).
Method of diagnosis: Routine diagnosis by the treating clinician
Age: Mean (SD) = 23.82 (6.46) years, range 18-59
Sex: 58.2% female: 50.8% in intervention group and 66.7% in control group
Number: 149 randomised at clinic intake, of which 110 followed up and included in
per protocol analysis (59 intervention group and 51 control)
Inclusion criteria:
• Consecutive centre clients who had at least 1 follow-up appointment
Exclusion criteria:
• Attending for an emergency drop-in appointment (where the client was in high
distress)
• Attending a scheduled screening for accessing online support
Co-morbidities: not stated
Losses to follow-up/withdrawal 32/180 originally assigned declined consent or
dropped out before the ﬁrst assessment. A further 39/149 (26.2%) failed to complete
the second assessment (18 intervention group, 21 control group)
Demographics considered: Not stated
Ethnicity: Not stated
Interventions PROM used as intervention: Outcome rating scale (ORS) scores. Feedback to both
clinician and participant who reviewed the scores together
Participants were randomly assigned to either:
1) Intervention group (59)
Duration: variable, number of clinic visits determined by therapist
Therapist received feedback that included a graph of projected progress, and actual
progress. Therapist given feedback while seeing client
2) Control group (51)
Duration: variable, number of clinic visits determined by therapist
The comparison group also completed ORS but their scores were kept hidden from the
therapists and clients
Outcomes Time points for assessment: at last clinic visit
Outcomes of the trial (as reported):
• ORS total score*
• Proportion with reliable change in score (>5), collectively and per diagnosis
• Length of treatment
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Murphy 2012 (Continued)
Subgroups: Both intervention and control groups were sub-divided into 4 diagnostic
groups (above)
*outcomes prespeciﬁed for this review
Notes Dates of study: Enrolment from November 2008-February 2009
Source of funding: University funded
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “For randomisation an online ran-
dom number generator was utilised”
Allocation concealment (selection bias) Low risk Quote: “Clients were randomly assigned at
intake to either the ’feedback’ or ’no feed-
back’ condition” (before assignment to a
therapist)
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not possible to blind participants and per-
sonnel due to the nature of the intervention
Blinding of outcome assessment (detection
bias)
All outcomes
High risk ThePROMused for feedbackwas also used
for outcome assessment, so the participants
themselves were the outcome assessors and
they were not blind to whether or not they
received the intervention
Incomplete outcome data (attrition bias)
All outcomes
High risk 180 originally assigned in total; 31 did not
complete ﬁrst assessment; 149 randomised;
39 (26.2%) failed to complete the second
assessment; 110/149 included in per pro-
tocol analysis
Selective reporting (reporting bias) Unclear risk Proportion with
clinically signiﬁcant change in ORS score
(to 25+/40) not reported
Other bias Low risk No other perceived bias
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Probst 2013
Methods Study design: Individual randomised controlled trial
Setting: Inpatient facility for people with psychosomatic disorder
Country: Germany
Participants Diagnosis: Psychosomatic disorder
Method of diagnosis: Not stated
Age: Mean (SD) = 47.62 (13.44) years, range not stated (participants in per protocol
analysis)
Sex: 60.6% female: 264/436 participants
Number: 436 randomised, of which 252 followed up and included in per protocol anal-
ysis (20 intervention group and 23 control of the ’not on track’ group, 111 intervention
group and 98 control group of the ’on track’ group)
Inclusion criteria:
• Inpatient with a psychosomatic disorder
Exclusion criteria:
• No baseline OQ-45 completed
Co-morbidities:
’Not on track’ group:
• Depressive disorders (76.7%): 78.3% of intervention group, 75.0% of control
group
• Somatoform disorders (58.1%): 52.2% of intervention group, 65.0% of control
group
• Anxiety disorders (20.9%): 30.4% of intervention group, 10.0% of control group
’On track’ group:
• Depressive disorders (64.6%): 62.2% of intervention group, 67.4% of control
group
• Somatoform disorders (58.9%): 58.6% of intervention group, 59.2% of control
group
• Anxiety disorders (26.3%): 23.4% of intervention group, 29.6% of control group
Losses to follow-up/withdrawal:
184/436 originally randomised excluded as treatment duration not long enough to
provide OQ-45 data for the intake week and at least 2 more weeks (69/184 due to severe
distress, 31/184 data available for only 1 or 2 weeks, 84/184 unclear)
’On-track’ group missing data:
• Intervention group 37/111, no dropouts
• Control group 29/98, no dropouts
Demographics considered:
• Education
Ethnicity: Not stated
Interventions PROM used as intervention: OQ-45 (German version), ASC (Assessment of Signal
Cases). Feedback given to clinician only, but free to discuss with clients
Participants were randomly assigned to either:
1) Intervention group (111 in ’on track’ group, 23 in ’not on track’ group)
Duration: Mean duration of treatment 3.6 weeks
OQ-45 scores andASCdata of each participant given to therapists on aweekly basis, after
being entered into OQ-Analyst. Therapist received feedback indicating if participant at
risk of deterioration: yellow: consider altering treatment; red: review and decide on new
course of action). Therapist given feedback prior to seeing client
2) Control group (98 in ’on track’ group, 20 in ’not on track’ group)
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Probst 2013 (Continued)
Duration: Mean duration of treatment 3.4 weeks
OQ-45 andASCcompleted by each participant everyweek but not sharedwith therapists
Outcomes Time points for assessment: (5), Baseline, weeks 1, 2, 3 and discharge week or last
available OQ-45 assessment
Outcomes of the trial (as reported):
• Mean change in OQ-45 total score*
• Mean change in OQ-45 symptom distress scale
• Mean change in OQ-45 interpersonal relations scale
• Mean change in OQ-45 social performance scale*
• Mean change from baseline OQ-45 score to last measurement point in ’not on
track’ group*
• Reliable change index (RCI)
*outcomes prespeciﬁed for this review
Notes Dates of study: October 2010-July 2012
Sources of funding: University Professorship awarded to Michael Lambert
Characteristics and data obtained from both Probst 2013 (primary reference) and Probst
2014
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No details provided. No response from au-
thors when contacted to clarify
Allocation concealment (selection bias) Unclear risk No details provided
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not possible to blind therapists due to the
nature of the intervention
Blinding of outcome assessment (detection
bias)
All outcomes
High risk ThePROMused for feedbackwas also used
for outcome assessment, so the participants
themselves were the outcome assessors and
they were not blind to whether or not they
received the intervention
Incomplete outcome data (attrition bias)
All outcomes
High risk 184/436 (42.2%) participants excluded as
did not complete 1 or more assessments.
Analysis done per protocol
Selective reporting (reporting bias) Low risk No evidence of selective reporting found
Other bias Low risk No other perceived bias
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Reese 2009a
Methods Study design: Individual randomised controlled trial (Study 1 of 2 described in paper)
Setting: University counselling service
Country: USA
Participants Diagnosis: Not stated in paper. The lead author conﬁrmed by email that more than
90% of the study participants would have had qualifying clinical diagnoses of anxiety
and depressive disorders
Method of diagnosis: Clinical only
Age: Mean (SD) = 20.17 (1.9) years, range 18 -27
Sex: 53 female, 18 male, 60 not reported
Number: 131 randomised at clinic intake, of which 74 followed up and included in per
protocol analysis (50 intervention group and 24 control)
Inclusion criteria:
• All clients referred to the services who attended for at least one follow-up
appointment
Exclusion criteria:
• Receiving couples therapy or family therapy
Co-morbidities: Not stated
Losses to follow-up/withdrawal: 57/131 (43.5%) either failed to return for a second
session (24), did not complete the PROMs consistently in the feedback arm (5) or did
not complete a post-treatment measure in the no-feedback arm (33)
Demographics considered: Not stated
Ethnicity:
• 78.4% white
• 4.1% African American
• 2.7% Asian American
• 6.8% Hispanic/Latino
• 5.4% ‘international students’
Interventions PROM used as intervention: PCOMS (Partners for Change Outcome Management
System) including ORS (Outcome Rating Scale) and SRS (Session Rating Scale)
Feedback to both clinician and participant who reviewed the scores together
Participants were randomly assigned to either:
1) Intervention group (50)
Duration: variable, number of clinic visits determined by therapist
Therapists received and viewed feedback together with clients
2) Control group (24)
Duration: variable, number of clinic visits determined by therapist
The comparison group also completed ORS but their scores were kept hidden from the
therapists and clients
Outcomes Time points for assessment: baseline, weekly, at last clinic visit
Outcomes of the trial (as reported):
• ORS total score*
• Proportion with reliable change in score (> 5)
• Survival plots for achieving reliable change
• Difference in number of treatment sessions between groups
*outcomes prespeciﬁed for this review
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Notes Dates of study: Not stated
Source of funding: Not stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: ...“roughly half of the participants
were originally randomly assigned to the
feedback...via a randomised block design to
help control for therapist effects”. and “.....
the ﬁrst client was randomized using a ran-
dom number generator to either the feed-
back or TAU condition.The second client
was then assigned to the other condition.”
(Author correspondence, see Table 1)
Allocation concealment (selection bias) Low risk “This was done by the person who assigned
clients at the respective centers, after en-
rollment into the study. Investigators and
client participants could not foresee which
condition a participant would placed into.
” (Author correspondence)
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not possible to blind participants and per-
sonnel due to the nature of the intervention
Blinding of outcome assessment (detection
bias)
All outcomes
High risk ThePROMused for feedbackwas also used
for outcome assessment, so the participants
themselves were the outcome assessors and
they were not blind to whether or not they
received the intervention
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Substantial proportion failed to complete
and were left out of per protocol analysis
(57/131, 43.5%)
Selective reporting (reporting bias) High risk SRS completed at end of each session in
feedback group, but results not reported
Other bias Unclear risk No other perceived bias
67Routine use of patient reported outcome measures (PROMs) for improving treatment of common mental health disorders in adults
(Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Reese 2009b
Methods Study design: Cluster randomised controlled trial (Study 2 of 2 studies described in
paper)
Setting: Community-based graduate (Masters) training clinic
Country: USA
Participants Diagnosis: Not stated in paper. The lead author conﬁrmed by email that more than
90% of the study participants would have had qualifying clinical diagnoses of anxiety
and depressive disorders
Method of diagnosis: Clinical only
Age: Mean (SD) = 32.96 (12.32) years, range 18-69
Sex: 51 female, 21 male, 24 not reported
Number: 96 randomised at clinic intake, of which 74 followed up and included in per
protocol analysis (45 intervention group and 29 control)
Inclusion criteria:
• All clients referred to the services who attended for at least one follow-up
appointment
Exclusion criteria:
• Receiving couples or family therapy
Co-morbidities: Not stated
Losses to follow-up/withdrawal: 22/96 (22.9%) either failed to return for a second
session (8), did not complete the PROMs consistently in the feedback arm (4) or did
not complete a post-treatment measure in the no-feedback arm (10)
Demographics considered: Not stated
Ethnicity:
• 79.6% white
• 3.7% African American
• 14.6% Hispanic/Latino
• 2.1% undeclared
Interventions PROM used as intervention: PCOMS (Partners for Change Outcome Management
System) including ORS (Outcome Rating Scale) and SRS (Session Rating Scale)
Feedback to both clinician and participant who reviewed the scores together
Participants were randomly assigned to either:
1) Intervention group (45)
Duration: variable, number of clinic visits determined by therapist
Therapists received and viewed feedback together with clients
2) Control group (29)
Duration: variable, number of clinic visits determined by therapist
The comparison group also completed ORS but their scores were kept hidden from the
therapists and clients
Outcomes Time points for assessment: baseline, weekly, at last clinic visit
Outcomes of the trial (as reported):
• ORS total score*
• Proportion with reliable change in score (>5)
• Survival plots for achieving reliable change
• Difference in number of treatment sessions between groups
*outcomes prespeciﬁed for this review
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Notes Dates of study: Not stated
Source of funding: Not stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote:“Therapists, rather than clients
were randomly assigned to the feedback
and no-feedback conditions”
Allocation concealment (selection bias) High risk Cluster randomisation means therapists
were aware of allocation
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not possible to blind participants and per-
sonnel due to the nature of the intervention
Blinding of outcome assessment (detection
bias)
All outcomes
High risk ThePROMused for feedbackwas also used
for outcome assessment, so the participants
themselves were the outcome assessors and
they were not blind to whether or not they
received the intervention
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Substantial proportion failed to complete
and were left out of per protocol analysis
(22/96, 23%)
Selective reporting (reporting bias) High risk SRS completed at end of each session in
feedback group, but results not reported
Other bias Unclear risk No other perceived bias
Scheidt 2012
Methods Study design: Cluster randomised controlled trial
Setting: Private outpatient psychotherapy
Country: Germany
Participants Diagnosis:Mean (SD) number of F-diagnoses according to ICD-10: Intervention group
1.71 (0.92), Control group 1.46 (0.77)
Method of diagnosis: According to ICD (intervention group: ICDL-Checklist, control
group: ICD -10 criteria)
Age: Intervention group:mean 40.16 years, SD11.38. Control group:mean 41.27 years,
SD 11.03. Range not reported
Sex: 1117 (68.6%) female (Wittmann et al., 2012)
Number: 4452 approached, 1708 patients gave consent to participate: 1031 intervention
group, 677 control group
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1629 randomised: 968 intervention group, 661 control (Wittmann et al. 2011)
Inclusion criteria: Starting outpatient psychotherapy, between 1 April 2005 and 30
June 2010; diagnosis F3-F6, 18 years or older
Exclusion criteria: Diagnosis F1 or F2
Co-morbidities: Not reported
Losses to follow-up/withdrawals: 1598 (98.2%) completed baseline assessment, 597
(36.7%) completed post-treatment assessment, and 468 (28.8%) completed follow-up
assessment 12 months post-treatment
Demographics considered: Marital status, partnership status, persons living in house-
hold, living situation, education, training qualiﬁcation, job status, income, ability to
work
Ethnicity: German nationality: intervention group 97.8%, control group 96.0%
Interventions PROM used as intervention: Comprehensive inventory of psychometric measurement
instruments. Decision rules (“reorientation of the expert system”) were developed and
optimised to guide decisions (on indications for and prolongation of psychotherapy)
based on the feedback. No extra contact or treatment was given to the participants in
the intervention group as a result of reorientation of the expert system
Participants were randomly assigned to either:
1) Intervention group:Feedback to clinician only on 4-point scale: consistent reduction
of problems; reduction of problems; no clinically relevant changes; increase of problems
2) Control group:No feedback to clinician or participant
Outcomes Outcomes:
• Brief Symptom Inventory BSI
• Inventar für Interpersonale Probleme IIP-D
• Secondary outcomes: Beck Depressionsinventar BDI; Fragebogen zu
Körperbezogenen Ängsten, Kognitionen und Vermeidung AKV; Hamburger
Zwangsinventar HZI; Eating Disorder Inventory EDI; Screening für Somatoforme
Störungen SOMS (Questionnaires on body-related anxiety and cognitions); and
Helping Alliance Questionnaire HAQ
• Fragebogen zum Gesundheitszustand SF-12
Time points for assessment: Pre-treatment, post-treatment, and 12 months post-treat-
ment
Notes Duration: 01/05/2005-31/05/2011, 73 months
Funding: Techniker Krankenkasse health insurance programme
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Drawing lots: “Aus jeder der Zellenwurden
per Zufall die teilnehmenden Therapeuten
zur IG oder KG zugelost” (Wittmann et al.
, 2011, p42)
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Allocation concealment (selection bias) High risk Cluster randomisation means therapists
were aware of allocation. Allocation was re-
stricted according to gender and treatment
modalities
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Blinding of participants not reported.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Blinding of outcome assessors not reported
Incomplete outcome data (attrition bias)
All outcomes
High risk Only 36.7% completed post-treatment as-
sessment, and 28.8% completed follow-up
assessment 12 months post-treatment
Selective reporting (reporting bias) Unclear risk Unclear whether selective reporting had
taken place
Other bias Unclear risk No other perceived bias
Simon 2012
Methods Study design: Individual randomised controlled trial
Setting: Hospital-based outpatient clinic
Country: USA
Participants Diagnosis:
• 64% mood
• 30% anxiety disorders
• 5% substance abuse
• 45.7% met criteria for two or more diagnoses
Method of diagnosis: Routine diagnosis by the treating therapist
Age: Mean age (SD) 36.10 (13.32), range not given
Sex: 64.2% female (241), 34.9% male (129) of the 370 included in analysis, 94 not
reported
Number: 464 recruited, of whom 370 were followed up. 163 ’on-track (OT)’ all im-
proved. 207 ’not on track (NOT)’ clients underwent ’Assessment for Signal Clients
(ASC)’ and were randomised to therapist and client feedback (109), or treatment as usual
(98)
Inclusion criteria:
• Attending OP psychotherapy clinic for a minimum of 2 sessions and willing to
complete outcome measures
Exclusion criteria:
• Failure to attend for a second session
• Age < 18
• Exclusively receiving medication or forms of treatment other than individual
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psychotherapy
Co-morbidities: Not stated
Losses to follow-up/withdrawal: 94 failed to attend for a second session
Demographics considered:
• Marital status
• Employment status
Ethnicity:
• 92.7% white
• 1.9% African American
• 2.4% Hispanic/Latino
• 1.9% Asian American
• 1.6% Paciﬁc Islander or other
Interventions PROM used as intervention: Outcome Questionnaire 45 (OQ-45), including 3 sub-
scales: subjective discomfort, interpersonal relationships, and social role performance
Participants were randomly assigned to either:
1) Feedback
Duration: variable, number of clinic visits determined by therapist
Feedback to clinicians consisted of session-by-session OQ-45 progress feedback along
with alerts to therapists each time a client took the measure. Therapists were given feed-
back prior to seeing clients that included four colour codes with actions recommended
for each (white: consider termination; green: no change; yellow: consider altering treat-
ment; red: review and decide on new course of action). Therapists were instructed to
share OQ-45 scores with clients
Subgroups: both intervention and control groups were sub-divided into ’on-track (OT)
’, i.e. green or white coded, and ’not on track (NOT)’, i.e. yellow or red coded. The ASC
was used for ’not on track (NOT)’ clients only, and results were reported for the NOT
subgroup only
Therapists were also provided with a Clinical Support Tool (CST) intervention manual,
which provided guidelines for interpreting the ASC, a decision tree, and an interventions
list to prompt therapist action
2) Control group
Duration: variable, number of clinic visits determined by therapist
The treatment-as-usual group also completed OQ-45s but their scores were kept hidden
from the therapists and clients
Outcomes Time points for assessment: Baseline, each clinic visit, at last clinic visit
Outcomes of the trial (as reported): All reported for NOT subgrouponly:
• OQ-45 total scores*
• Proportion with reliable change in score (14+)
• Proportion with clinically signiﬁcant change in score (to below 64/180)
• Comparisons of scores per therapist
• Effect of feedback on amount of psychotherapy
*outcomes prespeciﬁed for this review
Notes Dates of study: Not stated
Source of funding: Susa Young Gates University Professorship awarded to Michael J
Lambert
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Simon 2012 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “patients were randomly assigned
by the research staff ”. “Patients in this study
were randomly assigned to experimental
conditions using a block randomized de-
sign, with therapists serving as the blocking
variable.” p. 640
Allocation concealment (selection bias) Unclear risk No details
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not possible to blind participants and per-
sonnel due to the nature of the intervention
Blinding of outcome assessment (detection
bias)
All outcomes
High risk ThePROMused for feedbackwas also used
for outcome assessment, so the participants
themselves were the outcome assessors and
they were not blind to whether or not they
received the intervention
Incomplete outcome data (attrition bias)
All outcomes
High risk 94/464 (20.3%) failed to complete the sec-
ond assessment and were omitted from the
analysis
Selective reporting (reporting bias) Unclear risk No results reported for OT subgroup, ex-
cept that they all improved with no differ-
ences between feedback and no-feedback
groups
Other bias Low risk No other perceived bias
Trudeau 2001
Methods Study design: Individual randomised controlled trial
Setting: Rural community mental health centre - 3 sites
Country: USA
Participants Diagnosis:
• 67% Axis I disorder
• 24% severe/recurrent Axis I disorder
• < 2% psychotic disorders
• < 1% substance abuse
• 6% other
Method of diagnosis:Not stated. Author conﬁrmed by email that diagnosis was clinical,
and that more than 90% would have had diagnoses of anxiety and depressive disorders
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Trudeau 2001 (Continued)
Age: Control group mean age (SD) 37.5 (14.32), feedback group mean age (SD) 32.14
(10.51), non-feedback group mean age (SD) 32.91 (13.36)
Sex: 72% female (91/127)
Number: 127 (38 control, 66 feedback, 23 no feedback)
Inclusion criteria:
• People presenting for mental health therapy
Exclusion criteria:
• Not consenting to study
Co-morbidities: Not stated
Losses to follow-up/withdrawal: 14/38 in control group, 26/66 in feedback group and
10/23 in non-feedback group withdrew after T1. A further 18 withdrew after T2 (group
status not given). No reasons given for drop-outs
Demographics considered:
• Education
• Employment status
• Income
• Marital status
• Family size
Ethnicity:
• 97% white
• Remainder unreported
Interventions PROM used as intervention: Outcome Questionnaire (OQ-45) with subscales
3 groups:
1) a feedback condition, in which the clients completed the OQ at each session, and
the clinicians were provided with information regarding client progress following each
session
2) a non-feedback condition in which clients completed the OQ at each session, but
the clinicians were not provided with the results of the measures
3) a control condition in which clients were not assessed with the OQmeasures at each
session
Outcomes Time points for assessment: (3) Baseline, 2 months, 4 months
Outcomes as reported by study authors:
• OQ scores*
• Total Mental Health score*
• RAND health survey
• Work/school questionnaire
• AABH Service Utiilization questionnaire
• AABH patient satisfaction questionnaire
• Clinician evaluation of managed care
*outcomes prespeciﬁed for this review
= no usable data provided for inclusion in this review
Notes Dates of study: Not stated
Source of funding: Study conducted for doctoral thesis, no source of funding disclosed
Risk of bias
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Trudeau 2001 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Clients were randomly assigned by case
number to either the control condition for
case numbers ending in 3, 6 or 9”
Allocation concealment (selection bias) Unclear risk No details provided
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not possible to blind participants and per-
sonnel due to the nature of the intervention
Blinding of outcome assessment (detection
bias)
All outcomes
High risk ThePROMused for feedbackwas also used
for outcome assessment, so the participants
themselves were the outcome assessors and
they were not blind to whether or not they
received the intervention
Incomplete outcome data (attrition bias)
All outcomes
High risk 14/38 dropped out in control group, 26/
66 dropped out in feedback group and 10/
23 dropped out in no feedback group. Fur-
ther 18 across groups dropped out between
T2 and T3. Balanced drop out rates but
high, and substantially higher participants
in feedback group compared to no feed-
back group
Selective reporting (reporting bias) Low risk No evidence of selective reporting
Other bias Low risk No other perceived bias
Whipple 2003
Methods Study design: Individual randomised controlled trial
Setting: University counselling centre
Country: USA
Participants Diagnosis: 74.6% diagnosed:
• 35% ’V code’ diagnosis
• 29.2% mood disorder
• 12.4% adjustment disorder
• 10.1% anxiety disorder
• 7% eating disorder
• 6.3% ‘other’
Method of diagnosis: Routine diagnosis by the treating clinician
Age: Mean 22.88 (SD 3.54), range 18-54
Sex: 648 female, 333 male, 358 not reported
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Whipple 2003 (Continued)
Number: 1339 randomised, of whom 981 (73.2%) followed up and in per protocol
analysis (499 intervention, 482 control)
Inclusion criteria:
• Consecutive centre clients who had at least one follow-up appointment
Exclusion criteria:
• None stated
Co-morbidities: Not stated
Losses to follow-up/withdrawal 1339 included originally, of whom 358 (26.7%) ex-
cluded due to not completing an outcome measure, or not returning for a second session
Demographics considered: Not stated
Ethnicity:
• 86% white
• 4.8% Hispanic
• 2.1% Paciﬁc Islander/Asian
• 0.6% African American
• 6.5% other or mixed
Interventions PROM used as intervention: Outcome Questionnaire 45 (OQ-45) and algorithm on
recommended actions. Feedback to clinician (but could be shared with client)
Participants were randomly assigned to either:
1) Intervention group (499)
Duration: variable, number of clinic visits determined by therapist
Therapist received feedback that included 4 colour codes with actions recommended for
each (white: consider termination; green: no change; yellow: consider altering treatment;
red: review and decide on new course of action). Therapist given feedback prior to
seeing client. When clients identiﬁed as ’not on track (NOT)’, therapists had option of
using a clinical support tool (CST) which included a decision tree and a list of possible
interventions
2) Control group (482)
Duration: variable, number of clinic visits determined by therapist
The comparison group also completed OQ-45s but their scores were kept hidden from
the therapists and clients
Outcomes Time points for assessment: Baseline, per session and at last clinic visit
Outcomes of the trial (as reported):
• OQ-45 total score*
• Proportion with clinically signiﬁcant change in score (to below 64/180)
• Differences in treatment length
• Therapist effect on outcome
Subgroups: both intervention and control groups were sub-divided into ’on-track (OT)
’, i.e. green or white coded, and ’not on track (NOT)’, i.e. yellow or red coded, and
results reported separately for each subgroup within intervention and control arms
*outcomes prespeciﬁed for this review
Notes Dates of study: Not stated
Source of funding: Not stated
Risk of bias
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Whipple 2003 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “The participants in the experi-
mental (Fb) and control groups (NFb)were
divided into groups based on random as-
signment”
Allocation concealment (selection bias) Unclear risk Not stated
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not possible to blind participants and per-
sonnel due to the nature of the intervention
Blinding of outcome assessment (detection
bias)
All outcomes
High risk ThePROMused for feedbackwas also used
for outcome assessment, so the participants
themselves were the outcome assessors and
they were not blind to whether or not they
received the intervention
Incomplete outcome data (attrition bias)
All outcomes
High risk 1339 randomised, of whom 358 (26.7%)
excluded due to not completing an out-
come measure, or not returning for a sec-
ond session. Per protocol analysis under-
taken
Selective reporting (reporting bias) Low risk No evidence of selective reporting found
Other bias Low risk No other perceived bias
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Anker 2009 Ineligible population
Brodey 2005 PROMs not used for outcome monitoring
Brody 1990 PROMs not used for outcome monitoring
Dobscha 2006 Complex quality improvement programme
Fluckiger 2012 PROMs not used for outcome monitoring
Haderlie 2012 Non randomised study
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Harmon 2007 Non randomised study
Lambert 2002 Non randomised study
Newnham 2010 Non randomised study
Pedersen 2014 PROMs not used for outcome monitoring
Priebe 2007 Ineligible population
Puschner 2009 Ineligible population
Reese 2010 Ineligible population
Reese 2013 PROMs not used for outcome monitoring
Reeves 2010 Non randomised study
Rise 2012 PROMs not used for outcome monitoring (only therapeutic alliance and patient satisfaction reported)
Simon 2000 Complex quality improvement programme
Slade 2006 Ineligible population
Slade 2008 Non randomised study
Characteristics of studies awaiting assessment [ordered by study ID]
Gibbons 2015
Methods Randomised controlled trial with 2 arms. Patients individually randomised to 8 weeks of individual therapy with
either a clinician receiving weekly feedback reports, or a clinician not receiving weekly feedback reports
Participants People seeking services for depression at a community mental health centre (CMHC) in Philadelphia, USA. Inclusion
criterion: a clinically meaningful level of depressive symptoms (score of 11 or above on Inventory for Depressive
Symptomatology, QIDS). Pre-dominantly female African-Americans, with a mean age of 39
Interventions Community Clinician Feedback System (CCFS) including a clinical feedback report identifying patients who were
not progressing as expected judged on basis of scores on BASIS-24 (24-Item Behavior and Symptom Identiﬁcation
Scale). Scores presented on coloured graph showing line of expected recovery along with patient’s actual BASIS-
24 scores. Patients ’off track’ for improvement completed Community Clinician Feedback Questionnaire (CCFQ)
covering demographic background, treatment motivation, attitudes and expectations about treatment, therapeutic
alliance, suicide risk, substance use, perceived social support, psychosocial stressors, violence potential, personality
disorder, interpersonal distress, interpersonal patterns, cognitive distortions, compensatory skills, and trauma history
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Gibbons 2015 (Continued)
Outcomes Primary outcome: rate of change across treatment weeks on the total score of the BASIS-24, plus percentage of
patients achieving reliable change, clinically signiﬁcant change, and both reliable and clinically signiﬁcant change.
Secondary outcomes: patient and clinician satisfaction
Notes
Rise 2016
Methods Open, individually randomised parallel-group controlled trial
Participants Outpatients attending a mental health hospital in Norway. All patients offered treatment at the out-patient unit
between 6 weeks and 3 months after referral were invited
Interventions Partners for Change Outcome Management System (PCOMS) feedback scales, including the Outcome Rating Scale
(ORS), and Session rating Scale (SRS)
Outcomes Primary outcome measures: Behaviour and Symptom Identiﬁcation Scale 32 (BASIS-32) and Patient Activation
Measure (PAM)
Secondary outcome measures: Treatment Alliance Scale (TAS), Client Satisfaction Questionnaire-8 (CSQ), Short
Form-12 (SF-12), Outcome Rating Scale (ORS) and Session Rating Scale (SRS), “Patient motivation” (PM) and
“Patient participation” (PP)
Notes
Characteristics of ongoing studies [ordered by study ID]
Metz 2015
Trial name or title SharedDecisionMaking inmental health care using RoutineOutcomeMonitoring as a source of information:
a cluster randomised controlled trial
Methods Multi-centre 2-arm cluster randomised controlled trial: pairs of teams from the same mental health organi-
sation are randomly assigned to either the experimental or control conditions (matched pairs)
Participants Clients attending specialised mental health care treated in subgroups by: age (adolescents, adults and elderly
patients), diagnosis (psychotic, commonmental and personality disorders); and setting (outpatient, day-clinic
and clinic)
Interventions Shared Decision Making (SDM) using Routine Outcome Monitoring (ROM) as a source of information
(SDM-ROM model), using ROMs tailored to patient subgroup
Outcomes Primary outcome: degree of decisional conﬂict, measured using Decisional Conﬂict Scale (DCS). Secondary
outcomes: patient-clinician relationship assessed using Dutch version of Working Alliance Inventory Short
Form (WAI-S); treatment outcome using either Manchester Short Quality of Live Measurement (MANSA-
VN-16) for long-term patients or the Outcome Questionnaire (OQ-45) for short term patients
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Metz 2015 (Continued)
Starting date August 2015
Contact information Margot Metz, Trimbos Institute of Mental Health and Addiction, Utrecht, and GGZ Breburg, Tilburg, The
Netherlands, email: m.metz@ggzbreburg.nl
Notes
NCT01796223
Trial name or title Effects of systematic patient feedback on therapy outcome and dropout: A randomized controlled study on
adult out-patients at a community mental health centre
Methods 2 groups: Control (psychotherapy as usual); Intervention (psychotherapy along with feedback to therapist of
a PROM administered at the beginning and end of every therapy session)
Participants 18 years or older
Referred for treatment of mental disorder
Interventions Partners for Change Outcome Management System (PCOMS) (KOR - Norwegian)
Outcomes Health care utilisation (referral and drop out rate); symptom level; patient satisfaction; level of functioning;
preferences for involvement in decision making; patient activation measure; use of health services (number
of visits at General Practitioner or use of other health services)
Starting date December 2012
Contact information John Morten Koksvik, MD 0047 73 86 40 00 john.morten.koksvik@stolav.no
Mariela Lara 0047 73 86 40 00 mariela.lara@stolav.no
Notes Sponsors and Collaborators: Norwegian University of Science and Technology
Principal Investigator: Mariela M Lara MA
NCT02023736
Trial name or title Assessing psychotherapy outcome in treatment as usual versus treatment as usual with the STIC feedback
system
Methods 2 groups: treatment-as-usual (TAU) versus TAU plus feedback to therapist through weekly online client
questionnaires
Participants Individuals, couples, and families
Interventions Systemic Therapy Inventory of Change (STIC)
Outcomes Change in mental health symptoms at termination, tailored to client demographics, including some or all of:
Beck Depression Inventory II; Beck Anxiety Inventory; Outcome Questionnaire 45; Short-form 36 Health
Survey; Revised Dyadic Adjustment Scale; Family Assessment Device; Strengths-Difﬁculties Questionnaire
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NCT02023736 (Continued)
Starting date December 2013
Contact information Contact: Tara Latta:847 733 4300 ext 322 taralatta2008@u.northwestern.edu; Jacob Goldsmith, Ph.D. 847
733 4300 ext 860 jgoldsmith2@family-institute.org
Notes
NCT02095457
Trial name or title A randomised trial of routine computerised outcome and process clinical measures monitoring in mental
health outpatient services: preparing for the planned public mental health reform in Israel
Methods The suggested study is a 2-stage (implementation and intervention) open trial. 900 new outpatients in ’Shal-
vata’ clinics will be recruited and randomised to intervention (ROM) and control groups. Assessment ques-
tionnaires will be ﬁlled periodically using ’CORE-NET’, a computerised system enabling repeated measure-
ments and feedback in a user-friendly and efﬁcient manner
Participants New patients attending clinic and beginning therapy
Interventions Control group: Infrequently complete CORE-OM (once a year) and results not fed back to therapists
Intervention group: Feedback of CORE-OM rating scale to therapists (completed between once a week and
every 3 months)
Outcomes Overall clinical wellbeing as measured by the CORE-OM rating scale
Hospitalisation rates
Starting date July 2014
Contact information Ori Ganor, MD 972-54-5454886 origa1@clalit.org.il
Lior Biran, Clinical Psychologist 972-54-4708886 liorbiran@gmail.com; liorbi@clalit.org.il
Notes Sponsors and Collaborators: Shalvata Mental Health Center
Principal Investigators: Ori Ganor MD, Lior Biran
NCT02656641
Trial name or title Using the PHQ-9 and GAD-7 as feedback instruments in brief psychotherapy
Methods Randomised controlled trial with 3 arms: Continuous Client Feedback (scores given to client and discussed
with therapist); Continuous Self Feedback (scores given to to client only); Control (clients complete symptom
and quality-of-life scales only before ﬁrst session and before last or 10th session, whichever occurs ﬁrst)
Participants Aged 18-64, with diagnosis of major depressive disorder, generalized anxiety disorder, or adjustment disorder,
undergoing brief psychotherapy
Interventions Patient Health Questionnaire-9 (PHQ-9) and Generalized Anxiety Disorder 7-Item Scale (GAD-7) PROMs
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NCT02656641 (Continued)
Outcomes Primary outcome measures: Change in depressive symptoms on PHQ-9 and change in anxiety symptoms on
GAD-7 at end of treatment (up to 10 weeks) Secondary outcome measures: WHO - Quality of Life BREF
Scale for physical health, psychological health, social relationships, and environment; and Schwartz Outcome
Scale
Starting date November 2015
Contact information Contact: Krystal G Ludwig, MA, 6104135983, kludwig@40christianacare.org David York, PhD,
3026230201, dyork@40christianacare.org, Christiana Healthcare, Wilmington, Delaware, United States
Notes
NTR5466
Trial name or title Routine Process Monitoring, systematic patient feedback in the primary and specialised mental healthcare
Methods Randomised controlled trial with 2 arms: Routine Process Monitoring + Treatment as usual (TAU-RPM),
and Treatment as Usual (TAU)
Participants Patients aged 18 years or older, assigned to have psychological treatment in primary care or specialised mental
healthcare
Interventions Feedback of Session Rating Scale (SRS) and Outcome Rating Scale (ORS) scores completed in each treatment
session
Outcomes Primary outcomes: Outcome Questionaire 45 symptom score and Dutch Mental Health Continuum - Short
Form (MHC-SF). Secondary outcomes: dropout, patient-satisfaction, duration of therapy, and treatment
costs. Assessed at 5 weeks’, 13 weeks’, and 26 weeks’ follow-up
Starting date December 2015
Contact information Dr AM Bovendeerd, Steenwijk, The Netherlands Tel: +31 (0)521 534140 email: b.bovendeerd@dimence.nl
Notes
NTR5707
Trial name or title Self-monitoring and personalised feedback as a tool to boost depression treatment
Methods Randomised controlled trial with 3 arms: ‘Do’-module (n =50): patients report ESMdata via their smartphone,
5 times a day for 28 days, with weekly feedback (to the patient) on positive affect (PA) and activities. ‘Think’-
module (n = 50): patients report ESM data via their smartphone, 5 times a day for 28 days, with weekly
feedback (to the patient) on negative affect (NA) and thinking patterns. Control group (n = 50): patients on
the wait list
Participants Patients aged between 18 and 65 years for whom depression treatment is indicated by the practitioner
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NTR5707 (Continued)
Interventions Self-monitoring and personalised feedback through the Experience Sampling Method (ESM)
Outcomes Change in depression symptom severity on self-report Inventory of Depressive Symptomatology; change in
psychosocial functioning on Outcome Questionnaire 45; self-esteem and control over own lives on Dutch
Empowerment questionnaire
Starting date March 2016
Contact information Dr JACJ Bastiaansen, Groningen, The Netherlands Tel: +31 (0)503 611169 email: j.bastiaansen@umcg.nl
Notes
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D A T A A N D A N A L Y S E S
Comparison 1. Difference in outcome feeding back OQ-45 or ORS scores versus no feedback
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mean improvement in symptom
scores: OQ-45 PROMS
9 3438 Mean Difference (IV, Random, 95% CI) -1.14 [-3.15, 0.86]
2 Mean improvement in symptom
scores: OQ-45 or ORS PROMs
12 3696 Std. Mean Difference (IV, Random, 95% CI) -0.07 [-0.16, 0.01]
3 Number of treatment sessions
received: all participants
7 2608 Mean Difference (IV, Random, 95% CI) -0.02 [-0.42, 0.39]
Comparison 2. Subgroup analysis: Setting
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mean improvement in symptom
scores by setting
12 3696 Std. Mean Difference (IV, Random, 95% CI) -0.07 [-0.16, 0.01]
1.1 Multidisciplinary mental
health care setting
7 1848 Std. Mean Difference (IV, Random, 95% CI) -0.05 [-0.18, 0.07]
1.2 Psychological therapy
setting
5 1848 Std. Mean Difference (IV, Random, 95% CI) -0.10 [-0.23, 0.03]
Comparison 3. Subgroup analysis: Whether participants were given a formal diagnosis or not
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mean improvement in symptom
scores by whether participants
were given a formal diagnosis
or not
12 3696 Std. Mean Difference (IV, Random, 95% CI) -0.07 [-0.16, 0.01]
1.1 Mean improvement in
symptom scores: participants
given a formal diagnosis
3 1144 Std. Mean Difference (IV, Random, 95% CI) -0.01 [-0.23, 0.21]
1.2 Mean difference in
symptom scores: participants
not given a formal diagnosis
9 2552 Std. Mean Difference (IV, Random, 95% CI) -0.08 [-0.15, 0.00]
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Comparison 4. Subgroup analysis: Feeback given to clinician, participant or both
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mean improvement in symptom
scores: feedback given to
clinician, participant or both
12 3696 Std. Mean Difference (IV, Random, 95% CI) -0.07 [-0.16, 0.01]
1.1 Mean improvement in
symptom scores: feedback
given only to the clinician
2 140 Std. Mean Difference (IV, Random, 95% CI) -0.17 [-0.63, 0.30]
1.2 Mean improvement in
symptom scores: feedback given
explicitly to both clinician and
participant
6 862 Std. Mean Difference (IV, Random, 95% CI) -0.12 [-0.30, 0.05]
1.3 Mean improvement in
symptom scores: clinicians
permitted or encouraged to
share feedback with participant
6 2694 Std. Mean Difference (IV, Random, 95% CI) -0.05 [-0.16, 0.06]
Comparison 5. Subgroup analysis: Whether feedback included treatment instructions or an algorithm
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mean improvement in symptom
scores by whether feedback
included treatment instructions
or an algorithm
12 3696 Std. Mean Difference (IV, Random, 95% CI) -0.07 [-0.16, 0.01]
1.1 Mean improvement in
symptom scores: treatment
instructions or algorithm
2 1184 Std. Mean Difference (IV, Random, 95% CI) -0.03 [-0.14, 0.09]
1.2 Mean improvement in
symptom scores: no treatment
instructions or algorithm
10 2512 Std. Mean Difference (IV, Random, 95% CI) -0.09 [-0.20, 0.02]
Comparison 6. Subgroup analysis: studies involving Michael Lambert versus studies not involving him
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mean improvement in symptom
scores by whether studies
involved Michael Lambert
9 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
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1.1 Mean improvement
in symptom scores: studies
involving Michael Lambert
5 2032 Std. Mean Difference (IV, Random, 95% CI) -0.06 [-0.15, 0.03]
1.2 Mean improvement in
symptom scores: studies not
involving Michael Lambert
4 1406 Std. Mean Difference (IV, Random, 95% CI) -0.02 [-0.19, 0.15]
Comparison 7. Post hoc analyses - ’on track’ and ’not on track’ participants
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mean improvement in
symptom scores: ’not on track’
participants only
10 923 Std. Mean Difference (IV, Random, 95% CI) -0.22 [-0.35, -0.09]
2 Number of treatment sessions
received by ’on track’ and ’not
on track’ participants
5 2114 Mean Difference (IV, Random, 95% CI) 0.06 [-0.91, 1.02]
2.1 Number of treatment
sessions received by ”on track”
participants only
4 1633 Mean Difference (IV, Random, 95% CI) -0.69 [-1.10, -0.29]
2.2 Number of treatment
sessions received by ”not on
track” participants only
5 481 Mean Difference (IV, Random, 95% CI) 0.73 [-2.04, 3.50]
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Analysis 1.1. Comparison 1 Difference in outcome feeding back OQ-45 or ORS scores versus no feedback,
Outcome 1 Mean improvement in symptom scores: OQ-45 PROMS.
Review: Routine use of patient reported outcome measures (PROMs) for improving treatment of common mental health disorders in adults
Comparison: 1 Difference in outcome feeding back OQ-45 or ORS scores versus no feedback
Outcome: 1 Mean improvement in symptom scores: OQ-45 PROMS
Study or subgroup Feedback No feedback
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Amble 2014 144 75.5 (28.6) 115 84.6 (25.1) 7.6 % -9.10 [ -15.65, -2.55 ]
De Jong 2012 206 67.43 (25.78) 207 67.53 (24.16) 12.0 % -0.10 [ -4.92, 4.72 ]
De Jong 2014 171 54.18 (23.99) 71 51.76 (26.84) 6.5 % 2.42 [ -4.78, 9.62 ]
De Jong 2014 159 57.55 (25.91) 71 51.76 (26.84) 6.1 % 5.79 [ -1.64, 13.22 ]
Hansson 2013 136 88.49 (17.82) 126 88.97 (18.53) 13.6 % -0.48 [ -4.89, 3.93 ]
Hawkins 2004 67 62.49 (25.82) 32 69.33 (23.42) 3.5 % -6.84 [ -17.04, 3.36 ]
Hawkins 2004 70 69.41 (24.56) 32 69.33 (23.42) 3.7 % 0.08 [ -9.87, 10.03 ]
Lambert 2001 307 63.32 (23.83) 302 65.12 (22.31) 17.1 % -1.80 [ -5.47, 1.87 ]
Probst 2013 107 71.32 (25.66) 96 72.95 (25.27) 6.8 % -1.63 [ -8.64, 5.38 ]
Trudeau 2001 27 89.17 (22.43) 11 101.48 (27.32) 1.2 % -12.31 [ -30.54, 5.92 ]
Whipple 2003 499 58.15 (22.25) 482 58.56 (23.38) 22.0 % -0.41 [ -3.27, 2.45 ]
Total (95% CI) 1893 1545 100.0 % -1.14 [ -3.15, 0.86 ]
Heterogeneity: Tau2 = 2.63; Chi2 = 13.30, df = 10 (P = 0.21); I2 =25%
Test for overall effect: Z = 1.12 (P = 0.26)
Test for subgroup differences: Not applicable
-20 -10 0 10 20
Favours feedback Favours no feedback
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Analysis 1.2. Comparison 1 Difference in outcome feeding back OQ-45 or ORS scores versus no feedback,
Outcome 2 Mean improvement in symptom scores: OQ-45 or ORS PROMs.
Review: Routine use of patient reported outcome measures (PROMs) for improving treatment of common mental health disorders in adults
Comparison: 1 Difference in outcome feeding back OQ-45 or ORS scores versus no feedback
Outcome: 2 Mean improvement in symptom scores: OQ-45 or ORS PROMs
Study or subgroup Feedback No feedback
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Amble 2014 144 75.5 (28.6) 115 84.6 (25.1) 8.4 % -0.33 [ -0.58, -0.09 ]
De Jong 2012 206 67.43 (25.78) 207 67.53 (24.16) 11.5 % 0.00 [ -0.20, 0.19 ]
De Jong 2014 159 57.55 (25.91) 71 51.76 (26.84) 7.0 % 0.22 [ -0.06, 0.50 ]
De Jong 2014 171 54.18 (23.99) 71 51.76 (26.84) 7.1 % 0.10 [ -0.18, 0.37 ]
Hansson 2013 136 88.49 (17.82) 126 88.97 (18.53) 8.6 % -0.03 [ -0.27, 0.22 ]
Hawkins 2004 70 69.41 (24.56) 32 69.33 (23.42) 3.7 % 0.00 [ -0.41, 0.42 ]
Hawkins 2004 67 62.49 (25.82) 32 69.33 (23.42) 3.6 % -0.27 [ -0.69, 0.15 ]
Lambert 2001 307 63.32 (23.83) 302 65.12 (22.31) 14.1 % -0.08 [ -0.24, 0.08 ]
Murphy 2012 59 -24.39 (7.13) 51 -23.77 (6.87) 4.4 % -0.09 [ -0.46, 0.29 ]
Probst 2013 107 71.32 (25.66) 96 72.95 (25.27) 7.2 % -0.06 [ -0.34, 0.21 ]
Reese 2009a 50 -31.28 (6.63) 24 -29.53 (7.26) 2.8 % -0.25 [ -0.74, 0.24 ]
Reese 2009b 45 -29.51 (9.58) 29 -24.33 (7.51) 2.9 % -0.58 [ -1.06, -0.10 ]
Trudeau 2001 27 89.17 (22.43) 11 101.48 (27.32) 1.4 % -0.50 [ -1.22, 0.21 ]
Whipple 2003 499 58.15 (22.25) 482 58.56 (23.38) 17.2 % -0.02 [ -0.14, 0.11 ]
Total (95% CI) 2047 1649 100.0 % -0.07 [ -0.16, 0.01 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 18.46, df = 13 (P = 0.14); I2 =30%
Test for overall effect: Z = 1.63 (P = 0.10)
Test for subgroup differences: Not applicable
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Analysis 1.3. Comparison 1 Difference in outcome feeding back OQ-45 or ORS scores versus no feedback,
Outcome 3 Number of treatment sessions received: all participants.
Review: Routine use of patient reported outcome measures (PROMs) for improving treatment of common mental health disorders in adults
Comparison: 1 Difference in outcome feeding back OQ-45 or ORS scores versus no feedback
Outcome: 3 Number of treatment sessions received: all participants
Study or subgroup Feedback No feedback
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Amble 2014 144 9.7 (8.6) 115 10.3 (9.2) 3.4 % -0.60 [ -2.79, 1.59 ]
De Jong 2014 140 36 (56.7) 63 33.5 (40.5) 0.1 % 2.50 [ -11.22, 16.22 ]
De Jong 2014 144 27.5 (17.2) 63 33.5 (40.5) 0.2 % -6.00 [ -16.39, 4.39 ]
Hawkins 2004 70 8.2 (6.39) 32 8.66 (8.63) 1.5 % -0.46 [ -3.80, 2.88 ]
Hawkins 2004 67 7.79 (5.52) 32 8.66 (8.63) 1.5 % -0.87 [ -4.14, 2.40 ]
Lambert 2001 307 3.55 (3.89) 302 3.7 (3.87) 42.9 % -0.15 [ -0.77, 0.47 ]
Reese 2009a 50 6.27 (5.22) 24 5.99 (4.66) 2.9 % 0.28 [ -2.08, 2.64 ]
Reese 2009b 45 8.02 (5.82) 29 5.79 (3.4) 3.7 % 2.23 [ 0.13, 4.33 ]
Whipple 2003 499 5.47 (4.86) 482 5.46 (4.88) 43.9 % 0.01 [ -0.60, 0.62 ]
Total (95% CI) 1466 1142 100.0 % -0.02 [ -0.42, 0.39 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 6.64, df = 8 (P = 0.58); I2 =0.0%
Test for overall effect: Z = 0.08 (P = 0.93)
Test for subgroup differences: Not applicable
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Analysis 2.1. Comparison 2 Subgroup analysis: Setting, Outcome 1 Mean improvement in symptom scores
by setting.
Review: Routine use of patient reported outcome measures (PROMs) for improving treatment of common mental health disorders in adults
Comparison: 2 Subgroup analysis: Setting
Outcome: 1 Mean improvement in symptom scores by setting
Study or subgroup Experimental Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Multidisciplinary mental health care setting
Amble 2014 144 75.5 (28.6) 115 84.6 (25.1) 8.4 % -0.33 [ -0.58, -0.09 ]
De Jong 2012 206 67.43 (25.78) 207 67.53 (24.16) 11.5 % 0.00 [ -0.20, 0.19 ]
De Jong 2014 171 54.18 (23.99) 71 51.76 (26.84) 7.1 % 0.10 [ -0.18, 0.37 ]
De Jong 2014 159 57.55 (25.91) 71 51.76 (26.84) 7.0 % 0.22 [ -0.06, 0.50 ]
Hansson 2013 136 88.49 (17.82) 126 88.97 (18.53) 8.6 % -0.03 [ -0.27, 0.22 ]
Hawkins 2004 67 62.49 (25.82) 32 69.33 (23.42) 3.6 % -0.27 [ -0.69, 0.15 ]
Hawkins 2004 70 69.41 (24.56) 32 69.33 (23.42) 3.7 % 0.00 [ -0.41, 0.42 ]
Probst 2013 107 71.32 (25.66) 96 72.95 (25.27) 7.2 % -0.06 [ -0.34, 0.21 ]
Trudeau 2001 27 89.17 (22.43) 11 101.48 (27.32) 1.4 % -0.50 [ -1.22, 0.21 ]
Subtotal (95% CI) 1087 761 58.5 % -0.05 [ -0.18, 0.07 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 12.70, df = 8 (P = 0.12); I2 =37%
Test for overall effect: Z = 0.84 (P = 0.40)
2 Psychological therapy setting
Lambert 2001 307 63.32 (23.83) 302 65.12 (22.31) 14.1 % -0.08 [ -0.24, 0.08 ]
Murphy 2012 59 -24.39 (7.13) 51 -23.77 (6.87) 4.4 % -0.09 [ -0.46, 0.29 ]
Reese 2009a 50 -31.28 (6.63) 24 -29.53 (7.26) 2.8 % -0.25 [ -0.74, 0.24 ]
Reese 2009b 45 -29.51 (9.58) 29 -24.33 (7.51) 2.9 % -0.58 [ -1.06, -0.10 ]
Whipple 2003 499 58.15 (22.25) 482 58.56 (23.38) 17.2 % -0.02 [ -0.14, 0.11 ]
Subtotal (95% CI) 960 888 41.5 % -0.10 [ -0.23, 0.03 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 5.63, df = 4 (P = 0.23); I2 =29%
Test for overall effect: Z = 1.49 (P = 0.14)
Total (95% CI) 2047 1649 100.0 % -0.07 [ -0.16, 0.01 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 18.46, df = 13 (P = 0.14); I2 =30%
Test for overall effect: Z = 1.63 (P = 0.10)
Test for subgroup differences: Chi2 = 0.23, df = 1 (P = 0.63), I2 =0.0%
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Analysis 3.1. Comparison 3 Subgroup analysis: Whether participants were given a formal diagnosis or not,
Outcome 1 Mean improvement in symptom scores by whether participants were given a formal diagnosis or
not.
Review: Routine use of patient reported outcome measures (PROMs) for improving treatment of common mental health disorders in adults
Comparison: 3 Subgroup analysis: Whether participants were given a formal diagnosis or not
Outcome: 1 Mean improvement in symptom scores by whether participants were given a formal diagnosis or not
Study or subgroup Experimental Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Mean improvement in symptom scores: participants given a formal diagnosis
Amble 2014 144 75.5 (28.6) 115 84.6 (25.1) 8.4 % -0.33 [ -0.58, -0.09 ]
De Jong 2012 206 67.43 (25.78) 207 67.53 (24.16) 11.5 % 0.00 [ -0.20, 0.19 ]
De Jong 2014 159 57.55 (25.91) 71 51.76 (26.84) 7.0 % 0.22 [ -0.06, 0.50 ]
De Jong 2014 171 54.18 (23.99) 71 51.76 (26.84) 7.1 % 0.10 [ -0.18, 0.37 ]
Subtotal (95% CI) 680 464 34.0 % -0.01 [ -0.23, 0.21 ]
Heterogeneity: Tau2 = 0.04; Chi2 = 9.78, df = 3 (P = 0.02); I2 =69%
Test for overall effect: Z = 0.10 (P = 0.92)
2 Mean difference in symptom scores: participants not given a formal diagnosis
Hansson 2013 136 88.49 (17.82) 126 88.97 (18.53) 8.6 % -0.03 [ -0.27, 0.22 ]
Hawkins 2004 70 69.41 (24.56) 32 69.33 (23.42) 3.7 % 0.00 [ -0.41, 0.42 ]
Hawkins 2004 67 62.49 (25.82) 32 69.33 (23.42) 3.6 % -0.27 [ -0.69, 0.15 ]
Lambert 2001 307 63.32 (23.83) 302 65.12 (22.31) 14.1 % -0.08 [ -0.24, 0.08 ]
Murphy 2012 59 -24.39 (7.13) 51 -23.77 (6.87) 4.4 % -0.09 [ -0.46, 0.29 ]
Probst 2013 107 71.32 (25.66) 96 72.95 (25.27) 7.2 % -0.06 [ -0.34, 0.21 ]
Reese 2009a 50 -31.28 (6.63) 24 -29.53 (7.26) 2.8 % -0.25 [ -0.74, 0.24 ]
Reese 2009b 45 -29.51 (9.58) 29 -24.33 (7.51) 2.9 % -0.58 [ -1.06, -0.10 ]
Trudeau 2001 27 89.17 (22.43) 11 101.48 (27.32) 1.4 % -0.50 [ -1.22, 0.21 ]
Whipple 2003 499 58.15 (22.25) 482 58.56 (23.38) 17.2 % -0.02 [ -0.14, 0.11 ]
Subtotal (95% CI) 1367 1185 66.0 % -0.08 [ -0.15, 0.00 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 8.15, df = 9 (P = 0.52); I2 =0.0%
Test for overall effect: Z = 1.88 (P = 0.060)
Total (95% CI) 2047 1649 100.0 % -0.07 [ -0.16, 0.01 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 18.46, df = 13 (P = 0.14); I2 =30%
Test for overall effect: Z = 1.63 (P = 0.10)
Test for subgroup differences: Chi2 = 0.28, df = 1 (P = 0.60), I2 =0.0%
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Analysis 4.1. Comparison 4 Subgroup analysis: Feeback given to clinician, participant or both, Outcome 1
Mean improvement in symptom scores: feedback given to clinician, participant or both.
Review: Routine use of patient reported outcome measures (PROMs) for improving treatment of common mental health disorders in adults
Comparison: 4 Subgroup analysis: Feeback given to clinician, participant or both
Outcome: 1 Mean improvement in symptom scores: feedback given to clinician, participant or both
Study or subgroup Experimental Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Mean improvement in symptom scores: feedback given only to the clinician
Hawkins 2004 70 69.41 (24.56) 32 69.33 (23.42) 3.7 % 0.00 [ -0.41, 0.42 ]
Trudeau 2001 27 89.17 (22.43) 11 101.48 (27.32) 1.4 % -0.50 [ -1.22, 0.21 ]
Subtotal (95% CI) 97 43 5.1 % -0.17 [ -0.63, 0.30 ]
Heterogeneity: Tau2 = 0.04; Chi2 = 1.45, df = 1 (P = 0.23); I2 =31%
Test for overall effect: Z = 0.69 (P = 0.49)
2 Mean improvement in symptom scores: feedback given explicitly to both clinician and participant
De Jong 2014 172 54.18 (23.99) 71 51.76 (26.84) 7.1 % 0.10 [ -0.18, 0.37 ]
Hansson 2013 136 88.49 (17.82) 126 88.97 (18.53) 8.6 % -0.03 [ -0.27, 0.22 ]
Hawkins 2004 67 62.49 (25.82) 32 69.33 (23.42) 3.6 % -0.27 [ -0.69, 0.15 ]
Murphy 2012 59 -24.39 (7.13) 51 -23.77 (6.87) 4.4 % -0.09 [ -0.46, 0.29 ]
Reese 2009a 50 -31.28 (6.63) 24 -29.53 (7.26) 2.8 % -0.25 [ -0.74, 0.24 ]
Reese 2009b 45 -29.51 (9.58) 29 -24.33 (7.51) 2.9 % -0.58 [ -1.06, -0.10 ]
Subtotal (95% CI) 529 333 29.5 % -0.12 [ -0.30, 0.05 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 7.21, df = 5 (P = 0.21); I2 =31%
Test for overall effect: Z = 1.38 (P = 0.17)
3 Mean improvement in symptom scores: clinicians permitted or encouraged to share feedback with participant
Amble 2014 144 75.5 (28.6) 115 84.6 (25.1) 8.4 % -0.33 [ -0.58, -0.09 ]
De Jong 2012 206 67.43 (25.78) 207 67.53 (24.16) 11.5 % 0.00 [ -0.20, 0.19 ]
De Jong 2014 158 57.55 (25.91) 71 51.76 (26.84) 7.0 % 0.22 [ -0.06, 0.50 ]
Lambert 2001 307 63.32 (23.83) 302 65.12 (22.31) 14.1 % -0.08 [ -0.24, 0.08 ]
Probst 2013 107 71.32 (25.66) 96 72.95 (25.27) 7.2 % -0.06 [ -0.34, 0.21 ]
Whipple 2003 499 58.15 (22.25) 482 58.56 (23.38) 17.2 % -0.02 [ -0.14, 0.11 ]
Subtotal (95% CI) 1421 1273 65.4 % -0.05 [ -0.16, 0.06 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 9.26, df = 5 (P = 0.10); I2 =46%
Test for overall effect: Z = 0.86 (P = 0.39)
Total (95% CI) 2047 1649 100.0 % -0.07 [ -0.16, 0.01 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 18.45, df = 13 (P = 0.14); I2 =30%
Test for overall effect: Z = 1.63 (P = 0.10)
Test for subgroup differences: Chi2 = 0.65, df = 2 (P = 0.72), I2 =0.0%
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Analysis 5.1. Comparison 5 Subgroup analysis: Whether feedback included treatment instructions or an
algorithm, Outcome 1 Mean improvement in symptom scores by whether feedback included treatment
instructions or an algorithm.
Review: Routine use of patient reported outcome measures (PROMs) for improving treatment of common mental health disorders in adults
Comparison: 5 Subgroup analysis: Whether feedback included treatment instructions or an algorithm
Outcome: 1 Mean improvement in symptom scores by whether feedback included treatment instructions or an algorithm
Study or subgroup Experimental Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Mean improvement in symptom scores: treatment instructions or algorithm
Probst 2013 107 71.32 (25.66) 96 72.95 (25.27) 7.2 % -0.06 [ -0.34, 0.21 ]
Whipple 2003 499 58.15 (22.25) 482 58.56 (23.38) 17.2 % -0.02 [ -0.14, 0.11 ]
Subtotal (95% CI) 606 578 24.4 % -0.03 [ -0.14, 0.09 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.09, df = 1 (P = 0.77); I2 =0.0%
Test for overall effect: Z = 0.44 (P = 0.66)
2 Mean improvement in symptom scores: no treatment instructions or algorithm
Amble 2014 144 75.5 (28.6) 115 84.6 (25.1) 8.4 % -0.33 [ -0.58, -0.09 ]
De Jong 2012 206 67.43 (25.78) 207 67.53 (24.16) 11.5 % 0.00 [ -0.20, 0.19 ]
De Jong 2014 172 54.18 (23.99) 71 51.76 (26.84) 7.1 % 0.10 [ -0.18, 0.37 ]
De Jong 2014 158 57.55 (25.91) 71 51.76 (26.84) 7.0 % 0.22 [ -0.06, 0.50 ]
Hansson 2013 136 88.49 (17.82) 126 88.97 (18.53) 8.6 % -0.03 [ -0.27, 0.22 ]
Hawkins 2004 70 69.41 (24.56) 32 69.33 (23.42) 3.7 % 0.00 [ -0.41, 0.42 ]
Hawkins 2004 67 62.49 (25.82) 32 69.33 (23.42) 3.6 % -0.27 [ -0.69, 0.15 ]
Lambert 2001 307 63.32 (23.83) 302 65.12 (22.31) 14.1 % -0.08 [ -0.24, 0.08 ]
Murphy 2012 59 -24.39 (7.13) 51 -23.77 (6.87) 4.4 % -0.09 [ -0.46, 0.29 ]
Reese 2009a 50 -31.28 (6.63) 24 -29.53 (7.26) 2.8 % -0.25 [ -0.74, 0.24 ]
Reese 2009b 45 -29.51 (9.58) 29 -24.33 (7.51) 2.9 % -0.58 [ -1.06, -0.10 ]
Trudeau 2001 27 89.17 (22.43) 11 101.48 (27.32) 1.4 % -0.50 [ -1.22, 0.21 ]
Subtotal (95% CI) 1441 1071 75.6 % -0.09 [ -0.20, 0.02 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 17.86, df = 11 (P = 0.08); I2 =38%
Test for overall effect: Z = 1.60 (P = 0.11)
Total (95% CI) 2047 1649 100.0 % -0.07 [ -0.16, 0.01 ]
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(. . . Continued)
Study or subgroup Experimental Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Heterogeneity: Tau2 = 0.01; Chi2 = 18.45, df = 13 (P = 0.14); I2 =30%
Test for overall effect: Z = 1.63 (P = 0.10)
Test for subgroup differences: Chi2 = 0.64, df = 1 (P = 0.42), I2 =0.0%
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Analysis 6.1. Comparison 6 Subgroup analysis: studies involving Michael Lambert versus studies not
involving him, Outcome 1 Mean improvement in symptom scores by whether studies involved Michael
Lambert.
Review: Routine use of patient reported outcome measures (PROMs) for improving treatment of common mental health disorders in adults
Comparison: 6 Subgroup analysis: studies involving Michael Lambert versus studies not involving him
Outcome: 1 Mean improvement in symptom scores by whether studies involved Michael Lambert
Study or subgroup Feedback No Feedback
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Mean improvement in symptom scores: studies involving Michael Lambert
Hawkins 2004 70 69.41 (24.56) 32 69.33 (23.42) 4.4 % 0.00 [ -0.41, 0.42 ]
Hawkins 2004 67 62.49 (25.82) 32 69.33 (23.42) 4.3 % -0.27 [ -0.69, 0.15 ]
Lambert 2001 307 63.32 (23.83) 302 65.12 (22.31) 30.5 % -0.08 [ -0.24, 0.08 ]
Probst 2013 107 71.32 (25.66) 96 72.95 (25.27) 10.1 % -0.06 [ -0.34, 0.21 ]
Trudeau 2001 27 89.17 (22.43) 11 101.48 (27.32) 1.5 % -0.50 [ -1.22, 0.21 ]
Whipple 2003 499 58.15 (22.25) 482 58.56 (23.38) 49.1 % -0.02 [ -0.14, 0.11 ]
Subtotal (95% CI) 1077 955 100.0 % -0.06 [ -0.15, 0.03 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 3.02, df = 5 (P = 0.70); I2 =0.0%
Test for overall effect: Z = 1.30 (P = 0.19)
2 Mean improvement in symptom scores: studies not involving Michael Lambert
Amble 2014 144 75.5 (28.8) 115 84.6 (25.1) 20.0 % -0.33 [ -0.58, -0.09 ]
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Study or subgroup Feedback No Feedback
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
De Jong 2012 206 67.43 (25.78) 207 67.53 (24.16) 23.9 % 0.00 [ -0.20, 0.19 ]
De Jong 2014 158 57.55 (25.91) 71 51.76 (26.84) 17.8 % 0.22 [ -0.06, 0.50 ]
De Jong 2014 172 54.18 (23.99) 71 51.76 (26.84) 18.1 % 0.10 [ -0.18, 0.37 ]
Hansson 2013 136 88.49 (17.82) 126 88.97 (18.53) 20.3 % -0.03 [ -0.27, 0.22 ]
Subtotal (95% CI) 816 590 100.0 % -0.02 [ -0.19, 0.15 ]
Heterogeneity: Tau2 = 0.02; Chi2 = 9.72, df = 4 (P = 0.05); I2 =59%
Test for overall effect: Z = 0.19 (P = 0.85)
Test for subgroup differences: Chi2 = 0.18, df = 1 (P = 0.67), I2 =0.0%
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Analysis 7.1. Comparison 7 Post hoc analyses - ’on track’ and ’not on track’ participants, Outcome 1 Mean
improvement in symptom scores: ’not on track’ participants only.
Review: Routine use of patient reported outcome measures (PROMs) for improving treatment of common mental health disorders in adults
Comparison: 7 Post hoc analyses - ’on track’ and ’not on track’ participants
Outcome: 1 Mean improvement in symptom scores: ’not on track’ participants only
Study or subgroup Feedback No feedback
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
De Jong 2012 34 83.56 (30.73) 33 83.69 (28.96) 7.7 % 0.00 [ -0.48, 0.47 ]
De Jong 2014 33 64.42 (28.7) 11 64.38 (25.84) 3.8 % 0.00 [ -0.68, 0.68 ]
De Jong 2014 33 65.3 (27.51) 11 64.38 (25.84) 3.8 % 0.03 [ -0.65, 0.72 ]
Hansson 2013 37 98.35 (18.36) 35 99.63 (22.83) 8.3 % -0.06 [ -0.52, 0.40 ]
Hawkins 2004 30 69.82 (23.23) 16 78.64 (23.95) 4.7 % -0.37 [ -0.98, 0.24 ]
Hawkins 2004 39 76.31 (24.93) 16 78.64 (23.95) 5.2 % -0.09 [ -0.68, 0.49 ]
Lambert 2001 35 74.57 (19.81) 31 83.13 (19.92) 7.4 % -0.43 [ -0.92, 0.06 ]
Murphy 2012 15 -25.4 (5.94) 18 -23.95 (6.59) 3.7 % -0.22 [ -0.91, 0.46 ]
Probst 2013 23 92.57 (25.4) 20 98.65 (25.46) 4.9 % -0.23 [ -0.84, 0.37 ]
Reese 2009b 16 -31.14 (8.18) 11 -22.54 (7.13) 2.6 % -1.07 [ -1.90, -0.24 ]
Simon 2012 109 80.11 (17.99) 98 84.78 (18.48) 23.6 % -0.26 [ -0.53, 0.02 ]
Whipple 2003 88 71.3 (23.23) 131 76.11 (20.26) 24.1 % -0.22 [ -0.49, 0.05 ]
Total (95% CI) 492 431 100.0 % -0.22 [ -0.35, -0.09 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 7.40, df = 11 (P = 0.77); I2 =0.0%
Test for overall effect: Z = 3.24 (P = 0.0012)
Test for subgroup differences: Not applicable
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Analysis 7.2. Comparison 7 Post hoc analyses - ’on track’ and ’not on track’ participants, Outcome 2
Number of treatment sessions received by ’on track’ and ’not on track’ participants.
Review: Routine use of patient reported outcome measures (PROMs) for improving treatment of common mental health disorders in adults
Comparison: 7 Post hoc analyses - ’on track’ and ’not on track’ participants
Outcome: 2 Number of treatment sessions received by ’on track’ and ’not on track’ participants
Study or subgroup Feedback No feedback
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Number of treatment sessions received by ”on track” participants only
De Jong 2014 121 26.35 (16.67) 54 29.95 (37.61) 0.8 % -3.60 [ -14.06, 6.86 ]
De Jong 2014 111 33.75 (60.42) 54 29.95 (37.61) 0.4 % 3.80 [ -11.27, 18.87 ]
Lambert 2001 272 2.81 (2.89) 271 3.59 (3.92) 25.4 % -0.78 [ -1.36, -0.20 ]
Reese 2009b 29 5.9 (5.01) 18 5.5 (5.12) 7.6 % 0.40 [ -2.59, 3.39 ]
Whipple 2003 352 3.88 (3.14) 351 4.53 (4.41) 25.5 % -0.65 [ -1.22, -0.08 ]
Subtotal (95% CI) 885 748 59.7 % -0.69 [ -1.10, -0.29 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.26, df = 4 (P = 0.87); I2 =0.0%
Test for overall effect: Z = 3.40 (P = 0.00068)
2 Number of treatment sessions received by ”not on track” participants only
De Jong 2014 23 33.65 (19.28) 8 56.47 (51.43) 0.1 % -22.82 [ -59.32, 13.68 ]
De Jong 2014 29 44.62 (38.75) 8 56.47 (51.43) 0.1 % -11.85 [ -50.18, 26.48 ]
Hawkins 2004 39 9.15 (6.51) 16 11.22 (10.86) 2.6 % -2.07 [ -7.77, 3.63 ]
Hawkins 2004 30 10.87 (8.34) 16 11.22 (10.86) 2.3 % -0.35 [ -6.45, 5.75 ]
Lambert 2001 35 9.68 (5.19) 31 5.03 (3.92) 11.4 % 4.65 [ 2.45, 6.85 ]
Reese 2009b 16 6.94 (5.67) 11 5.91 (4.01) 5.6 % 1.03 [ -2.62, 4.68 ]
Whipple 2003 88 7.44 (4.66) 131 7.96 (5.21) 18.3 % -0.52 [ -1.84, 0.80 ]
Subtotal (95% CI) 260 221 40.3 % 0.73 [ -2.04, 3.50 ]
Heterogeneity: Tau2 = 6.61; Chi2 = 18.67, df = 6 (P = 0.005); I2 =68%
Test for overall effect: Z = 0.52 (P = 0.61)
Total (95% CI) 1145 969 100.0 % 0.06 [ -0.91, 1.02 ]
Heterogeneity: Tau2 = 0.86; Chi2 = 25.86, df = 11 (P = 0.01); I2 =57%
Test for overall effect: Z = 0.12 (P = 0.91)
Test for subgroup differences: Chi2 = 0.99, df = 1 (P = 0.32), I2 =0.0%
-20 -10 0 10 20
Favours feedback Favours no feedback
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A D D I T I O N A L T A B L E S
Table 1. Contact with investigators
Study ID Response Additional info Outcome
Chang 2012 No Failed to respond Email sent to techang@partners.org and aye-
ung@partners.org on 22 January 2015 regarding ran-
domisation process, CGI-S and PGI-S outcomes and
criteria for diagnosis
De Jong 2012; De Jong 2014 Yes Invited to become a co-author Replied immediately to an email sent on 17 June
2015. Provided details of data on OQ-45 scores and
further information on generation of random se-
quence and allocation concealment
All data extraction was done by TK andMEG as KdJ
became a co-author of the review
Haderlie 2012 Yes Reply on 28 January 2015 in response to email sent
on 22 January:
“We collected the data in a naturalistic setting at 2
clinics with clients who were already in treatment in
some cases. We did collect outcome data over the
course of the study period, but we do not have ﬁrst
and last measurements in all cases. I also do not have
speciﬁc information regarding the clients (such as
diagnoses). Therapists were aware which condition
they were in as the independent variable was whether
or not they received progress feedback. Clients did
not know which condition they were in”
Hansson 2013 Yes Emails sent to helena.hansson@med.lu.se on 22 Jan-
uary 2015, 29 July 2015 and 10 August 2015 en-
quiring about separate outcome data per diagnostic
group. Reply on 30 August with requested informa-
tion
Mathias 1994 No Failed to contact Study too old - contact details of authors unobtain-
able
Probst 2013 No Failed to respond Email sent to thomas.probst@psychologie.uni-re-
gensburg.de on 22 January 2015 regarding details of
randomisation and blinding
Puschner 2009 Yes Reply on 3 February 2015 in response to email sent
22 January 2015: query about breakdown of out-
come data per diagnostic group, with tabulated data
provided
Reese 2009a; Reese 2009b Yes Reply on 3 February 2015 in response to email sent
22 January 2015: to query about randomisation, al-
location concealment and outcome blinding:
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Table 1. Contact with investigators (Continued)
Randomisation:
“When a client was assigned to a therapist, the ﬁrst
client was randomised using a random number gen-
erator to either the feedback or TAU condition. The
second client was then assigned to the other condi-
tion.”
Allocation concealment:
“This was done by the person who assigned clients
at the respective centres. This was done after enrol-
ment into the study. Investigators and client partici-
pants could not foresee which condition a participant
would be placed into.”
Outcome blinding:
“The researchers did not know which condition par-
ticipants were in until the time of analysis.”
Query over discrepancy in data presented in main
text and table:
“The table is correct and it should be 4.69. That is
what was used in the analyses as well.”
Further data regarding number of treatment sessions
and standard deviations provided on request in De-
cember 2015
Further information provided on diagnoses of study
participants on 3 May 2016, conﬁrming that more
than 90% of themwould have had qualifying clinical
diagnoses of anxiety or depressive disorders, or both
Trudeau 2001 Yes Reply on 26 March 2015 in response to email sent
on 26 March 2015 enquiring about the details of
managed care in place in some of the study partici-
pants, and about outcome data. “Managed care con-
sisted of session limits and utilization review”. Fur-
ther email exchanges from 31March to 2 April to en-
quire about blinding details. Reply on 13 May 2016
to email sent 13 May 2016, enquiring whether study
participants would have met our review inclusion/
exclusion characteristics, conﬁrming that they would
have met them
Lambert 2001; Simon 2012;
Probst 2013; Whipple 2003
No Failed to respond Email sent to Michael lambert@byu.edu on 22 Jan-
uary 2015 as listed as corresponding author on all
four studies. Enquiries about randomisation proce-
dure and allocation concealment. No reply regard-
ing any of the studies was made. Further email sent
to witold.simon@wp.pl and Michael Lambert on 17
July 2015, no reply received
Hawkins 2004 Yes Email sent to eric.hawkins@va.gov on 18 November
2015, reply received: further data provided on OQ-
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Table 1. Contact with investigators (Continued)
45 outcomes and number of treatment sessions on 7
December 2015
A P P E N D I C E S
Appendix 1. PsycINFO search strategy (2014)
Ovid PsycINFO was initially searched using the following terms:
[Conditions]
1. *MENTAL DISORDERS/
2. (affective disorder* or common mental disorder* or mental health).ti,ab,id.
3. exp MAJOR DEPRESSION/
(major depression/ or anaclitic depression/ or dysthymic disorder/ or endogenous depression/ or postpartum depression/ or reactive depression/ or
recurrent depression/ or treatment resistant depression/)
4. ATYPICAL DEPRESSION/
5. “DEPRESSION (emotion)”/
6. (depressi* or dysthymi*).ti,ab,id.
7. SEASONAL AFFECTIVE DISORDER/
8. exp ANXIETY/
(anxiety/ or computer anxiety/ or mathematics anxiety/ or performance anxiety/ or social anxiety/ or speech anxiety/ or test anxiety/)
9. exp ANXIETY DISORDERS/
(anxiety disorders/ or acute stress disorder/ or castration anxiety/ or death anxiety/ or generalized anxiety disorder/ or obsessive compulsive
disorder/ or panic disorder/ or posttraumatic stress disorder/ or separation anxiety/)
10. exp NEUROSIS/
(neurosis/ or childhood neurosis/ or experimental neurosis/ or occupational neurosis/ or traumatic neurosis/)
11. OBSESSIONS/
12. PANIC ATTACK/ or PANIC/
13. (anxiety or compulsi* or obsess* or OCD or neurosis or neuroses or neurotic or panic or agoraphobi* or PTSD or posttrauma* or
post-trauma* or acute stress or stress disorder* or psychotrauma* or psychological trauma*).ti,ab,id.
14. exp PHOBIAS/
15. (phobi* or fear or acrophobi* or arachnophobi* or claustrophobi*).ti,ab,id.
16. ADJUSTMENT DISORDERS/ or EMOTIONAL ADJUSTMENT/
17. adjustment reaction.ti,ab.id.
18. or/1-17
[Patient Reported Outcomes]
19. PROMS.ti,ab,id.
20. (patient reported outcome* or patient reported assessment* or patient reported symptom*).ti,ab,id.
21. (patient outcome*).ti,ab,id.
22. ((patient* or client* or tailored) adj2 feedback).ti,ab,id.
23. (patient* adj1 (self-assess* or self-report* or self-monitor*)).ti,ab,id.
24. (patient* adj2 progress*).ti,ab,id.
25. (client report*).ti,ab,id.
26. ((active or routine* or regular*) adj2 (feedback or measurement* or monitor*)).ti,ab,id.
27. (monitor* and feedback*).ti,ab,id.
28. (symptom* monitor* or treatment monitor*).ti,ab,id.
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29. (monitor* adj2 (common mental disorder* or anxi* or compulsi* or obsess* or OCD or depressi* or neurosis or neuroses or neurotic
or panic or phobi* or agoraphobi* or PTSD or posttrauma* or post-trauma* or acute stress or stress disorder* or trauma*)).ti,ab.
30. (follow up* assess*).ti,ab,id.
31. (needs assess*).ti,ab,id.
32. (outcome* adj3 (feedback or manag* or monitor*)).ti,ab,id.
33. severity questionnaire*.ti,ab,id,tm.
34. severity.ti,sh,tm. and (assess* or measure* or outcome* or questionnaire* or score*).ti.
35. (case management or enhanced care).ti,ab,id,sh.
36. “SEVERITY (disorders)”/
37. or/19-36
[RCT Filter]
38. Treatment Effectiveness Evaluation/
39. Clinical Trials/
40. Mental Health Program Evaluation/
41. Placebo/
42. placebo.ti,ab,id.
43. randomly.ab.
44. randomi#ed.ti,ab,id.
45. (control* adj3 (trial or study or group*1)).ti,ab,id.
46. factorial*.ti,ab.
47. allocat*.ti,ab.
48. assign*.ti,ab.
49. (crossover* or cross over*).ti,ab,id.
50. (quasi adj (experimental or random*)).ti,ab,id.
51. “2000”.md.
52. (waitlist* or (wait* and list* and (control* or group))).ti,ab,id.
53. (treatment as usual or TAU or usual care or care as usual).ti,ab,id.
54. or/34-51
55. (18 and 37 and 54)
Key:
ab:abstract; id:key concepts; ti:title; tm:tests and measures
“2000”.md.: methodology = treatment outcome/clinical trial
Appendix 2. Update searches (2015)
1. CCDANCTR-Studies and References Register was re-searched (all years to 18 May 2015) using the following terms:
#1. ((physician* or psychiatri* or psychotherapist* or therapist* or “primary care” or “general practi*”) and (client* or patient* or
oupatient*) near (feedback or feed-back)):ti,ab,kw,ky,mh,mc,emt
#2. ((“psychotherapeutic outcome*” or “treatment outcome*”) and (feedback or feed-back)):ti,ab,kw,ky,mh,mc,emt
#3. (“patient reported” near (information or outcome* or progress*)):ti,ab,kw,ky,mh,mc,emt
#4. (#1 or #2 or #3)
2. The Cochrane Central Register of Controlled Trials (CENTRAL) was searched (all years to 18 May 2015) using the following
terms:
#1. ((psychiatri* or psychotherapist* or therapist*) and ((client* or patient* or oupatient*) near (feedback or feed-back))):ti,ab,kw
#2. ((psychiatri* or psychotherapist* or therapist*) and (patient-reported near (outcome* or progress))):ti,ab,kw
#3. ((“psychotherapeutic outcome*” or “treatment outcome*”) near (feedback or feed-back or (patient-reported near (information or
outcome* or progress)))):ti,ab,kw
#4. ((physician or “primary care” or “general practi*”) and ((client* or patient* or oupatient*) near (feedback or feed-back or progress))):
ti,ab,kw
#5. MeSH descriptor: [MENTAL DISORDERS] explode all trees
#6. MeSH descriptor: [MENTAL HEALTH] explode all trees
#7. MeSH descriptor: [PSYCHOLOGICAL PHENOMENA and PROCESSES] explode all trees
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#8. ((#1 or #2 or #3) or (#4 and (#5 or #6 or #7)))
OVID PsycINFO was re-searched (all years to 18 May 2015) using the following terms:
[Condition = ’receiving treatment/in therapy’]
1. COUNSELING/
2. PSYCHOTHERAPY/
3. PSYCHOTHERAPEUTIC OUTCOMES/
4. TREATMENT OUTCOMES/
5. THERAPISTS/
6. “3310”.cc. [Classification Code:Psychotherapy & Psychotherapeutic Counselling]
7. or/1-6
[Intervention]
8. FEEDBACK/
9. (feedback or feed-back).ti,id.10. or/8-9
[Condition + Intervention]
11. 7 and 10
12. ((physician* or psychiatri* or psychotherapist* or therapist* or primary care or general practi*) and ((client* or patient* or oupatient*)
adj5 (feedback or feed-back))).ti,ab,id.
13. ((physician* or psychiatri* or psychotherapist* or therapist* or primary care or general practi*) and (patient reported adj3 (infor-
mation or outcome*))).ti,ab,id.
14. (psychotherapeutic outcome* and (feedback or feed-back or (patient reported adj3 (information or outcome*)))).ti,ab,id.
15. or/11-14
[RCT filter]
16. TREATMENT EFFECTIVENESS EVALUATION/
17. CLINICAL TRIALS/
18. MENTAL HEALTH PROGRAM EVALUATION/
19. randomly.ab.
20. randomi#ed.ti,ab,id.
21. (control* adj3 (trial or study or group*1)).ti,ab,id.
22. “2000”.md.
23. (waitlist* or (wait* and list* and (control* or group))).ti,ab,id.
24. (treatment as usual or TAU or usual care or care as usual).ti,ab,id.
25. or/16-24
[Condition + Intervention + RCTs]
26. 15 and 25
27. (3 or 4) and 10 [no RCT filter]
28. 26 or 27
F E E D B A C K
Feedback submitted, 15 July 2016
Summary
1) For many of the Cognitive Behaviour Therapy (CBT) programmes strongly supported in NICE recommendations, therapists are
expected to use outcome and process measures every session in order to guide treatment.
For all the Cognitive Therapy (CT) for anxiety programmes that our group created (CT for panic, hypochondriasis, social anxiety
disorder, PTSD) it is essential that therapists give process (inventories of condition speciﬁc automatic thoughts with belief ratings,
attention & avoidance measures) as well as a relevant symptom measures before EVERY session in order to help decide on the content
of the session. If a therapist fails to do this, they get heavily down rated on the therapist competency scales.
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Improving Access to Psychological Therapies (IAPT) therapists are all supposed to give relevant symptom measures each session and
encouraged to consider process measures. This is in line with the original implementation of CBT for depression as well as most of
the most strongly evidence based anxiety programmes. In Beck’s clinic (where I learned the depression treatment) patients have always
been required to complete the Beck Depression Inventory and Beck Anxiety Inventory in the waiting room before the start of every
session, along with other measures that the therapist might consider relevant. I would be gravely concerned that therapists are ﬂying
blind and insufﬁciently aware without this.
2) The few trials that look at giving therapists feedback from PROMs versus not giving feedback have always seemed strange to me
as they have come from a way of working that seems completely alien to the competent delivery of the CBT programmes that have
been evaluated in trials. The originators of those therapies mostly used process and outcome measures every session as an integral part
of the clinical protocol. The feedback versus no feedback studies have often come from people with a counselling or psychodynamic
background who haven’t a tradition of using sessional measures to guide the content of interventions on a week-by-week basis.
3) The most common measure (OQ-45) is not one that we would consider useful for guiding CBT of a speciﬁc condition.
4) Feedback seems to be delayed, not like in IAPT where the patient ﬁlls in the questionnaire in the waiting room before a session and
it is reviewed and acted on by the clinician immediately. Delayed/occasional feedback would be much less useful for guiding therapy.
5) Difﬁcult to see how one could operate stepped care, a key aspect of IAPT, without recording outcomes. Perhaps for this reason, there
don’t seem to be any relevant RCTs looking at PROMS in such a complex, but routine clinical system.
6) The review doesn’t discuss the value of standardised measures for identifying between and within service variation in outcomes and
taking action to reduce them. We are working hard on this in IAPT, with some success.
Do you have any afﬁliation with or involvement in any organisation with a ﬁnancial interest in the subject matter of your comment?
National Clinical Advisor for Improving Access to Psychological Therapies (IAPT) programme.
Reply
Thank you for your thoughtful and detailed feedback.
1) In our view, although inventories of condition speciﬁc thoughts, beliefs, attention, and avoidance measures may be an inseparable
part of the therapeutic process in CBT, you could actually deliver it without routinely administering the set of symptom (PHQ-9,
GAD-7) and social functioning (WSAS) questionnaires used at every IAPT session.
2) While it is true that a number of the studies included counselling or psychodynamic therapies, CBT was provided by at least some
of the therapists in 11 of our included studies (Amble 2014, Berking 2006, de Jong 2012, de Jong 2014, Hawkins 2004, Lambert
2001, Murphy 2012, Reese 2009, Simon 2012, Trudeau 2001, and Whipple 2003). It is therefore possible to randomise patients to
being monitored with PROMs even when using CBT. Furthermore, the large majority of patients with CMHDs don’t get CBT - even
within IAPT (which sees only 15% of all patients with CMHDs in the UK at most) only a proportion of those who are seen get full
CBT - most get low intensity treatment. The large majority of all patients with CMHDs in the UK and other countries with well-
developed primary care systems are prescribed antidepressants by their GPs, if they get any treatment at all. That is why we believe
further research is needed in primary care as well as psychological therapy settings.
3) While the OQ-45 measure is non-speciﬁc for particular disorders - unlike the condition-speciﬁc scales used in IAPT - it has been
used to monitor responses by therapists who used CBT in several of the included studies (Amble 2014, de Jong 2012, de Jong 2014,
Hawkins 2004, Lambert 2001, Simon 2012, Trudeau 2001, and Whipple 2003).
4) In the included studies, the PROMs were usually completed immediately before, or during, the therapy session, so the scores would
be available to guide therapy at that session, at least in psychological andmental health care settings. It is true that in the two primary care
(family practice) studies included in our review (Mathias 1994 and Chang 2012), researchers working outside the practices administered
the PROMs to participants, and fed back summary results to the clinicians, so there might have been some delay in giving feedback in
those studies. We make the point in the review that systematising the administration of PROMs for CMHDs in primary care is more
difﬁcult, as only a minority of patients are attending for a CMHD, unlike in mental health or psychological therapy services, where all
patients are attending for mental health problems and every patient can be given a PROM to complete as a routine on arrival.
5) Although the data collected in IAPT are used at least partly to determine whether patients should be stepped up to high intensity
treatment, presumably they do not have to be completed at every therapy session, but could be done towards the end of a course of low
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intensity treatment? It would be interesting, if it is possible to randomise patients to different frequencies of feedback within IAPT,
to see whether completing PROMs at every session does confer an advantage, because the downside is that it may add to the burden
of treatment for patients. Could a randomised trial of different frequencies of feedback with PROMs be conducted within the IAPT
service?
6) We recognise that the data collected in IAPT are also used as performance measures to compare services with each other and to
justify continued funding, but we were not looking at the use of PROMs to evaluate services in our review.
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
In the protocol we referred to ’psychiatric practice’ or ’specialised psychiatric practice’ as one of the three service settings in which
research has been done. We decided to revise the term to ’multidisciplinary mental health care’ to reﬂect the fact that the clinicians
treating patients with CMHDs in that setting were not only psychiatrists, but also included psychologists, mental health social workers,
and mental health nurses.
A decision was made to include studies in which the diagnoses of the large majority of participants were reported as CMHDs, even if
a proportion of participants were not given a speciﬁc diagnosis, or were reported as having ’relationship’ or ’interpersonal’ difﬁculties,
’somatoform disorders’, ’other’ diagnoses not further speciﬁed, or ’administrative codes’. This was a change from the protocol as we
planned originally to include only studies with participants diagnosed with one of the disorders listed in the protocol, but after discussion
within the review group we decided to include these studies as they included a large majority of participants with CMHDs, and we
considered that excluding them would be to the detriment of the review, through the omission of data that would otherwise be valid
and available.
A decision was also made to include studies where a small number of participants carried a diagnosis of exclusion including substance
misuse, eating disorder or psychosis, where the total number of such participants constituted less than 10% of the total study population.
This was because many of the larger studies included a small number of these participants, and again we considered that excluding
these studies would be to the detriment of the review through omission of data that would otherwise be valid and available.
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Where studies did not report the diagnoses of participants, we decided to contact the corresponding authors to request any available
information on the participants’ diagnoses, and whether they would have met the review inclusion and exclusion criteria. This was an
addition to the protocol agreed after discussion within the review study group, again in order not to omit data that would otherwise be
valid and available.
Consequently, we agreed to carry out additional, post-hoc sensitivity analyses of the meta-analyses of studies using the OQ-45 or ORS,
omitting three studies included in the meta-analyses which did not report the speciﬁc diagnoses of their participants (Reese 2009a;
Reese 2009b; Trudeau 2001), and ﬁve which did not assign a speciﬁc diagnosis to 20% or more of their participants (Amble 2014; De
Jong 2014; Lambert 2001; Murphy 2012; Trudeau 2001; Whipple 2003).
In the protocol for the review, we planned to use logistic regression to calculate and present odds ratios (ORs) and associated 95% CIs
for dichotomous (binary) outcomes, such as changes in antidepressant drug prescriptions or referrals for psychological or psychiatric
treatment. However, in the event, dichotomous outcomes were uncommon ﬁndings in the review and therefore it was agreed such data
should be presented in narrative form only.
We decided post-hoc to conduct an additional subgroup analysis, comparing studies involving Michael Lambert, the originator and
owner of the OQ-45 system, with studies not involving him, to explore whether potential beneﬁts of the system were identiﬁed in
independent evaluations. This was because the OQ-45 was the PROM used in the large majority of studies in the meta-analyses, and
Michael Lambert was author or co-author of a signiﬁcant proportion of those studies.
Two further post-hoc subgroup comparisons were also agreed between the authors of subgroups of participants who were identiﬁed in a
number of studies as being at higher or lower risk for treatment failure, which was determined by the trajectory of their initial response
to therapy. The low risk group was described as ’on-track’ (OT) for a good clinical response, and the high risk group as ’not on track’
(NOT) or alternatively ’at risk’, ’signal cases’, or ’signal alert cases’. This was because several studies using the OQ-45 or ORS PROM
systems reported positive ﬁndings among the NOT participants in the absence of signiﬁcant ﬁndings among their samples overall. One
comparison included only the NOT subgroup, comparing outcomes in terms of symptom scores between feedback and non-feedback
arms. The second comparison included both the OT and NOT subgroups, comparing the number of treatment sessions received
between feedback and non-feedback arms, and including a formal test for subgroup differences to look for evidence of differences
between OT and NOT subgroups. This was also a change from the protocol, as the number of treatment sessions was a secondary
outcome, and originally we planned to conduct subgroup analyses restricted to the primary outcomes (namely symptoms and adverse
effects).
I N D E X T E R M S
Medical Subject Headings (MeSH)
∗Patient Outcome Assessment; Antipsychotic Agents [therapeutic use]; Feedback; Mental Disorders [psychology; ∗therapy]; Quality
of Life; Randomized Controlled Trials as Topic; Suicidal Ideation
MeSH check words
Adult; Aged; Female; Humans; Male; Middle Aged
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